{
  "country": "England",
  "keywords": " ",
  "references": "15674362;23614766;11468183;11136261;15521919;22289918;22297721;8479523;1614522;17311302;21319261;22980425;23531342;18689542;14726385;22983585;15728813;19491257;21115975;18200038;16312222;21483000;19519319;17283363;22675167;7888675;18216293;23057966;18843282;8353276;8402885;22829111;20697090;19188171;17658394;20068100;19098429;11099028;17959854",
  "pmc": " ",
  "affiliations": " ",
  "medline_ta": "J Hematol Oncol",
  "title": "Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.",
  "delete": " ",
  "content": "期刊:6()\n页数:83\n摘要:BACKGROUND\nTP53 defects, i.e., 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gene does not evaluate TP53 functionality, a functional assessment of TP53 pathway may be of interest to identify high risk CLL. By taking advantage of a training cohort of 100 CLL and a validation cohort of 40 CLL with different patterns of TP53 mutation/deletion by FISH and sequencing, we propose an in-vitro assay in which the modulation of TP53 protein and CDKN1A mRNA were investigated upon 24-hour exposure of CLL cells to Nutlin-3.\n\n\nMETHODS\nThe functional assay was set-up on cell lines recapitulating all TP53 genotypes (EHEB, TP53(wt/wt); RAJI, TP53(mut/wt); MEC-1 and MAVER1, TP53(mut/del); HL-60, TP53(del/del)) and evaluated in two multi-institutional cohorts, purposely enriched in CLL bearing TP53 disruption: a training cohort of 100 cases and a validation cohort of 40 cases, both characterized by FISH and TP53 direct sequencing. Cells were exposed to 10 µM Nutlin-3 for 24 hours; TP53 accumulation was evaluated by Western blotting; TP53 transcriptional activity was determined by quantitative realtime PCR (qRT-PCR) of the TP53 target gene CDKN1A.\n\n\nRESULTS\nAccording to TP53 protein modulation, in the training cohort we identified: (i) 63 cases (51 TP53wt/wt, 12 TP53del/wt) with absence of basal TP53 and induction after treatment (normal pattern); (ii) 18 cases (3 TP53(mut/wt), 15 TP53(mut/del)) with high basal TP53 without increase after treatment (mutant pattern); (iii) 19 cases (5 TP53(mut/wt); 3 TP53(mut/del); 11 TP53(wt/wt)) with basal TP53 that increases upon treatment (intermediate pattern). Evaluation of CDKN1A mRNA levels upon Nutlin-3 exposure showed that the 26 TP53 mutated (TP53(mut/del) or TP53(mut/wt)) cases had lower induction levels than the majority (57/63) of cases with normal pattern, and 10/12 cases with intermediate pattern without evidence of TP53 derangement by FISH and sequencing. These results were confirmed in the independent validation cohort of 40 cases (13 TP53(wt/wt), 3 TP53(del/wt), 12 TP53(mut/del), 12 TP53(mut/wt)).\n\n\nCONCLUSIONS\nThe proposed functional assay may integrate the conventional analyses for the identification of TP53 dysregulated CLL.\n期刊:Journal of hematology & oncology\n作者:Federico Pozzo; Michele Dal Bo; Nadia Peragine; Riccardo Bomben; Antonella Zucchetto; Francesca Rossi; Massimo Degan; Davide Rossi; Annalisa Chiarenza; Alberto Grossi; Francesco Di Raimondo; Francesco Zaja; Gabriele Pozzato; Paola Secchiero; Gianluca Gaidano; Giovanni Del Poeta; Giorgio Zauli; Robin Fo À; Anna Guarini; Valter Gattei\n出版日期:2013.0\npmid:2.4283248E7\nmesh_terms:D015153:Blotting, Western; D015331:Cohort Studies; D016158:Genes, p53; D005838:Genotype; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D010879:Piperazines; D011379:Prognosis; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D007093:Imidazoles; D010879:Piperazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3\ndoi:10.1186/1756-8722-6-83\n参考文献:15674362;23614766;11468183;11136261;15521919;22289918;22297721;8479523;1614522;17311302;21319261;22980425;23531342;18689542;14726385;22983585;15728813;19491257;21115975;18200038;16312222;21483000;19519319;17283363;22675167;7888675;18216293;23057966;18843282;8353276;8402885;22829111;20697090;19188171;17658394;20068100;19098429;11099028;17959854\n语言:eng\nmedline_ta:J Hematol Oncol\nnlm_unique_id:101468937\nissn:1756-8722\n国家:England\ngrant_ids:[]",
  "pages": "83",
  "journal": "Journal of hematology & oncology",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D015153:Blotting, Western; D015331:Cohort Studies; D016158:Genes, p53; D005838:Genotype; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D010879:Piperazines; D011379:Prognosis; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D007093:Imidazoles; D010879:Piperazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2013.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "6()",
  "languages": "eng",
  "abstract": "BACKGROUND\nTP53 defects, i.e., 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gene does not evaluate TP53 functionality, a functional assessment of TP53 pathway may be of interest to identify high risk CLL. By taking advantage of a training cohort of 100 CLL and a validation cohort of 40 CLL with different patterns of TP53 mutation/deletion by FISH and sequencing, we propose an in-vitro assay in which the modulation of TP53 protein and CDKN1A mRNA were investigated upon 24-hour exposure of CLL cells to Nutlin-3.\n\n\nMETHODS\nThe functional assay was set-up on cell lines recapitulating all TP53 genotypes (EHEB, TP53(wt/wt); RAJI, TP53(mut/wt); MEC-1 and MAVER1, TP53(mut/del); HL-60, TP53(del/del)) and evaluated in two multi-institutional cohorts, purposely enriched in CLL bearing TP53 disruption: a training cohort of 100 cases and a validation cohort of 40 cases, both characterized by FISH and TP53 direct sequencing. Cells were exposed to 10 µM Nutlin-3 for 24 hours; TP53 accumulation was evaluated by Western blotting; TP53 transcriptional activity was determined by quantitative realtime PCR (qRT-PCR) of the TP53 target gene CDKN1A.\n\n\nRESULTS\nAccording to TP53 protein modulation, in the training cohort we identified: (i) 63 cases (51 TP53wt/wt, 12 TP53del/wt) with absence of basal TP53 and induction after treatment (normal pattern); (ii) 18 cases (3 TP53(mut/wt), 15 TP53(mut/del)) with high basal TP53 without increase after treatment (mutant pattern); (iii) 19 cases (5 TP53(mut/wt); 3 TP53(mut/del); 11 TP53(wt/wt)) with basal TP53 that increases upon treatment (intermediate pattern). Evaluation of CDKN1A mRNA levels upon Nutlin-3 exposure showed that the 26 TP53 mutated (TP53(mut/del) or TP53(mut/wt)) cases had lower induction levels than the majority (57/63) of cases with normal pattern, and 10/12 cases with intermediate pattern without evidence of TP53 derangement by FISH and sequencing. These results were confirmed in the independent validation cohort of 40 cases (13 TP53(wt/wt), 3 TP53(del/wt), 12 TP53(mut/del), 12 TP53(mut/wt)).\n\n\nCONCLUSIONS\nThe proposed functional assay may integrate the conventional analyses for the identification of TP53 dysregulated CLL.",
  "pmid": "2.4283248E7",
  "nlm_unique_id": "101468937",
  "issn_linking": "1756-8722",
  "filename": "pubmed24n0777.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Federico Pozzo; Michele Dal Bo; Nadia Peragine; Riccardo Bomben; Antonella Zucchetto; Francesca Rossi; Massimo Degan; Davide Rossi; Annalisa Chiarenza; Alberto Grossi; Francesco Di Raimondo; Francesco Zaja; Gabriele Pozzato; Paola Secchiero; Gianluca Gaidano; Giovanni Del Poeta; Giorgio Zauli; Robin Fo À; Anna Guarini; Valter Gattei",
  "doi": "10.1186/1756-8722-6-83"
}
{
  "country": "Ireland",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita-shi, Osaka, Japan.",
  "medline_ta": "Cancer Lett",
  "title": "Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.",
  "delete": " ",
  "content": "期刊:307(2)\n页数:149_57\n摘要:PURPOSE\nThe aim of this study was to determine whether TP53 mutation status (MS) can predict response of breast cancer to paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). TP53 gene expression signature (GES) was also examined for its predictive capability of response to P-FEC since TP53 GES provides a more accurate measure of the functional configuration of TP53.\n\n\nMETHODS\nTumor samples were obtained from 72 primary breast cancer patients (stage II/III) before neoadjuvant chemotherapy (P-FEC) and analyzed for identification of TP53 MS (genomic sequencing), TP53 GES (DNA microarray), and p53 protein expression (immunohistochemistry).\n\n\nRESULTS\nOf 72 breast tumors, 16 were TP53 mutant-type (TP53 mt) and 56 were wild-type (TP53 wt). 29 tumors (40%) were positive for p53 protein by immunohistochemistry. DNA microarray analysis showed that 27 were TP53 mt-like tumors and 45 were TP53 wt-like tumors, depending on the expression signature of the TP53-related 31-genes. There was no statistically significant difference in pathological complete response (pCR) rates between TP53 mt and wt tumors (19% vs 23%) and between p53 positive and negative tumors (24% vs 21%) but TP53 mt-like tumors showed a significantly (P=0.019) higher pCR rate (37%) than TP53 wt-like tumors (13%) (Hazard ratio, 3.82; 95% C.I., 1.20-12.21).\n\n\nCONCLUSIONS\nTP53 GES, but not TP53 MS and p53 protein expression, is predictive of response to neoadjuvant P-FEC, suggesting that TP53 GES more correctly reflects the functionality of TP53.\n期刊:Cancer letters\n作者:Kazuteru Oshima; Yasuto Naoi; Kazuki Kishi; Yukiko Nakamura; Takashi Iwamoto; Kenzo Shimazu; Takahiro Nakayama; Seung Jin Kim; Yosuke Baba; Yasuhiro Tamaki; Shinzaburo Noguchi\n出版日期:2011.0\npmid:2.1514041E7\nmesh_terms:D000970:Antineoplastic Agents; D001943:Breast Neoplasms; D016000:Cluster Analysis; D003520:Cyclophosphamide; D015251:Epirubicin; D005472:Fluorouracil; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D017239:Paclitaxel; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil\ndoi:10.1016/j.canlet.2011.03.027\n语言:eng\n附属机构:Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita-shi, Osaka, Japan.\nmedline_ta:Cancer Lett\nnlm_unique_id:7600053\nissn:0304-3835\n国家:Ireland\ngrant_ids:[]",
  "pages": "149_57",
  "journal": "Cancer letters",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000970:Antineoplastic Agents; D001943:Breast Neoplasms; D016000:Cluster Analysis; D003520:Cyclophosphamide; D015251:Epirubicin; D005472:Fluorouracil; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D017239:Paclitaxel; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2011.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "307(2)",
  "languages": "eng",
  "abstract": "PURPOSE\nThe aim of this study was to determine whether TP53 mutation status (MS) can predict response of breast cancer to paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). TP53 gene expression signature (GES) was also examined for its predictive capability of response to P-FEC since TP53 GES provides a more accurate measure of the functional configuration of TP53.\n\n\nMETHODS\nTumor samples were obtained from 72 primary breast cancer patients (stage II/III) before neoadjuvant chemotherapy (P-FEC) and analyzed for identification of TP53 MS (genomic sequencing), TP53 GES (DNA microarray), and p53 protein expression (immunohistochemistry).\n\n\nRESULTS\nOf 72 breast tumors, 16 were TP53 mutant-type (TP53 mt) and 56 were wild-type (TP53 wt). 29 tumors (40%) were positive for p53 protein by immunohistochemistry. DNA microarray analysis showed that 27 were TP53 mt-like tumors and 45 were TP53 wt-like tumors, depending on the expression signature of the TP53-related 31-genes. There was no statistically significant difference in pathological complete response (pCR) rates between TP53 mt and wt tumors (19% vs 23%) and between p53 positive and negative tumors (24% vs 21%) but TP53 mt-like tumors showed a significantly (P=0.019) higher pCR rate (37%) than TP53 wt-like tumors (13%) (Hazard ratio, 3.82; 95% C.I., 1.20-12.21).\n\n\nCONCLUSIONS\nTP53 GES, but not TP53 MS and p53 protein expression, is predictive of response to neoadjuvant P-FEC, suggesting that TP53 GES more correctly reflects the functionality of TP53.",
  "pmid": "2.1514041E7",
  "nlm_unique_id": "7600053",
  "issn_linking": "0304-3835",
  "filename": "pubmed24n0692.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Kazuteru Oshima; Yasuto Naoi; Kazuki Kishi; Yukiko Nakamura; Takashi Iwamoto; Kenzo Shimazu; Takahiro Nakayama; Seung Jin Kim; Yosuke Baba; Yasuhiro Tamaki; Shinzaburo Noguchi",
  "doi": "10.1016/j.canlet.2011.03.027"
}
{
  "country": "United States",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Division of Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada; Manitoba Institute of Cell Biology, CancerCare Manitoba, Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada.",
  "medline_ta": "Genes Chromosomes Cancer",
  "title": "Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.",
  "delete": " ",
  "content": "期刊:53(11)\n页数:934_50\n摘要:TP53 mutations are the most common mutations in human cancers, and TP53-R175H and TP53-R273H are the most frequent. The impact of these mutations on genomic instability after tumor initiation is still uncovered. To gain insight into this, we studied the effects of three specific TP53 mutants (TP53-V143A, TP53-R175H, and TP53-R273H) on genomic instability using four isogenic lines of LoVo cells. Multicolor fluorescence in situ hybridization (FISH), three-dimensional (3D) quantitative FISH (Q-FISH) on interphase and Q-FISH on metaphases were used to investigate genomic instability. We found that LoVo cells expressing mutant TP53-R175H displayed the highest level of chromosomal instability among the LoVo cell lines. Furthermore, we observed that mutant TP53-R175H and TP53-V143A showed more alterations in their 3D nuclear architecture of telomeres than the mutant TP53-R273H and the wild type. Moreover, we noted an association between some chromosomal abnormalities and telomere elongation in the mutant TP53-R175H. Taken together, our results indicate that the mutation TP53-R175H is more likely to cause higher levels of genomic instability than the other TP53 mutations. We proposed that the type of TP53 mutations and the genetic background of a cancer cell are major determinants of the TP53-dependent genomic instability.\n期刊:Genes, chromosomes & cancer\n作者:Oumar Samassekou; Nathalie Bastien; Daniel Lichtensztejn; Ju Yan; Sabine Mai; Régen Drouin\n出版日期:2014.0\npmid:2.5059482E7\nmesh_terms:D045744:Cell Line, Tumor; D002467:Cell Nucleus; D049109:Cell Proliferation; D043171:Chromosomal Instability; D003110:Colonic Neoplasms; D006801:Humans; D009154:Mutation; D000089804:Shelterin Complex; D016615:Telomere; D034501:Telomere-Binding Proteins; D059467:Transcriptome; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D000089804:Shelterin Complex; C495901:TP53 protein, human; D034501:Telomere-Binding Proteins; D016159:Tumor Suppressor Protein p53\ndoi:10.1002/gcc.22205\n语言:eng\n附属机构:Division of Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada; Manitoba Institute of Cell Biology, CancerCare Manitoba, Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada.\nmedline_ta:Genes Chromosomes Cancer\nnlm_unique_id:9007329\nissn:1045-2257\n国家:United States\ngrant_ids:[]",
  "pages": "934_50",
  "journal": "Genes, chromosomes & cancer",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D045744:Cell Line, Tumor; D002467:Cell Nucleus; D049109:Cell Proliferation; D043171:Chromosomal Instability; D003110:Colonic Neoplasms; D006801:Humans; D009154:Mutation; D000089804:Shelterin Complex; D016615:Telomere; D034501:Telomere-Binding Proteins; D059467:Transcriptome; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D000089804:Shelterin Complex; C495901:TP53 protein, human; D034501:Telomere-Binding Proteins; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2014.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "53(11)",
  "languages": "eng",
  "abstract": "TP53 mutations are the most common mutations in human cancers, and TP53-R175H and TP53-R273H are the most frequent. The impact of these mutations on genomic instability after tumor initiation is still uncovered. To gain insight into this, we studied the effects of three specific TP53 mutants (TP53-V143A, TP53-R175H, and TP53-R273H) on genomic instability using four isogenic lines of LoVo cells. Multicolor fluorescence in situ hybridization (FISH), three-dimensional (3D) quantitative FISH (Q-FISH) on interphase and Q-FISH on metaphases were used to investigate genomic instability. We found that LoVo cells expressing mutant TP53-R175H displayed the highest level of chromosomal instability among the LoVo cell lines. Furthermore, we observed that mutant TP53-R175H and TP53-V143A showed more alterations in their 3D nuclear architecture of telomeres than the mutant TP53-R273H and the wild type. Moreover, we noted an association between some chromosomal abnormalities and telomere elongation in the mutant TP53-R175H. Taken together, our results indicate that the mutation TP53-R175H is more likely to cause higher levels of genomic instability than the other TP53 mutations. We proposed that the type of TP53 mutations and the genetic background of a cancer cell are major determinants of the TP53-dependent genomic instability.",
  "pmid": "2.5059482E7",
  "nlm_unique_id": "9007329",
  "issn_linking": "1045-2257",
  "filename": "pubmed24n0801.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Oumar Samassekou; Nathalie Bastien; Daniel Lichtensztejn; Ju Yan; Sabine Mai; Régen Drouin",
  "doi": "10.1002/gcc.22205"
}
{
  "country": "England",
  "keywords": "MDM2; TP53; computational biology; human; human biology; inhibitor sensitivity; medicine; pharmacogenomics; predictive signature; systems biology; translational oncology",
  "references": "19924296;22460905;24142049;25965177;12490442;17671205;17982454;19518143",
  "pmc": " ",
  "affiliations": "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, United States.",
  "medline_ta": "Elife",
  "title": "Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.",
  "delete": " ",
  "content": "期刊:4()\n摘要:A number of TP53-MDM2 inhibitors are currently under investigation as therapeutic agents in a variety of clinical trials in patients with TP53 wild type tumors. Not all wild type TP53 tumors are sensitive to such inhibitors. In an attempt to improve selection of patients with TP53 wild type tumors, an mRNA expression signature based on 13 TP53 transcriptional target genes was recently developed (Jeay et al. 2015). Careful reanalysis of TP53 status in the study validation data set of cancer cell lines considered to be TP53 wild type detected TP53 inactivating alterations in 23% of cell lines. The subsequent reanalysis of the remaining TP53 wild type cell lines clearly demonstrated that unfortunately the 13-gene signature cannot predict response to TP53-MDM2 inhibitor in TP53 wild type tumors.\n期刊:eLife\n作者:Dmitriy Sonkin\n出版日期:2015.0\npmid:2.6491944E7\nmesh_terms:D000970:Antineoplastic Agents; D002460:Cell Line; D020869:Gene Expression Profiling; D006801:Humans; D009369:Neoplasms; D051736:Proto-Oncogene Proteins c-mdm2; D018085:Regulon; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article\n化学列表:D000970:Antineoplastic Agents; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2\n关键词:MDM2; TP53; computational biology; human; human biology; inhibitor sensitivity; medicine; pharmacogenomics; predictive signature; systems biology; translational oncology\n参考文献:19924296;22460905;24142049;25965177;12490442;17671205;17982454;19518143\n语言:eng\n附属机构:Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, United States.\nmedline_ta:Elife\nnlm_unique_id:101579614\nissn:2050-084X\n国家:England\ngrant_ids:[]",
  "pages": " ",
  "journal": "eLife",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000970:Antineoplastic Agents; D002460:Cell Line; D020869:Gene Expression Profiling; D006801:Humans; D009369:Neoplasms; D051736:Proto-Oncogene Proteins c-mdm2; D018085:Regulon; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D000970:Antineoplastic Agents; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2015.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "4()",
  "languages": "eng",
  "abstract": "A number of TP53-MDM2 inhibitors are currently under investigation as therapeutic agents in a variety of clinical trials in patients with TP53 wild type tumors. Not all wild type TP53 tumors are sensitive to such inhibitors. In an attempt to improve selection of patients with TP53 wild type tumors, an mRNA expression signature based on 13 TP53 transcriptional target genes was recently developed (Jeay et al. 2015). Careful reanalysis of TP53 status in the study validation data set of cancer cell lines considered to be TP53 wild type detected TP53 inactivating alterations in 23% of cell lines. The subsequent reanalysis of the remaining TP53 wild type cell lines clearly demonstrated that unfortunately the 13-gene signature cannot predict response to TP53-MDM2 inhibitor in TP53 wild type tumors.",
  "pmid": "2.6491944E7",
  "nlm_unique_id": "101579614",
  "issn_linking": "2050-084X",
  "filename": "pubmed24n0846.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Dmitriy Sonkin",
  "doi": " "
}
{
  "country": "United States",
  "keywords": "TP53; cancer; cd80; colon; immune surveillance",
  "references": "31365877;31072360;10980383;27449973;30059832;25351767;22588877;31646078;32144194;32312843;31310659;31940491;31959281;28280037;28123894;19426219;19935675;16489051;21555531;26496037;31952115;28944167;25595911;30710145;29625055;31448437;29900037",
  "pmc": " ",
  "affiliations": "Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.;Department of Molecular Medicine DMM, University of Padua, Padua, Italy.;Clinica Chirurgica I, Azienda Ospedaliera Di Padova, Padua, Italy.;Department of Molecular Medicine DMM, University of Padua, Padua, Italy.",
  "medline_ta": "Oncoimmunology",
  "title": "CD80 expression is upregulated by TP53 activation in human cancer epithelial cells.",
  "delete": " ",
  "content": "期刊:10(1)\n页数:1907912\n摘要:CD80 is recognized as one of the most potent costimulatory molecules by which immune cells limit cancer progression; however, the current understanding of the regulation of its expression on human tumor cells is limited. The TP53 tumor suppressor plays a critical role in cancer and its significant role in the control of immune responses is emerging. Here, we evaluated the role of TP53 as a regulator of CD80 expression in human cancer cells. A set of well-known TP53-reactivating compounds were used on TP53-wild-type, TP53-deficient, TP53-mutated and TP53-knockdown cancer cell lines to determine if TP53 can regulate CD80. CD80 expression was analyzed in samples from patients with TP53-active vs TP53-inactive Colon Adenocarcinomas (COAD) from TCGA panCancer Atlas. We report that the pharmacological activation of TP53 can stimulate the expression of CD80 in human tumor cells of epithelial origin. We also provide evidence that CD80 expression exhibits a strong correlation with TP53 activation in a subgroup of colon tumors with better overall survival. These results confirm the link between TP53 and immune surveillance in human cancer and provide the possibility that conventional TP53-activation approaches for tumoricidal effects may be repurposed for immunotherapy strategies.\n期刊:Oncoimmunology\n作者:Melania Scarpa; Chiara Marchiori; Marco Scarpa; Ignazio Castagliuolo\n出版日期:2021.0\npmid:3.3868791E7\nmesh_terms:D018122:B7-1 Antigen; D015815:Cell Adhesion Molecules; D003110:Colonic Neoplasms; D004847:Epithelial Cells; D006801:Humans; D007167:Immunotherapy; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D018122:B7-1 Antigen; D015815:Cell Adhesion Molecules; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\n关键词:TP53; cancer; cd80; colon; immune surveillance\ndoi:10.1080/2162402X.2021.1907912\n参考文献:31365877;31072360;10980383;27449973;30059832;25351767;22588877;31646078;32144194;32312843;31310659;31940491;31959281;28280037;28123894;19426219;19935675;16489051;21555531;26496037;31952115;28944167;25595911;30710145;29625055;31448437;29900037\n语言:eng\n附属机构:Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.;Department of Molecular Medicine DMM, University of Padua, Padua, Italy.;Clinica Chirurgica I, Azienda Ospedaliera Di Padova, Padua, Italy.;Department of Molecular Medicine DMM, University of Padua, Padua, Italy.\nmedline_ta:Oncoimmunology\nnlm_unique_id:101570526\nissn:2162-4011\n国家:United States\ngrant_ids:[]",
  "pages": "1907912",
  "journal": "Oncoimmunology",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D018122:B7-1 Antigen; D015815:Cell Adhesion Molecules; D003110:Colonic Neoplasms; D004847:Epithelial Cells; D006801:Humans; D007167:Immunotherapy; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D018122:B7-1 Antigen; D015815:Cell Adhesion Molecules; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2021.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "10(1)",
  "languages": "eng",
  "abstract": "CD80 is recognized as one of the most potent costimulatory molecules by which immune cells limit cancer progression; however, the current understanding of the regulation of its expression on human tumor cells is limited. The TP53 tumor suppressor plays a critical role in cancer and its significant role in the control of immune responses is emerging. Here, we evaluated the role of TP53 as a regulator of CD80 expression in human cancer cells. A set of well-known TP53-reactivating compounds were used on TP53-wild-type, TP53-deficient, TP53-mutated and TP53-knockdown cancer cell lines to determine if TP53 can regulate CD80. CD80 expression was analyzed in samples from patients with TP53-active vs TP53-inactive Colon Adenocarcinomas (COAD) from TCGA panCancer Atlas. We report that the pharmacological activation of TP53 can stimulate the expression of CD80 in human tumor cells of epithelial origin. We also provide evidence that CD80 expression exhibits a strong correlation with TP53 activation in a subgroup of colon tumors with better overall survival. These results confirm the link between TP53 and immune surveillance in human cancer and provide the possibility that conventional TP53-activation approaches for tumoricidal effects may be repurposed for immunotherapy strategies.",
  "pmid": "3.3868791E7",
  "nlm_unique_id": "101570526",
  "issn_linking": "2162-4011",
  "filename": "pubmed24n1080.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Melania Scarpa; Chiara Marchiori; Marco Scarpa; Ignazio Castagliuolo",
  "doi": "10.1080/2162402X.2021.1907912"
}
{
  "country": "Switzerland",
  "keywords": "TP53 mutation; acute myeloid leukemia",
  "references": "28637690;28288132;31424436;35797463;33357454;27881874;25455271;32569759;24836762;31282934;21343334;35297213;30309854;34570179;15238427;26801896;27352800;36706355;35390143;27150056;12909720;30193102;22007292;27959731;32007736;31685430;31835844;37078412;22932223;33449813;33194757;25487151;37435002;27463065;30567725;11805092;20937277;30500073;34933333;33600210;31552170;14749784;30409776;34583722;17606709;34182597;12623843;29258181;24493299;32915972;32811132;27141080;27998224;33057635;33649166;19667193;37139921;37370821;18094376;2525423;24522528;15607980;35483929;33302031;33211826;35073573;10449408;33411954;20182602;25634208;36990622;32585821;35816664;16131611;37339484;19411067;16138827;32164171;15607981;16508005;24415648;36807649;34255353;36332187;24132290;22186996;16413492;17242190;30115541;25426837;1301998;31447067;36315007;29988143;32786187;12826609;35767897",
  "pmc": " ",
  "affiliations": "Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.",
  "medline_ta": "Cancers (Basel)",
  "title": "TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited.",
  "delete": " ",
  "content": "期刊:15(19)\n摘要:INTRODUCTION\nTP53 is the most commonly mutated gene in human cancers and was the first tumor suppressor gene to be discovered in the history of medical science. Mutations in the TP53 gene occur at various genetic locations and exhibit significant heterogeneity among patients. Mutations occurring primarily within the DNA-binding domain of TP53 result in the loss of the p53 protein's DNA-binding capability. However, a complex phenotypic landscape often combines gain-of-function, dominant negative, or altered specificity features. This complexity poses a significant challenge in developing an effective treatment strategy, which eradicates TP53-mutated cancer clones. This review summarizes the current understanding of TP53 mutations in AML and their implications. TP53 mutation in AML: In patients with acute myeloid leukemia (AML), six hotspot mutations (R175H, G245S, R248Q/W, R249S, R273H/S, and R282W) within the DNA-binding domain are common. TP53 mutations are frequently associated with a complex karyotype and subgroups of therapy-related or secondary AML. The presence of TP53 mutation is considered as a poor prognostic factor. TP53-mutated AML is even classified as a distinct subgroup of AML by itself, as TP53-mutated AML exhibits a significantly distinct landscape in terms of co-mutation and gene expression profiles compared with wildtype (WT)-TP53 AML.\n\n\nCLINICAL IMPLICATIONS\nTo better predict the prognosis in cancer patients with different TP53 mutations, several predictive scoring systems have been proposed based on screening experiments, to assess the aggressiveness of TP53-mutated cancer cells. Among those scoring systems, a relative fitness score (RFS) could be applied to AML patients with TP53 mutations in terms of overall survival (OS) and event-free survival (EFS). The current standard treatment, which includes cytotoxic chemotherapy and allogeneic hematopoietic stem cell transplantation, is largely ineffective for patients with TP53-mutated AML. Consequently, most patients with TP53-mutated AML succumb to leukemia within several months, despite active anticancer treatment. Decitabine, a hypomethylating agent, is known to be relatively effective in patients with AML. Numerous trials are ongoing to investigate the effects of novel drugs combined with hypomethylating agents, TP53-targeting agents or immunologic agents.\n\n\nCONCLUSIONS\nDeveloping an effective treatment strategy for TP53-mutated AML through innovative and multidisciplinary research is an urgent task. Directly targeting mutated TP53 holds promise as an approach to combating TP53-mutated AML, and recent developments in immunologic agents for AML offer hope in this field.\n期刊:Cancers\n作者:Dong-Yeop Shin\n出版日期:2023.0\npmid:3.783551E7\n出版物类型:D016428:Journal Article; D016454:Review\n关键词:TP53 mutation; acute myeloid leukemia\ndoi:10.3390/cancers15194816\n参考文献:28637690;28288132;31424436;35797463;33357454;27881874;25455271;32569759;24836762;31282934;21343334;35297213;30309854;34570179;15238427;26801896;27352800;36706355;35390143;27150056;12909720;30193102;22007292;27959731;32007736;31685430;31835844;37078412;22932223;33449813;33194757;25487151;37435002;27463065;30567725;11805092;20937277;30500073;34933333;33600210;31552170;14749784;30409776;34583722;17606709;34182597;12623843;29258181;24493299;32915972;32811132;27141080;27998224;33057635;33649166;19667193;37139921;37370821;18094376;2525423;24522528;15607980;35483929;33302031;33211826;35073573;10449408;33411954;20182602;25634208;36990622;32585821;35816664;16131611;37339484;19411067;16138827;32164171;15607981;16508005;24415648;36807649;34255353;36332187;24132290;22186996;16413492;17242190;30115541;25426837;1301998;31447067;36315007;29988143;32786187;12826609;35767897\n语言:eng\n附属机构:Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.\nmedline_ta:Cancers (Basel)\nnlm_unique_id:101526829\nissn:2072-6694\n国家:Switzerland\ngrant_ids:[{'grant_id': '0420230560', 'grant_acronym': '', 'country': None, 'agency': 'Seoul National University Hospital'}]",
  "pages": " ",
  "journal": "Cancers",
  "_inference.semantic_vector": "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",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[{'grant_id': '0420230560', 'grant_acronym': '', 'country': None, 'agency': 'Seoul National University Hospital'}]",
  "other_id": " ",
  "pubdate": "2023.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D016454:Review",
  "issue": "15(19)",
  "languages": "eng",
  "abstract": "INTRODUCTION\nTP53 is the most commonly mutated gene in human cancers and was the first tumor suppressor gene to be discovered in the history of medical science. Mutations in the TP53 gene occur at various genetic locations and exhibit significant heterogeneity among patients. Mutations occurring primarily within the DNA-binding domain of TP53 result in the loss of the p53 protein's DNA-binding capability. However, a complex phenotypic landscape often combines gain-of-function, dominant negative, or altered specificity features. This complexity poses a significant challenge in developing an effective treatment strategy, which eradicates TP53-mutated cancer clones. This review summarizes the current understanding of TP53 mutations in AML and their implications. TP53 mutation in AML: In patients with acute myeloid leukemia (AML), six hotspot mutations (R175H, G245S, R248Q/W, R249S, R273H/S, and R282W) within the DNA-binding domain are common. TP53 mutations are frequently associated with a complex karyotype and subgroups of therapy-related or secondary AML. The presence of TP53 mutation is considered as a poor prognostic factor. TP53-mutated AML is even classified as a distinct subgroup of AML by itself, as TP53-mutated AML exhibits a significantly distinct landscape in terms of co-mutation and gene expression profiles compared with wildtype (WT)-TP53 AML.\n\n\nCLINICAL IMPLICATIONS\nTo better predict the prognosis in cancer patients with different TP53 mutations, several predictive scoring systems have been proposed based on screening experiments, to assess the aggressiveness of TP53-mutated cancer cells. Among those scoring systems, a relative fitness score (RFS) could be applied to AML patients with TP53 mutations in terms of overall survival (OS) and event-free survival (EFS). The current standard treatment, which includes cytotoxic chemotherapy and allogeneic hematopoietic stem cell transplantation, is largely ineffective for patients with TP53-mutated AML. Consequently, most patients with TP53-mutated AML succumb to leukemia within several months, despite active anticancer treatment. Decitabine, a hypomethylating agent, is known to be relatively effective in patients with AML. Numerous trials are ongoing to investigate the effects of novel drugs combined with hypomethylating agents, TP53-targeting agents or immunologic agents.\n\n\nCONCLUSIONS\nDeveloping an effective treatment strategy for TP53-mutated AML through innovative and multidisciplinary research is an urgent task. Directly targeting mutated TP53 holds promise as an approach to combating TP53-mutated AML, and recent developments in immunologic agents for AML offer hope in this field.",
  "pmid": "3.783551E7",
  "nlm_unique_id": "101526829",
  "issn_linking": "2072-6694",
  "filename": "pubmed24n1210.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Dong-Yeop Shin",
  "doi": "10.3390/cancers15194816"
}
{
  "country": "Iran",
  "keywords": "BRCA1 protein; Immunoprecipitation; RAD51 protein; TP53",
  "references": "11239456;18508631;20064378;17593043;20952512;23242655;17417627;19693097;20719876;9582019;9380510;10880452;16765891;19776742;21338495;18223686;8617246;942051;11090615;1923504;14576433;21125670",
  "pmc": " ",
  "affiliations": "Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.;Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.",
  "medline_ta": "Avicenna J Med Biotechnol",
  "title": "TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.",
  "delete": " ",
  "content": "期刊:7(2)\n页数:76_9\n摘要:BACKGROUND\nTumour suppressor genes such as TP53, BRCA1 and RAD51 are involved in DNA repair and their malfunctions result in genomic instability and cancer. Wild type (WT) TP53 binds to BRCA1and RAD51 in vivo and in vitro. However, mutated TP53 in tumours can interfere with WT TP53 function. We studied how mutation of TP53 in MDA-MB-468 cell line could affect its binding capacity and interfere with WT TP53 interaction with these DNA repair proteins.\n\n\nMETHODS\nBinding capacity of mutated TP53 in MDA-MB-468 breast cancer cell line to BRCA1 and RAD51 proteins in comparison to WT TP53 in MCF7 cell line was studied by Immunoprecipitation. In vitro studies were performed by GST-WT p53 pull-down assays in these cell lines to assess the interaction of GST-WT p53 with BRCA1 and RAD51 proteins.\n\n\nRESULTS\nThe results showed that mutated TP53 in MDA-MB-468 cells interacted with BRCA1 protein in vivo and did not effect WT TP53 binding to this protein in vitro. The Immunoprecipitation assays revealed that the mutated TP53 did not bind to RAD51 in comparison to WT TP53. However, this mutated protein could not interfere with binding of RAD51 to GST-WT p53 in MDA-MB-468 cell line by in vitro experiment.\n\n\nCONCLUSION\nIt was found that WT TP53 interactions with BRCA1 and RAD51 did not interfere with mutated TP53 in MDA-MB-468 cell line. In addition, RAD51 did not bind to TP53 with R273C mutation in vivo.\n期刊:Avicenna journal of medical biotechnology\n作者:Mozhgan Rasti; Tayebeh Azimi\n出版日期:2015.0\npmid:2.6140185E7\n出版物类型:D016428:Journal Article\n关键词:BRCA1 protein; Immunoprecipitation; RAD51 protein; TP53\n参考文献:11239456;18508631;20064378;17593043;20952512;23242655;17417627;19693097;20719876;9582019;9380510;10880452;16765891;19776742;21338495;18223686;8617246;942051;11090615;1923504;14576433;21125670\n语言:eng\n附属机构:Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.;Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.\nmedline_ta:Avicenna J Med Biotechnol\nnlm_unique_id:101511065\nissn:2008-2835\n国家:Iran\ngrant_ids:[]",
  "pages": "76_9",
  "journal": "Avicenna journal of medical biotechnology",
  "_inference.semantic_vector": "AGD9vgAAcr0AYCM+AAAfvgCgoD4AwB08AEDavgBA0b4AYH4+AIDFPQAA8T4AQKW+AOCBPgBgHT8AYEG/AMBNPwAApj0AoPm9AOAmPgAgb74AgDI/ACC7vgBAEj4A4Hs+AMAWvABgl74AgMc+AEA8PQBgT74AgMM+AOAovgAgjj4AwFK+AGD3PQDAeb4AQDU/AGAdPgBAYD8AoP4+AEBJPQDgyj0AgKa+ACA9vwCAhj4AgB28AIDIvgBAgMAAYAk/AKCHvgCgcbwAwGU+AEBIPwAAuj4AQOM+AKDVPgCAxj4AAGg+AGCAvACgsD4AQH6/AOA1PgCg5D4A4C0+AODbvQDAZT4AAPI+AACCuwDAHr4AAAK/AIAmvwCARTwAoM+9AKABvwCANz4AYNU+AKAcPgBADr8AoGw+AIB+PwAADz8AQPA+ACDjvgDgPT0AwJc+AKCTPgCApr4AQJQ9AKAxvQDAeTwA4Jw8AIDmvAAgmL0AICk9AICoPgDgmLwAgK89AMBfPwDA9b0AoK0+AMBovgAgO78AQDI+AIDavQDAEj4A4CO/AMC0vQDAEr8AgPK9AED6vgBAMz4AwIW+AED3PAAAFL8A4E6/AIDQvgDgFDwAQJC+ACCCvgAgGr4AABS7AKBTPgBgYj8AAAa+AKCNvgDgybwAIMC+AEDavQCA6b0AYOe+ACAFPQCAoLwAQAM/AICwPgDgKr8A4IM+AACUPgAAFT8AAOG9AEAoPgCALTwAQCC/AICMPACAJT8AIPY+AECLPQCAWb8AALy+AOD4vgBA+r0AYN8+AEBbvQCADrwAYA69ACCcvgAggL4AAF8/AICePQDg2z4AYOG9AAC/vgAgbT0AAG++AICbvQBg+z0AYPU+AAAGPwAAIz0AgEA+AKAcvQAgCr8AIBM+AACevgAgyz4A4Cy/AGAjvgDgzz4AgAs+AACXvgAgpL4AYE8+AADjvgBAnz0AQDK6AIDgPQBg9T4AQCU+AAA2PwDghj4AIKc+AIB7PwCgeL8AIAa/ACDJPgCAj74AAJc/AECQvgDAzb4AIEo/AKBwPgAgnL0AILc9AAAavgBgvD8A4Gm+AAADvwCgP78AwBC/AABfvgDgPb4AYOK+AMAIPgAA3z4AYKG+AAALPwBA9D0AgIm9ACBnPwCAJr4A4EY/AIC0vgBAlj4AYAG/AMAuPgCAGj8AQCs+AGCqPgBA3T4AYF6+AAAiPwCgAz8AgGM8AOAVPgCgzz4AgJI7ACD/vQCgIL4A4Ke+AMCEPgAADTwA4B89AACvPABAFj8AYPq+AMCZvgDghb4AoAS+AGAtvQAAgD0AABi+AGD1uwCAGL8AABO/AEDhPgDgmj4AQCM/AEBHvQCAizsAYBu+AGA9vgBggj4A4Li+AADSvgCgQL0AwKe+AAA9PgCgw74AYEK+AACovQDgCj8AwCA+AKBaPwBg3L4AwAS/AMADPgCAej4A4O29AGB7PQBAzL0AQBy9AAAJvACA5L0AAA2+AIDfvQAg5b8AIMK8AMCKPgBgJj8AYAe/ACD9vQCglb0AQPW+AIDcvgCAsD0AAB49AEDGvQBgYT4AADC+AOALvQBAGj8AIEq+ACBZvwBAkD4AQMe+AACePgDAjz4AgJm+AODkPgBgp74AgJLAAABPPwDAWj4A4Le9AEDFvADghz4A4D0/AEA0PgAguT0AILe+AMCyPgBAmT0AwI6+ACCBvgCgCj4AYJG/AMDwPQAANb4AgHU+AAASPwBAQz4A4A2/AEAavgBgL74AQCU+AMAWvgAgF78AIAE/AAB5PgCAML8AABA8AKANPgCAkT4AYPi9AAD+PgDAMj4AwDO+AKCBvgDgDz0AYHK+AAASPwBgCL0AIAY+AMB/vwBgEL0AgFG/AKAyPACAIT8AoBS+AICHPQAgLD4AILY+AMDwPgBgOD8AYAS+AOARvAAgOz0AYHK+AGAgvgCg7j0A4Em+AEDVvgCgRr8AYJS/AIDtvgCgOr4AwNQ+AMBFvwDARj8AoE6+AECkvgCA3r4AwJq+AOAnPgAgmL4AQPU9AMAFvwCgiz0AADG9AIB9PgDgvz0AoAq/AGAgPgDAojwAgEu+AAAZvwCg974AwCK/AGCLvwAART4AYJY+AEDsvgCgPr4AANG9AEBTPwCAjb4AYBu+AED3PgCgWT8AwLo9AAAZPwAAYL4AYPg+ACByvwAAjL4AACO+AIAgvwAgoj4AQLg8AICBvgDAHb8A4Ba+AMAIvwBAP78AILc9AMArPQCA3T4AgP2+AACwOwDASj0AgCS/AKCePQCAiL8AYMW9AIB9vgCgET4AIAM/AGCpvAAAgb0AAP2+AKBlPgBgpT4A4Ku+AGDLPgBAnD4AwBw/AICLPQCADj8AoJA+AOBwvQBAPb4AIIC+ACBMPAAg4j0AIMe+ACDRvgCAiz4AoFC/AKA6vgDg4T0AwDC9AGClPgDA1j0AYDg+AMCIPgCAET4AABM/AGCAvACghD0AoDy/ACBsvgBAwj4AQDe/AIBavgBgwrsAwKU7AABSPgAA174A4Ge+AKDruwBAbr4AAFe+AEAhPgCgXDoAoNk9AIDuPAAAOD4AIPq+AGAQPwAA+j4A4KS+AAALvgBAyj4AgFe+AOB2PgBAtj4AoGK/AKB6vgAgO74A4Lm+AIA3vwDA6b0AwBW+AAD3vQCAiz0AgPa+AOAGPwCgaD8A4Li+AKBOPgBgqb0AIDg/AMA6PgAgy7wAQBk+AACbvAAgl74AIF8+AIADvwCAeT4AQI09AECIvgDAAD8AoG09ACAjvQBgPr0AoOE+AKD6PgCg3z4AIBs/AEAFPwDAHj0AgAE/AIA4vgBgmr8AoJS+ACDAPQCALL8AwAM/ACAxvgDABj8AgPO+AKDwPgAAoT4AgAy/AGBtvgBgvL4AgAE8AGAzPQDgFL8AwBY/AMD+vQBghD4A4E69AABgvQAg1b4A4Jy9AIAyPwCg4b4AYIk+AGAkvgAAJb4AgJE+AMD3PgBAMb4AIM4+AOAxvgDgmb4AIIK9AECovgDA3b0AAFk/AIAEPgBAnT4AAPM9AKA+vgDgc70AwJi/ACDhPABgiD4AwAQ+AEBCvwDACL8AwNo+AECHvgCADj0AgAI9AGBcPgDggj4AING+AIDBPgAArz0AIGA+AIDPvgBAdb4AYBg+AABJvgAgB78AwDu+AMA7PAAATz0AIK0+AGC4PgDAx7sAoPo8AIDYvgCAFz4AoCs/AEAbPwDgjz4A4Hu/AMBkPQDgXL4A4IC+AICdOwCA/L0AYB09AODJvgAgRr4AYPc+AGAIPwBAtD4AoPY9AEDxvQDASb4AQIG+AKCCvgCASb4AwJU+ACBWPADAIT4AoJO+ACCnvABAmL4AIG8+ACDePgAAgbwAwGY+AACkPQBAQD8AYNO8AEApvwDgjz0AwGk+AKAbvwDAD74AgKE+AACnvQDgZT4AYI6/AGC5PgCATD8AALW+AKBiPQCg7b0AoMC9AMB7vgCgfT4AwCU/AACAPwBggz4AoMM+AECYvgAgBz4AgIM+ACDMPQDgnz4AwEq+AMDbvgCAyL0AYBi/AOAwPwCAKz8AIPk+AIDiPQAgzr4AwHw7AABjPgAg5z4AQFA+AKD+vgBArr4AQBa/AMAEvgAgdD4AAAS+AEDMPgCA8b4AQCm+AMAPPgAAlb0AYPK+ACARPgAADL8AAKa+ACAPPgCgBT8AoJu9AAAxPgDAYL8AIBA+AIBvvwCAzz4AgAU+AODZPQDgxD4AQMQ7AEBDvgCAAz0AIA8/AGCDvgAg470AIAA+AKD9PADgC78AQLG+AMBoPgBAgD4AgBq/AACcvgDgLL4A4A4+AGB1vgCAaz4AwLw9AOD+vQBAJb4AAC4+AEA2vgAAwj4A4P8+AKAvvgDAhT8A4Ck+AEDxvgDgvz4AoOY+ACAXvgDAhj4AAPI+AGDEPQDAxD0AgH2+AOD4vQBAR78AoGK/AKBQvwCgLT8AYMu9AABTvgCADj4A4M8+AECePgAgwLwAwNY+AADEvgAg1j4A4Ca/AADKvQDAUb4A4AY/AIDnvACgFj4AQJ69ACAgvQCg3b4AINS9AGCAvgCgbj4AoM4+",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2015.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "7(2)",
  "languages": "eng",
  "abstract": "BACKGROUND\nTumour suppressor genes such as TP53, BRCA1 and RAD51 are involved in DNA repair and their malfunctions result in genomic instability and cancer. Wild type (WT) TP53 binds to BRCA1and RAD51 in vivo and in vitro. However, mutated TP53 in tumours can interfere with WT TP53 function. We studied how mutation of TP53 in MDA-MB-468 cell line could affect its binding capacity and interfere with WT TP53 interaction with these DNA repair proteins.\n\n\nMETHODS\nBinding capacity of mutated TP53 in MDA-MB-468 breast cancer cell line to BRCA1 and RAD51 proteins in comparison to WT TP53 in MCF7 cell line was studied by Immunoprecipitation. In vitro studies were performed by GST-WT p53 pull-down assays in these cell lines to assess the interaction of GST-WT p53 with BRCA1 and RAD51 proteins.\n\n\nRESULTS\nThe results showed that mutated TP53 in MDA-MB-468 cells interacted with BRCA1 protein in vivo and did not effect WT TP53 binding to this protein in vitro. The Immunoprecipitation assays revealed that the mutated TP53 did not bind to RAD51 in comparison to WT TP53. However, this mutated protein could not interfere with binding of RAD51 to GST-WT p53 in MDA-MB-468 cell line by in vitro experiment.\n\n\nCONCLUSION\nIt was found that WT TP53 interactions with BRCA1 and RAD51 did not interfere with mutated TP53 in MDA-MB-468 cell line. In addition, RAD51 did not bind to TP53 with R273C mutation in vivo.",
  "pmid": "2.6140185E7",
  "nlm_unique_id": "101511065",
  "issn_linking": "2008-2835",
  "filename": "pubmed24n0835.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Mozhgan Rasti; Tayebeh Azimi",
  "doi": " "
}
{
  "country": "United States",
  "keywords": "TP53 expression; TP53 interaction networks; TP53 mutations; human cancers; synthetic lethality",
  "references": "16199517;20179151;1317462;17944972;9551988;24025726;12606722;12719716;16778087;19270499;21404058;17694537;27278204;17401424;20571075;19332559;20504346;1905840;25354106;26718105;15099937;16110319;19776744;24071852;16489026;20679336;25852826;27397505;15870277;25884692;20962589;26937901;23955083;23098759;27009395;26931810;24577402;24132290;23868073;24071849;23201157;23203871;26753987;9529249;8339248;27213815;24651012;17311302;16798743",
  "pmc": " ",
  "affiliations": "Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.;School of Science, China Pharmaceutical University, Nanjing 211198, China.",
  "medline_ta": "Oncotarget",
  "title": "TP53 mutations, expression and interaction networks in human cancers.",
  "delete": " ",
  "content": "期刊:8(1)\n页数:624_643\n摘要:Although the associations of p53 dysfunction, p53 interaction networks and oncogenesis have been widely explored, a systematic analysis of TP53 mutations and its related interaction networks in various types of human cancers is lacking. Our study explored the associations of TP53 mutations, gene expression, clinical outcomes, and TP53 interaction networks across 33 cancer types using data from The Cancer Genome Atlas (TCGA). We show that TP53 is the most frequently mutated gene in a number of cancers, and its mutations appear to be early events in cancer initiation. We identified genes potentially repressed by p53, and genes whose expression correlates significantly with TP53 expression. These gene products may be especially important nodes in p53 interaction networks in human cancers. This study shows that while TP53-truncating mutations often result in decreased TP53 expression, other non-truncating TP53 mutations result in increased TP53 expression in some cancers. Survival analyses in a number of cancers show that patients with TP53 mutations are more likely to have worse prognoses than TP53-wildtype patients, and that elevated TP53 expression often leads to poor clinical outcomes. We identified a set of candidate synthetic lethal (SL) genes for TP53, and validated some of these SL interactions using data from the Cancer Cell Line Project. These predicted SL genes are promising candidates for experimental validation and the development of personalized therapeutics for patients with TP53-mutated cancers.\n期刊:Oncotarget\n作者:Xiaosheng Wang; Qingrong Sun\n出版日期:2017.0\npmid:2.7880943E7\nmesh_terms:D045744:Cell Line, Tumor; D019295:Computational Biology; D030561:Databases, Nucleic Acid; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D053263:Gene Regulatory Networks; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D009154:Mutation; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009369:Neoplasms; D010641:Phenotype; D011379:Prognosis; D000072020:Synthetic Lethal Mutations; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article\n化学列表:D016159:Tumor Suppressor Protein p53\n关键词:TP53 expression; TP53 interaction networks; TP53 mutations; human cancers; synthetic lethality\ndoi:10.18632/oncotarget.13483\n参考文献:16199517;20179151;1317462;17944972;9551988;24025726;12606722;12719716;16778087;19270499;21404058;17694537;27278204;17401424;20571075;19332559;20504346;1905840;25354106;26718105;15099937;16110319;19776744;24071852;16489026;20679336;25852826;27397505;15870277;25884692;20962589;26937901;23955083;23098759;27009395;26931810;24577402;24132290;23868073;24071849;23201157;23203871;26753987;9529249;8339248;27213815;24651012;17311302;16798743\n语言:eng\n附属机构:Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.;School of Science, China Pharmaceutical University, Nanjing 211198, China.\nmedline_ta:Oncotarget\nnlm_unique_id:101532965\nissn:1949-2553\n国家:United States\ngrant_ids:[]",
  "pages": "624_643",
  "journal": "Oncotarget",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D045744:Cell Line, Tumor; D019295:Computational Biology; D030561:Databases, Nucleic Acid; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D053263:Gene Regulatory Networks; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D009154:Mutation; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009369:Neoplasms; D010641:Phenotype; D011379:Prognosis; D000072020:Synthetic Lethal Mutations; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2017.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "8(1)",
  "languages": "eng",
  "abstract": "Although the associations of p53 dysfunction, p53 interaction networks and oncogenesis have been widely explored, a systematic analysis of TP53 mutations and its related interaction networks in various types of human cancers is lacking. Our study explored the associations of TP53 mutations, gene expression, clinical outcomes, and TP53 interaction networks across 33 cancer types using data from The Cancer Genome Atlas (TCGA). We show that TP53 is the most frequently mutated gene in a number of cancers, and its mutations appear to be early events in cancer initiation. We identified genes potentially repressed by p53, and genes whose expression correlates significantly with TP53 expression. These gene products may be especially important nodes in p53 interaction networks in human cancers. This study shows that while TP53-truncating mutations often result in decreased TP53 expression, other non-truncating TP53 mutations result in increased TP53 expression in some cancers. Survival analyses in a number of cancers show that patients with TP53 mutations are more likely to have worse prognoses than TP53-wildtype patients, and that elevated TP53 expression often leads to poor clinical outcomes. We identified a set of candidate synthetic lethal (SL) genes for TP53, and validated some of these SL interactions using data from the Cancer Cell Line Project. These predicted SL genes are promising candidates for experimental validation and the development of personalized therapeutics for patients with TP53-mutated cancers.",
  "pmid": "2.7880943E7",
  "nlm_unique_id": "101532965",
  "issn_linking": "1949-2553",
  "filename": "pubmed24n0888.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Xiaosheng Wang; Qingrong Sun",
  "doi": "10.18632/oncotarget.13483"
}
{
  "country": "United States",
  "keywords": " ",
  "references": "21984974;9349508;10861635;18199724;8986812;21038427;21115003;11255264;8176018;21900401;10802655;1607418;18503604;12567188;16082224;8676476;16318864;18753241;10501499;1946433;21798893;9399837;11429426;16462765;16721787;15846070;8068178;21316118;19671129;17918207;10719058;8633021;8483937;8387954;18715924;8266092;17403527;8027315;16499995;21798897;1651607;17171684;21245379;9891044;15814626;16537831;20225330;18185530;19129997;11274625;19178978;18729188;12060398;12164929;20658010;15982309;21566457;15230885;18548109;17390072;9276614;1435901;8632898;18986829;16739124;17703418;10549356;1310805;18049450;8825462;7798610;9607760;8151121;18796715;20875869;16678481;9122183;21098702;10712886;17223878;8099841;9137102;18510673;7554506;19165225;8943054;9285684;17079356;18412244;17872517;19577857;20587514;18462472;17195958;17906639;17970074;19212643;19256304;21490616;11114894",
  "pmc": " ",
  "affiliations": "Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.",
  "medline_ta": "PLoS One",
  "title": "Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.",
  "delete": " ",
  "content": "期刊:7(4)\n页数:e34422\n摘要:BACKGROUND\nNon-melanoma skin cancers are one of the most common human malignancies accounting for 2-3% of tumors in the US and represent a significant health burden. Epidemiology studies have implicated Tp53 mutations triggered by UV exposure, and human papilloma virus (HPV) infection to be significant causes of non-melanoma skin cancer. However, the relationship between Tp53 and cutaneous HPV infection is not well understood in skin cancers. In this study we assessed the association of HPV infection and Tp53 polymorphisms and mutations in lesional specimens with squamous cell carcinomas.\n\n\nMETHODS\nWe studied 55 cases of histologically confirmed cutaneous squamous cell carcinoma and 41 controls for the presence of HPV infection and Tp53 genotype (mutations and polymorphism).\n\n\nRESULTS\nWe found an increased number of Tp53 mutations in the squamous cell carcinoma samples compared with perilesional or control samples. There was increased frequency of homozygous Tp53-72R polymorphism in cases with squamous cell carcinomas, while the Tp53-72P allele (Tp53-72R/P and Tp53-72P/P) was more frequent in normal control samples. Carcinoma samples positive for HPV showed a decreased frequency of Tp53 mutations compared to those without HPV infection. In addition, carcinoma samples with a Tp53-72P allele showed an increased incidence of Tp53 mutations in comparison carcinomas samples homozygous for Tp53-72R.\n\n\nCONCLUSIONS\nThese studies suggest there are two separate pathways (HPV infection and Tp53 mutation) leading to cutaneous squamous cell carcinomas stratified by the Tp53 codon-72 polymorphism. The presence of a Tp53-72P allele is protective against cutaneous squamous cell carcinoma, and carcinoma specimens with Tp53-72P are more likely to have Tp53 mutations. In contrast Tp53-72R is a significant risk factor for cutaneous squamous cell carcinoma and is frequently associated with HPV infection instead of Tp53 mutations. Heterozygosity for Tp53-72R/P is protective against squamous cell carcinomas, possibly reflecting a requirement for both HPV infection and Tp53 mutations.\n期刊:PloS one\n作者:Keith R Loeb; Maryam M Asgari; Stephen E Hawes; Qinghua Feng; Joshua E Stern; Mingjun Jiang; Zsolt B Argenyi; Ethel-Michele de Villiers; Nancy B Kiviat\n出版日期:2012.0\npmid:2.2545084E7\nmesh_terms:D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell; D003062:Codon; D004279:DNA, Viral; D005260:Female; D005838:Genotype; D006801:Humans; D009154:Mutation; D027383:Papillomaviridae; D030361:Papillomavirus Infections; D011110:Polymorphism, Genetic; D012867:Skin; D012878:Skin Neoplasms; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't\n化学列表:D003062:Codon; D004279:DNA, Viral; D016159:Tumor Suppressor Protein p53\ndoi:10.1371/journal.pone.0034422\n参考文献:21984974;9349508;10861635;18199724;8986812;21038427;21115003;11255264;8176018;21900401;10802655;1607418;18503604;12567188;16082224;8676476;16318864;18753241;10501499;1946433;21798893;9399837;11429426;16462765;16721787;15846070;8068178;21316118;19671129;17918207;10719058;8633021;8483937;8387954;18715924;8266092;17403527;8027315;16499995;21798897;1651607;17171684;21245379;9891044;15814626;16537831;20225330;18185530;19129997;11274625;19178978;18729188;12060398;12164929;20658010;15982309;21566457;15230885;18548109;17390072;9276614;1435901;8632898;18986829;16739124;17703418;10549356;1310805;18049450;8825462;7798610;9607760;8151121;18796715;20875869;16678481;9122183;21098702;10712886;17223878;8099841;9137102;18510673;7554506;19165225;8943054;9285684;17079356;18412244;17872517;19577857;20587514;18462472;17195958;17906639;17970074;19212643;19256304;21490616;11114894\n语言:eng\n附属机构:Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.\nmedline_ta:PLoS One\nnlm_unique_id:101285081\nissn:1932-6203\n国家:United States\ngrant_ids:[{'grant_id': 'R01 CA084087', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'F32 AR047552', 'grant_acronym': 'AR', 'country': 'United States', 'agency': 'NIAMS NIH HHS'}, {'grant_id': 'K08 ES000382', 'grant_acronym': 'ES', 'country': 'United States', 'agency': 'NIEHS NIH HHS'}, {'grant_id': 'F32 AR47552', 'grant_acronym': 'AR', 'country': 'United States', 'agency': 'NIAMS NIH HHS'}, {'grant_id': 'K08-ES00382', 'grant_acronym': 'ES', 'country': 'United States', 'agency': 'NIEHS NIH HHS'}]",
  "pages": "e34422",
  "journal": "PloS one",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell; D003062:Codon; D004279:DNA, Viral; D005260:Female; D005838:Genotype; D006801:Humans; D009154:Mutation; D027383:Papillomaviridae; D030361:Papillomavirus Infections; D011110:Polymorphism, Genetic; D012867:Skin; D012878:Skin Neoplasms; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D003062:Codon; D004279:DNA, Viral; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[{'grant_id': 'R01 CA084087', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'F32 AR047552', 'grant_acronym': 'AR', 'country': 'United States', 'agency': 'NIAMS NIH HHS'}, {'grant_id': 'K08 ES000382', 'grant_acronym': 'ES', 'country': 'United States', 'agency': 'NIEHS NIH HHS'}, {'grant_id': 'F32 AR47552', 'grant_acronym': 'AR', 'country': 'United States', 'agency': 'NIAMS NIH HHS'}, {'grant_id': 'K08-ES00382', 'grant_acronym': 'ES', 'country': 'United States', 'agency': 'NIEHS NIH HHS'}]",
  "other_id": " ",
  "pubdate": "2012.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't",
  "issue": "7(4)",
  "languages": "eng",
  "abstract": "BACKGROUND\nNon-melanoma skin cancers are one of the most common human malignancies accounting for 2-3% of tumors in the US and represent a significant health burden. Epidemiology studies have implicated Tp53 mutations triggered by UV exposure, and human papilloma virus (HPV) infection to be significant causes of non-melanoma skin cancer. However, the relationship between Tp53 and cutaneous HPV infection is not well understood in skin cancers. In this study we assessed the association of HPV infection and Tp53 polymorphisms and mutations in lesional specimens with squamous cell carcinomas.\n\n\nMETHODS\nWe studied 55 cases of histologically confirmed cutaneous squamous cell carcinoma and 41 controls for the presence of HPV infection and Tp53 genotype (mutations and polymorphism).\n\n\nRESULTS\nWe found an increased number of Tp53 mutations in the squamous cell carcinoma samples compared with perilesional or control samples. There was increased frequency of homozygous Tp53-72R polymorphism in cases with squamous cell carcinomas, while the Tp53-72P allele (Tp53-72R/P and Tp53-72P/P) was more frequent in normal control samples. Carcinoma samples positive for HPV showed a decreased frequency of Tp53 mutations compared to those without HPV infection. In addition, carcinoma samples with a Tp53-72P allele showed an increased incidence of Tp53 mutations in comparison carcinomas samples homozygous for Tp53-72R.\n\n\nCONCLUSIONS\nThese studies suggest there are two separate pathways (HPV infection and Tp53 mutation) leading to cutaneous squamous cell carcinomas stratified by the Tp53 codon-72 polymorphism. The presence of a Tp53-72P allele is protective against cutaneous squamous cell carcinoma, and carcinoma specimens with Tp53-72P are more likely to have Tp53 mutations. In contrast Tp53-72R is a significant risk factor for cutaneous squamous cell carcinoma and is frequently associated with HPV infection instead of Tp53 mutations. Heterozygosity for Tp53-72R/P is protective against squamous cell carcinomas, possibly reflecting a requirement for both HPV infection and Tp53 mutations.",
  "pmid": "2.2545084E7",
  "nlm_unique_id": "101285081",
  "issn_linking": "1932-6203",
  "filename": "pubmed24n0724.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Keith R Loeb; Maryam M Asgari; Stephen E Hawes; Qinghua Feng; Joshua E Stern; Mingjun Jiang; Zsolt B Argenyi; Ethel-Michele de Villiers; Nancy B Kiviat",
  "doi": "10.1371/journal.pone.0034422"
}
{
  "country": "United States",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA.",
  "medline_ta": "Clin Cancer Res",
  "title": "Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.",
  "delete": " ",
  "content": "期刊:13(22 Pt 1)\n页数:6568_78\n摘要:PURPOSE\nTo determine the nature and potential pharmacologic reversibility of deficient TP53 expression and function in head and neck squamous cell carcinomas (HNSCC) with wild-type TP53, previously associated with decreased sensitivity to cisplatin therapy.\n\n\nEXPERIMENTAL DESIGN\nTP53 genotype, mRNA and protein expression, TP53-induced p21 expression, and TP53 DNA-binding and reporter gene function were determined in a panel of nine previously characterized HNSCC cell lines from the University of Michigan squamous cell carcinoma (UM-SCC) series. The genotoxic drug doxorubicin and the anti-inflammatory and antimalarial drug quinacrine, previously identified as inducers of TP53, were used to examine the nature and potential reversibility of deficient TP53 expression and function. The specific role of inducible TP53 on function and cellular proliferation was confirmed using selective TP53 inhibitor pifithrin-alpha or short hairpin RNA knockdown. The capability of quinacrine to sensitize HNSCC to the cytotoxic effects of cisplatin was assessed.\n\n\nRESULTS\nUM-SCC cell lines with wild-type TP53 genotype underexpressed TP53 mRNA and protein when compared with normal human keratinocytes or UM-SCC with mutant TP53. Although doxorubicin failed to induce TP53 expression or functional activity, quinacrine induced TP53 mRNA and protein expression, increased TP53 reporter activity and p21 protein expression, and induced growth inhibition in these wild-type TP53 cell lines. Quinacrine-induced TP53 reporter activity and growth suppression were attenuated by pifithrin-alpha and TP53 short hairpin RNA knockdown. Furthermore, quinacrine sensitized UM-SCC to cisplatin in vitro.\n\n\nCONCLUSIONS\nDeficient TP53 mRNA and protein expression underlies decreased function in a subset of HNSCC with wild-type TP53 and can be restored together with cisplatin sensitization by quinacrine.\n期刊:Clinical cancer research : an official journal of the American Association for Cancer Research\n作者:Jay Friedman; Liesl Nottingham; Praveen Duggal; Francisco G Pernas; Bin Yan; Xin Ping Yang; Zhong Chen; Carter Van Waes\n出版日期:2007.0\npmid:1.8006756E7\nmesh_terms:D000970:Antineoplastic Agents; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin; D050759:Cyclin-Dependent Kinase Inhibitor p21; D019008:Drug Resistance, Neoplasm; D006258:Head and Neck Neoplasms; D006801:Humans; D011796:Quinacrine; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D052060:Research Support, N.I.H., Intramural; D013487:Research Support, U.S. Gov't, P.H.S.\n化学列表:D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; D011796:Quinacrine; D002945:Cisplatin\ndoi:10.1158/1078-0432.CCR-07-1591\n语言:eng\n附属机构:Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA.\nmedline_ta:Clin Cancer Res\nnlm_unique_id:9502500\nissn:1078-0432\n国家:United States\ngrant_ids:[{'grant_id': 'DC 00016', 'grant_acronym': 'DC', 'country': 'United States', 'agency': 'NIDCD NIH HHS'}, {'grant_id': '', 'grant_acronym': '', 'country': 'United States', 'agency': 'Intramural NIH HHS'}]",
  "pages": "6568_78",
  "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000970:Antineoplastic Agents; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin; D050759:Cyclin-Dependent Kinase Inhibitor p21; D019008:Drug Resistance, Neoplasm; D006258:Head and Neck Neoplasms; D006801:Humans; D011796:Quinacrine; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; D011796:Quinacrine; D002945:Cisplatin",
  "grant_ids": "[{'grant_id': 'DC 00016', 'grant_acronym': 'DC', 'country': 'United States', 'agency': 'NIDCD NIH HHS'}, {'grant_id': '', 'grant_acronym': '', 'country': 'United States', 'agency': 'Intramural NIH HHS'}]",
  "other_id": " ",
  "pubdate": "2007.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D052060:Research Support, N.I.H., Intramural; D013487:Research Support, U.S. Gov't, P.H.S.",
  "issue": "13(22 Pt 1)",
  "languages": "eng",
  "abstract": "PURPOSE\nTo determine the nature and potential pharmacologic reversibility of deficient TP53 expression and function in head and neck squamous cell carcinomas (HNSCC) with wild-type TP53, previously associated with decreased sensitivity to cisplatin therapy.\n\n\nEXPERIMENTAL DESIGN\nTP53 genotype, mRNA and protein expression, TP53-induced p21 expression, and TP53 DNA-binding and reporter gene function were determined in a panel of nine previously characterized HNSCC cell lines from the University of Michigan squamous cell carcinoma (UM-SCC) series. The genotoxic drug doxorubicin and the anti-inflammatory and antimalarial drug quinacrine, previously identified as inducers of TP53, were used to examine the nature and potential reversibility of deficient TP53 expression and function. The specific role of inducible TP53 on function and cellular proliferation was confirmed using selective TP53 inhibitor pifithrin-alpha or short hairpin RNA knockdown. The capability of quinacrine to sensitize HNSCC to the cytotoxic effects of cisplatin was assessed.\n\n\nRESULTS\nUM-SCC cell lines with wild-type TP53 genotype underexpressed TP53 mRNA and protein when compared with normal human keratinocytes or UM-SCC with mutant TP53. Although doxorubicin failed to induce TP53 expression or functional activity, quinacrine induced TP53 mRNA and protein expression, increased TP53 reporter activity and p21 protein expression, and induced growth inhibition in these wild-type TP53 cell lines. Quinacrine-induced TP53 reporter activity and growth suppression were attenuated by pifithrin-alpha and TP53 short hairpin RNA knockdown. Furthermore, quinacrine sensitized UM-SCC to cisplatin in vitro.\n\n\nCONCLUSIONS\nDeficient TP53 mRNA and protein expression underlies decreased function in a subset of HNSCC with wild-type TP53 and can be restored together with cisplatin sensitization by quinacrine.",
  "pmid": "1.8006756E7",
  "nlm_unique_id": "9502500",
  "issn_linking": "1078-0432",
  "filename": "pubmed24n0584.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Jay Friedman; Liesl Nottingham; Praveen Duggal; Francisco G Pernas; Bin Yan; Xin Ping Yang; Zhong Chen; Carter Van Waes",
  "doi": "10.1158/1078-0432.CCR-07-1591"
}
{
  "country": "United States",
  "keywords": "DINO; DINOL; DNA damage; E6-AP; TP53; UBE3A; cellular transformation; cervical cancer; chemoresistance; human papillomaviruses; lncRNA; metabolism",
  "references": "16129685;25631445;17060450;1648218;8840974;21067583;32326624;30875378;24854633;26196323;21765936;29427865;17251932;8221889;21376230;9819415;25478571;11602624;28622525;21285512;26151636;31693922;29440484;11158620;26014966;28112728;12460929;1535557;15047823;27062928;12502868;26789255;24190973;16793544;29170536;32269126;15838523;14967490;28886379;29866007;30991008;26858935;1614522;27216701;29593331;25383876;12499281;27668660;29440569;29242642;18657909;2175676;21048526;26241675;17804642;8380895;28442631;9153396;19617533;25062098;10673500;30598450;12403821;28868264;32203529;27990773;7686617;17251933;17182091;9060648;28270530;9153395;8843193;11900253;25435953;31223287;9053858;27070700;15866171;24598047",
  "pmc": " ",
  "affiliations": "Biochemistry Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.;Biochemistry Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA karl.munger@tufts.edu.",
  "medline_ta": "mBio",
  "title": "Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.",
  "delete": " ",
  "content": "期刊:11(3)\n摘要:Tumor cells overcome the cytostatic and cytotoxic restraints of TP53 tumor suppressor signaling through a variety of mechanisms. High-risk human papillomavirus (HPV)-positive tumor cells retain wild-type TP53 because the HPV E6/UBE3A ubiquitin ligase complex targets TP53 for proteasomal degradation. While restoration of TP53 in tumor cells holds great promise for cancer therapy, attempts to functionally restore the dormant TP53 tumor suppressor in HPV-positive cancer cells by inhibiting the HPV E6/UBE3A ubiquitin ligase complex have not yet been successful. The damage-induced long noncoding RNA, DINO (DINOL), is a TP53 transcriptional target that has been reported to bind to and stabilize TP53, thereby amplifying TP53 signaling. We show that HPV-positive cervical carcinoma cells contain low levels of DINO because of HPV E6/UBE3A-mediated TP53 degradation. Acute DINO expression overrides HPV16 E6/UBE3A-mediated TP53 degradation, causing TP53 stabilization and increased expression of TP53 transcriptional target genes. This causes a marked sensitization to chemotherapy agents and renders cells vulnerable to metabolic stress. Acute DINO expression in HPV-positive cervical cancer cells induces hallmarks of DNA damage response signaling, and TP53 activation involves ATM/CHK2 signaling. DINO upregulation in response to DNA damage is independent of ATM/CHK2 and can occur in cancer cells that express mutant TP53.IMPORTANCE Functional restoration of the TP53 tumor suppressor holds great promise for anticancer therapy. Current strategies are focused on modulating TP53 regulatory proteins. Long noncoding RNAs (lncRNAs) have emerged as important regulators of TP53 as well as modulators of downstream tumor-suppressive transcriptional responses. Unlike many other cancer types, human papillomavirus (HPV)-positive cancer cells retain wild-type TP53 that is rendered dysfunctional by the viral E6 protein. We show that acute expression of the damage-induced long noncoding RNA, DINO, a known TP53 transcriptional target and functional modulator, causes TP53 reactivation in HPV-positive cervical cancer cells. This causes increased vulnerability to standard chemotherapeutics as well as biguanide compounds that cause metabolic stress. Hence, strategies that target DINO may be useful for restoring TP53 tumor suppressor activity in HPV-positive cancers and other tumor types that retain wild-type TP53.\n期刊:mBio\n作者:Surendra Sharma; Karl Munger\n出版日期:2020.0\npmid:3.2546626E7\nmesh_terms:D064007:Ataxia Telangiectasia Mutated Proteins; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002584:Cervix Uteri; D064447:Checkpoint Kinase 2; D004249:DNA Damage; D005260:Female; D006367:HeLa Cells; D052162:Human papillomavirus 16; D006801:Humans; D015603:Keratinocytes; D009856:Oncogene Proteins, Viral; D062085:RNA, Long Noncoding; D012097:Repressor Proteins; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms\n出版物类型:D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't\n化学列表:C000619299:DINOL lncRNA, human; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D062085:RNA, Long Noncoding; D012097:Repressor Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D064447:Checkpoint Kinase 2; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C578634:CHEK2 protein, human\n关键词:DINO; DINOL; DNA damage; E6-AP; TP53; UBE3A; cellular transformation; cervical cancer; chemoresistance; human papillomaviruses; lncRNA; metabolism\ndoi:10.1128/mBio.01190-20\n参考文献:16129685;25631445;17060450;1648218;8840974;21067583;32326624;30875378;24854633;26196323;21765936;29427865;17251932;8221889;21376230;9819415;25478571;11602624;28622525;21285512;26151636;31693922;29440484;11158620;26014966;28112728;12460929;1535557;15047823;27062928;12502868;26789255;24190973;16793544;29170536;32269126;15838523;14967490;28886379;29866007;30991008;26858935;1614522;27216701;29593331;25383876;12499281;27668660;29440569;29242642;18657909;2175676;21048526;26241675;17804642;8380895;28442631;9153396;19617533;25062098;10673500;30598450;12403821;28868264;32203529;27990773;7686617;17251933;17182091;9060648;28270530;9153395;8843193;11900253;25435953;31223287;9053858;27070700;15866171;24598047\n语言:eng\n附属机构:Biochemistry Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.;Biochemistry Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA karl.munger@tufts.edu.\nmedline_ta:mBio\nnlm_unique_id:101519231\n国家:United States\ngrant_ids:[{'grant_id': 'R01 CA066980', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'R01 CA228543', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'R21 AI147176', 'grant_acronym': 'AI', 'country': 'United States', 'agency': 'NIAID NIH HHS'}]",
  "pages": " ",
  "journal": "mBio",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D064007:Ataxia Telangiectasia Mutated Proteins; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002584:Cervix Uteri; D064447:Checkpoint Kinase 2; D004249:DNA Damage; D005260:Female; D006367:HeLa Cells; D052162:Human papillomavirus 16; D006801:Humans; D015603:Keratinocytes; D009856:Oncogene Proteins, Viral; D062085:RNA, Long Noncoding; D012097:Repressor Proteins; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms",
  "chemical_list": "C000619299:DINOL lncRNA, human; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D062085:RNA, Long Noncoding; D012097:Repressor Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D064447:Checkpoint Kinase 2; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C578634:CHEK2 protein, human",
  "grant_ids": "[{'grant_id': 'R01 CA066980', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'R01 CA228543', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'R21 AI147176', 'grant_acronym': 'AI', 'country': 'United States', 'agency': 'NIAID NIH HHS'}]",
  "other_id": " ",
  "pubdate": "2020.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't",
  "issue": "11(3)",
  "languages": "eng",
  "abstract": "Tumor cells overcome the cytostatic and cytotoxic restraints of TP53 tumor suppressor signaling through a variety of mechanisms. High-risk human papillomavirus (HPV)-positive tumor cells retain wild-type TP53 because the HPV E6/UBE3A ubiquitin ligase complex targets TP53 for proteasomal degradation. While restoration of TP53 in tumor cells holds great promise for cancer therapy, attempts to functionally restore the dormant TP53 tumor suppressor in HPV-positive cancer cells by inhibiting the HPV E6/UBE3A ubiquitin ligase complex have not yet been successful. The damage-induced long noncoding RNA, DINO (DINOL), is a TP53 transcriptional target that has been reported to bind to and stabilize TP53, thereby amplifying TP53 signaling. We show that HPV-positive cervical carcinoma cells contain low levels of DINO because of HPV E6/UBE3A-mediated TP53 degradation. Acute DINO expression overrides HPV16 E6/UBE3A-mediated TP53 degradation, causing TP53 stabilization and increased expression of TP53 transcriptional target genes. This causes a marked sensitization to chemotherapy agents and renders cells vulnerable to metabolic stress. Acute DINO expression in HPV-positive cervical cancer cells induces hallmarks of DNA damage response signaling, and TP53 activation involves ATM/CHK2 signaling. DINO upregulation in response to DNA damage is independent of ATM/CHK2 and can occur in cancer cells that express mutant TP53.IMPORTANCE Functional restoration of the TP53 tumor suppressor holds great promise for anticancer therapy. Current strategies are focused on modulating TP53 regulatory proteins. Long noncoding RNAs (lncRNAs) have emerged as important regulators of TP53 as well as modulators of downstream tumor-suppressive transcriptional responses. Unlike many other cancer types, human papillomavirus (HPV)-positive cancer cells retain wild-type TP53 that is rendered dysfunctional by the viral E6 protein. We show that acute expression of the damage-induced long noncoding RNA, DINO, a known TP53 transcriptional target and functional modulator, causes TP53 reactivation in HPV-positive cervical cancer cells. This causes increased vulnerability to standard chemotherapeutics as well as biguanide compounds that cause metabolic stress. Hence, strategies that target DINO may be useful for restoring TP53 tumor suppressor activity in HPV-positive cancers and other tumor types that retain wild-type TP53.",
  "pmid": "3.2546626E7",
  "nlm_unique_id": "101519231",
  "issn_linking": " ",
  "filename": "pubmed24n1037.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Surendra Sharma; Karl Munger",
  "doi": "10.1128/mBio.01190-20"
}
{
  "country": "United States",
  "keywords": " ",
  "references": "17907599;21555372;8586466;8977030;21156036;19269895;21478269;12543796;11259619;16025287;11304577;2664471;9199206;10676641;15989956;19100509;14583454;15466178;11804744;19544111;20129251;19671129;16059649;21572037;1933891;15977639;10850866;9707425;3004941;8892589;1535557;15450401;8057151;12579314;8293182;19737147;24375041;19755387;22378045;16855375;8441640;9815715;11846609;3030531;18772890;19141386;10667596;17214319;11801559;19550145;19228619;7841034;19435942;19216795;12592393;17715673;11748635;20593219",
  "pmc": " ",
  "affiliations": "1 Department of Tumor Pathology, Medical University of Lodz , Poland .",
  "medline_ta": "DNA Cell Biol",
  "title": "TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.",
  "delete": " ",
  "content": "期刊:33(4)\n页数:217_26\n摘要:Reduced expression of TP53 by promoter methylation has been reported in several neoplasms. It remains unclear whether TP53 promoter methylation is associated with reduced transcriptional and protein expression in glioblastoma (GB). The aim of our work was to study the impact of TP53 methylation and mutations on TP53 mRNA level and protein expression in 42 molecularly characterized primary GB tumors. We also evaluate the impact of all molecular alterations on the overall patient survival. The frequency of TP53 promoter methylation was found in 21.4%. To the best of our knowledge, this is the first report showing such high frequency of TP53 promoter methylation in primary GB. There was no relation between TP53 promoter methylation and TP53 mRNA level (p=0.5722) and between TP53 promoter methylation and TP53 protein expression (p=0.2045). No significant associations were found between TP53 mRNA expression and mutation of TP53 gene (p=0.9076). However, significant association between TP53 mutation and TP53 protein expression was found (p=0.0016). Our data suggest that in primary GB TP53 promoter methylation does not play a role in silencing of TP53 transcriptional and protein expression and is probably regulated by other genetic and epigenetic mechanisms associated with genes involved in the TP53 pathway.\n期刊:DNA and cell biology\n作者:Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik\n出版日期:2014.0\npmid:2.4506545E7\nmesh_terms:D001483:Base Sequence; D019175:DNA Methylation; D017931:DNA Primers; D044127:Epigenesis, Genetic; D066246:ErbB Receptors; D005260:Female; D005909:Glioblastoma; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011044:Poland; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D018709:Statistics, Nonparametric; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D017931:DNA Primers; D012333:RNA, Messenger; C000606290:SOD1 protein, human; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D066246:ErbB Receptors\ndoi:10.1089/dna.2013.2201\n参考文献:17907599;21555372;8586466;8977030;21156036;19269895;21478269;12543796;11259619;16025287;11304577;2664471;9199206;10676641;15989956;19100509;14583454;15466178;11804744;19544111;20129251;19671129;16059649;21572037;1933891;15977639;10850866;9707425;3004941;8892589;1535557;15450401;8057151;12579314;8293182;19737147;24375041;19755387;22378045;16855375;8441640;9815715;11846609;3030531;18772890;19141386;10667596;17214319;11801559;19550145;19228619;7841034;19435942;19216795;12592393;17715673;11748635;20593219\n语言:eng\n附属机构:1 Department of Tumor Pathology, Medical University of Lodz , Poland .\nmedline_ta:DNA Cell Biol\nnlm_unique_id:9004522\nissn:1044-5498\n国家:United States\ngrant_ids:[]",
  "pages": "217_26",
  "journal": "DNA and cell biology",
  "_inference.semantic_vector": "AMChvgCgD78AIJO+AKAfvQCgtDwA4Ou8AODivgAg2L0A4D89AKBwvwAgb74AIB28AODFPQAgZT4AIFG/AIB0PwCAOr4AgBq8AAAmvQBAWT4AYNc+AOCCPACgAT8AoJE9AEDLPgCArL4AQN4+ACA1vQDgsz0A4Bo/AECRuwAA/D0AgOw+AGBjPgAgMbwAQLk+AECQPQBgJT8AwC4/AODOPgDA6T4AwKS9ACAIvgCA4j4AYGw+AGD9vgDAcsAA4IA+ACChvADgL78AYNq+AAAhPgDAGT8AILw+AKCVPgDAEz0AYLC8ACDwvQCAB70AQAa/AECZPgCAOz4AYPC9AEA2PQBgCD8AoJO8ACA/PgDACj4AYC2/AKBGvgCAbj4AYG4+ACAZvwAgmL0AwAM/ACBGPQDgb74AgLo+AKCQPwAA8D4A4J+9AKDZvgAAK74AYK4+ACDKvQDgq74AIKY+AEBZvgBAjT4AwLW9AKDWPQCAGr4AIHQ+AEBJPgBALb4AoDg+AAB/PwAgEb4AgA69AADMvgDAIL8AgFg+AEAbvgBg+r0AQBO/AIBlvADAVL4AYAg8AICSvgCAGD4AIJy+AMCNPgDgu74AQFu+AMAqPgBg2j4AQM++AEAuvwCgJT4AYI4+ACBjvgDARj8AwOO9AGBivgAAX74A4BG/AODwPQAgRr4AIMG+AIAyvgBgjz0A4Ku9AKCyPgAA2r4AQHe+ACAIPgCA+T4A4BG+ACCjPABgBT0A4Oc9AICevgCATz0AYPa+AKAQPgDAVb8AAII9AMCNvgCAyb4AoOI+AEBNvgDgjj0AwA8+AGDOvgBAfr4AQBE/AODyPgAAYT4AoJy+AIDfvgDgST4AIBy/AGCkvADAGj4AAOw+AABjPgBgqD0AoAM+AKDJvACgur4AQNk9AADAvgAAqj0A4CW/AGC4vgAA4z4AYB6+AMAovgCgTr4AANW9ACACvwDA7T4AoBi/AICrPgAABz8AIKE+AED5PgBgpD4AgNo9AIDCPgBgWb8AIBK/AABhPgCAwz0AAFg/AMBZPQCgtz4AICk/AGDwPgDApj4AwFS+AIDSPQCgXz8AIBK+AGB4vgBgIL8AwJC+AKA+vgBgkb4AIKO+AMDAPQBg6jwAIGm9AODOPgCApT4A4OG9AGBQPwBgCD4AAC8/AICDvgDAA7wAwK6+AMAPPgDAC7wAIDk+AICouQBALz0AoAy/AMD5PgCggr0AgCW9AMAfvgBgAj8A4Hs9AKAQPgDgvTwAYAi+AAB9PQCAlz4AAIC9AMDDPAAAzD4A4Ly+AMBNvgBAVL4AYBM+AEAnPQCA970AgAy7AEBQPQAACb8AIAu/AABevQAgpD0AQAQ+AMApPQBA2r4AgE2+AEC+vADggb4AAKs+AAC1OwDgS74AgJC+ACBtvgBgqb4A4EG/AGDvvQDAGT8AIAW/AMAHPwAglr4A4HC/AKCcPQCg0L4AIGC9AMC0PQDAHb8AIMk+AIBivgBg5L4AABO9AICHvgBAv78AoAQ+AEAAPwAANT0AYPi+ACCzvgBAR74AQIe+AIDpvgAgJ70AIJu+AICfPgCAqT4AgM6+AGA6vgBAJD8AoAc+AIBvvwBgXT4AYBY+AKAXPgAAET8A4IS+AEDrvQBgrD4AoJ7AAEA+PwBAijwAgGi+AMDXPgCgvz4AgKo+AGCqPgAgyT0AIHe9AGBSvgDgBrwAQGu9AKCZPQAgmL0A4Ji+AEC7PQCAMr0AALY+AKCCPABg9T4AYDm/AMA+PgCAST4AgI49AACYvADAZ78AoFm+AOAivwAAT78AoIo+AACYvADAGD4AYCa+AAADPwCg8j4AIFO+ACB6PQBgqb4A4AC/AACDPgDgxr0AoBO+AEAevwBgRj0AgBe/AGAJvgCgST8AABe/AGATPgAAWb4AIKg+AEAsPwDgRD4A4PI9AGCGvgAAEz4AoO2+AGADvgAAcTsAYJ69AACaPQCA674AoJ6/AMDkvgAAIb4A4NE+AIDZvgAgBT8AgNM9AOC6vQCAQz4AQNq+ACCGPQDgi74AwMC8AKA4PQCgmb4AgJy+AKCiPgDgNb0AAOq9AMBJPgAA9D4AQJ28AOBRvgDgP78AwIG9AGAFvwAgB70AIFg/AMDQvgBAU78AAMk9AGAmPwBApL4AwAO+AGDDPgDACD8AgI68ACCKPwCgZb4AYDs+AEArvgDgID0AQKM8AECfvgDgXboAwMk+AKDQvgAg1LwAYD0+AIC7vgCAlb4A4Kk7AKBrvgAAHj8A4CO/AECiPgCgob4AoPe+AKC+PgCAar8AoAs/AEAWvwBgUbsAAAw/ACAnPgCAq74AwDm+AMDxvABg3TwAoJC+AGCuvgAAcD4AwCU/AOBuPQBgPz4AYMq7AEChPgBgvT0AoOi9AMALPwCgGzwA4EG9AEC/vgAgGz8AwHC+AOAuvQDAjT4A4Js+AABWvgAg3b0AwCU9AOAoPgAAlz4A4Jy9AAArPgCA4b0AoJq+AGA4PgAAmz0AYMi+AODLvgCA970AQFE+AEBNPgAgDz4AAOK+AGBrvgBArL4AoCS+ACBnPgDAET4AoAE9ACBsPgDgHj4AIJy+ACDCPgBAVT4A4D2/AOBovgAgAL4AoDa+AKB4PgDADD8AYFi+ACAEvgBAT74AIMG+ACAJvwCgXb4AAM88AADOvgCAuT4AYEC/ACCtPgAAhz8AoIi9AACevgDglT4AgNY9AGAoPwDAPb4AwGU8AIBFuwDgP74AwKI+ACCzvgAAyz0AwB++AGAXvwAgEz8AAEi+AICSPgCA9r4AgHE+AMC2PgCAxr0AgLs/AIAFPwBgtz4AYKA9AEAmvwBA3L4AoM29AMDrPQBgyD0AII49AID2vgDg2z4A4CW+AODcPQCgtT4AwOC+ACBdvgCA2b4AQHM8AECQvAAgPL4AAAY/AAAOPQBAGz8AQFm8AIDlvQCgSD4AwOs+ACBHPwCgrL0AIKw+AKCGvQBgSL4AYIQ+AADrPgBgTD4AwAM9ACCDvQCAJr8AgAc+AADhvgBA1T0AYKG9ACD6vgAg/j0AQJg9AEBavQDA574AQCG/AKAMvQCAkz4AoJA+AEBNvwCgT78AoIo/AKCRvgAAxj4AgM8+AABFPgCAAz4AQDC/AGDQPQAgojsAAAY/AEAdvwDAkr4AAEC+AMBBvwCAXL4AgIi+AAAbPQCghL0A4D0+AEBfvgAABb4AQIs9AKDWvgCABD8AAFk/ACD2PgBATbwAgA2/AOBPPgDAY74A4Dq+AEAZPgAgsb4AIDO+AODQvQBAHj4AIJI9AAABPgBAIz4A4Eg+AAAdPgCgmL4AYBI+ACDBvgBgID8AgK8+AIAFvgCgCj8A4LW+AKAhPwCglT4AYNw+AOC5vgDAMr4AoJ68AGBuPgCgqz0AgLM+ACDdPQBAVj4AABE+AECnPQCAvb0AQNW+AGDdvACACz8AAOW+AGBxPgCgZj8AgO8+AMBavgDADT8AwOu9AIAbvgAA1T0A4A4/AMCzPgAACT8AoP29AOAYPgCgx74AQEe8AGAWvAAAoT4AwFk9AIAmvgCAr7wA4L++AKDoPgAg1z4AoIU+AOBCvgAA9DwA4EQ+AGDlPQDgfj8AoCC/AECjvgCg0b4AoNe9ACAVvgCAgzwAYLC+AIBZvQDAX74AIH++AGDyPgCA/D0AIDU8AKAdPgCgD78AIMe+AABzvgCAmrwAwHO9AEDGvQAgCb8AQNQ+AKBMvwCASj4AoLK9ACDgPQBADT4AwLc+AACuvgAgnD0AQEg+AECOPgBgKDsAwI0+AICZPgAgC74A4HE+AMDHvgAA2b4AgCm/ACAZPgAAhT4AoHw+AACBvQDAqj4AoBU/AEAAvwAARj4AYL4+AOCKvgDgIz8AgJc9AGCGvgAAAT8AAM8+AABcvgCgzD0AIBY/AMCovQCgmT4AING9AABMvgBAjLoAgCa+ACDCvQDAOr8AIOS+AMA9vgCgHz8AoDE9AECXvQDgHD4AYAi/AACoPgBgCb4AwO0+AODUvgDACj8AgCC/AIBUvwDA1z0AQNA+AEABPgDAk70AQEQ+AGDLPgAgir8AAJ++AGDUvgCA2j4AoIQ+",
  "mesh_terms": "D001483:Base Sequence; D019175:DNA Methylation; D017931:DNA Primers; D044127:Epigenesis, Genetic; D066246:ErbB Receptors; D005260:Female; D005909:Glioblastoma; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011044:Poland; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D018709:Statistics, Nonparametric; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D017931:DNA Primers; D012333:RNA, Messenger; C000606290:SOD1 protein, human; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D066246:ErbB Receptors",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2014.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "33(4)",
  "languages": "eng",
  "abstract": "Reduced expression of TP53 by promoter methylation has been reported in several neoplasms. It remains unclear whether TP53 promoter methylation is associated with reduced transcriptional and protein expression in glioblastoma (GB). The aim of our work was to study the impact of TP53 methylation and mutations on TP53 mRNA level and protein expression in 42 molecularly characterized primary GB tumors. We also evaluate the impact of all molecular alterations on the overall patient survival. The frequency of TP53 promoter methylation was found in 21.4%. To the best of our knowledge, this is the first report showing such high frequency of TP53 promoter methylation in primary GB. There was no relation between TP53 promoter methylation and TP53 mRNA level (p=0.5722) and between TP53 promoter methylation and TP53 protein expression (p=0.2045). No significant associations were found between TP53 mRNA expression and mutation of TP53 gene (p=0.9076). However, significant association between TP53 mutation and TP53 protein expression was found (p=0.0016). Our data suggest that in primary GB TP53 promoter methylation does not play a role in silencing of TP53 transcriptional and protein expression and is probably regulated by other genetic and epigenetic mechanisms associated with genes involved in the TP53 pathway.",
  "pmid": "2.4506545E7",
  "nlm_unique_id": "9004522",
  "issn_linking": "1044-5498",
  "filename": "pubmed24n0784.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik",
  "doi": "10.1089/dna.2013.2201"
}
{
  "country": "England",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Group of Molecular Carcinogenesis, International Agency for Research on Cancer, 150 cours A. Thomas, Lyon Cedex 08, France.",
  "medline_ta": "J Med Genet",
  "title": "TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.",
  "delete": " ",
  "content": "期刊:46(11)\n页数:766_72\n摘要:BACKGROUND\nLi-Fraumeni and Li-Fraumeni-like syndromes (LFS/LFL), characterised by the development of multiple early onset cancers with heterogeneous tumour patterns, are associated with germline TP53 mutations. Polymorphisms in the TP53 pathway (TP53 PEX4 at codon 72, rs1042522; MDM2 SNP309, rs2279744) have modifier effects on germline TP53 mutations that may account for the individual and familial diversity of tumour patterns.\n\n\nMETHODS AND RESULTS\nFour polymorphisms were analysed in a series of 135 Brazilian LFS/LFL cancer patients (32 TP53 mutation carriers and 103 wild-type subjects). We report for the first time that another polymorphism in the TP53 gene, TP53 PIN3 (rs17878362), has a strong modifier effect on germline TP53 mutations. This polymorphism, which consists of a 16 bp duplication in intron 3 (A1, non-duplicated allele; A2, duplicated allele), is associated with a difference of 19.0 years in the mean age at the first diagnosis in TP53 mutation carriers (n = 25, A1A1: 28.0 years; n = 7, A1A2: 47.0 years; p = 0.01). In addition, cancer occurrence before the age of 35 years is exclusively observed in A1A1 homozygotes. In this series, the effect of TP53 PEX4 and MDM2 SNP309 on age at diagnosis was similar to the one reported in other series and was smaller than the one of TP53 PIN3 (TP53 PIN3: difference of 19.0 years; TP53 PEX4: 8.3 years; MDM2 SNP309: 12.5 years).\n\n\nCONCLUSION\nThese results suggest that TP53 PIN3 is another polymorphism in the TP53 pathway that may have a modifier effect on germline TP53 mutations and may contribute to the phenotypic diversity of germline TP53 mutations associated with LFS/LFL patients.\n期刊:Journal of medical genetics\n作者:V Marcel; E I Palmero; P Falagan-Lotsch; G Martel-Planche; P Ashton-Prolla; M Olivier; R R Brentani; P Hainaut; M I Achatz\n出版日期:2009.0\npmid:1.9542078E7\nmesh_terms:D000328:Adult; D017668:Age of Onset; D001938:Brazil; D016009:Chi-Square Distribution; D004252:DNA Mutational Analysis; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D016864:Li-Fraumeni Syndrome; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D051736:Proto-Oncogene Proteins c-mdm2; D018709:Statistics, Nonparametric; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2\ndoi:10.1136/jmg.2009.066704\n语言:eng\n附属机构:Group of Molecular Carcinogenesis, International Agency for Research on Cancer, 150 cours A. Thomas, Lyon Cedex 08, France.\nmedline_ta:J Med Genet\nnlm_unique_id:2985087R\nissn:0022-2593\n国家:England\ngrant_ids:[]",
  "pages": "766_72",
  "journal": "Journal of medical genetics",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000328:Adult; D017668:Age of Onset; D001938:Brazil; D016009:Chi-Square Distribution; D004252:DNA Mutational Analysis; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D016864:Li-Fraumeni Syndrome; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D051736:Proto-Oncogene Proteins c-mdm2; D018709:Statistics, Nonparametric; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2009.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "46(11)",
  "languages": "eng",
  "abstract": "BACKGROUND\nLi-Fraumeni and Li-Fraumeni-like syndromes (LFS/LFL), characterised by the development of multiple early onset cancers with heterogeneous tumour patterns, are associated with germline TP53 mutations. Polymorphisms in the TP53 pathway (TP53 PEX4 at codon 72, rs1042522; MDM2 SNP309, rs2279744) have modifier effects on germline TP53 mutations that may account for the individual and familial diversity of tumour patterns.\n\n\nMETHODS AND RESULTS\nFour polymorphisms were analysed in a series of 135 Brazilian LFS/LFL cancer patients (32 TP53 mutation carriers and 103 wild-type subjects). We report for the first time that another polymorphism in the TP53 gene, TP53 PIN3 (rs17878362), has a strong modifier effect on germline TP53 mutations. This polymorphism, which consists of a 16 bp duplication in intron 3 (A1, non-duplicated allele; A2, duplicated allele), is associated with a difference of 19.0 years in the mean age at the first diagnosis in TP53 mutation carriers (n = 25, A1A1: 28.0 years; n = 7, A1A2: 47.0 years; p = 0.01). In addition, cancer occurrence before the age of 35 years is exclusively observed in A1A1 homozygotes. In this series, the effect of TP53 PEX4 and MDM2 SNP309 on age at diagnosis was similar to the one reported in other series and was smaller than the one of TP53 PIN3 (TP53 PIN3: difference of 19.0 years; TP53 PEX4: 8.3 years; MDM2 SNP309: 12.5 years).\n\n\nCONCLUSION\nThese results suggest that TP53 PIN3 is another polymorphism in the TP53 pathway that may have a modifier effect on germline TP53 mutations and may contribute to the phenotypic diversity of germline TP53 mutations associated with LFS/LFL patients.",
  "pmid": "1.9542078E7",
  "nlm_unique_id": "2985087R",
  "issn_linking": "0022-2593",
  "filename": "pubmed24n0632.extract.xlsx",
  "vernacular_title": " ",
  "authors": "V Marcel; E I Palmero; P Falagan-Lotsch; G Martel-Planche; P Ashton-Prolla; M Olivier; R R Brentani; P Hainaut; M I Achatz",
  "doi": "10.1136/jmg.2009.066704"
}
{
  "country": "United States",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Department of Biology, Nara Medical University, Kashihara, Japan.",
  "medline_ta": "Radiat Res",
  "title": "Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone.",
  "delete": " ",
  "content": "期刊:151(4)\n页数:498_500\n摘要:We have previously reported that heat stress induces expression of wild-type TP53 (formerly known as p53) activated factor 1 (CDKN1A, formerly known as WAF1) only when TP53 protein is wild-type using cells of a human glioblastoma cell line (A-172) and cells of its transformant (A-172/mp53/ 143) with a mutant TP53 (point mutation at codon 143 from Val to Ala) vector. Transfection of A-172 cells with the mutant TP53 vector abolished the heat-induced expression of CDKN1A, demonstrating the dominant negative nature of this TP53 mutant over the endogenous wild-type TP53. This kind of dominant negative TP53 mutant occurs frequently in various types of cancer. Overcoming this dominance or restoring the normal functions to these TP53 mutants is a new strategy for TP53-targeted cancer therapies. We examined whether glycerol can act as a chemical chaperone to correct the mutant TP53 conformation. No CDKN1A expression was induced after heating or treatment with glycerol at concentrations of 0.6 and 1.2 M in these transformants. In contrast, A-172/mp53/ 143 cells showed CDKN1A expression when they were heated in the presence of glycerol at 0.6 or 1.2 M, which was similar to the response of the parental and neo vector-transfected control cells. To test the generality of the effects of glycerol on mutant TP53, we used human osteosarcoma Saos-2 cells (lacking TP53) transfected with mutant TP53 and cells of two other human glioblastoma cell lines carrying mutant TP53. These cells showed similar CDKN1A expression when heated in the presence of glycerol at 0.6 or 1.2 M. These results suggest that glycerol is effective in restoring several TP53 mutants to normal TP53 function, leading to normal CDKN1A expression after heat stress. This observation provides a novel tool for correction of mutant TP53 conformation and may be applicable for TP53-targeted cancer therapy.\n期刊:Radiation research\n作者:T Ohnishi; K Ohnishi; X Wang; A Takahashi; K Okaichi\n出版日期:1999.0\npmid:1.0190503E7\nmesh_terms:D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D005990:Glycerol; D006358:Hot Temperature; D006801:Humans; D009154:Mutation; D011487:Protein Conformation; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53; D005990:Glycerol\n语言:eng\n附属机构:Department of Biology, Nara Medical University, Kashihara, Japan.\nmedline_ta:Radiat Res\nnlm_unique_id:0401245\nissn:0033-7587\n国家:United States\ngrant_ids:[]",
  "pages": "498_500",
  "journal": "Radiation research",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D005990:Glycerol; D006358:Hot Temperature; D006801:Humans; D009154:Mutation; D011487:Protein Conformation; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53; D005990:Glycerol",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "1999.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "151(4)",
  "languages": "eng",
  "abstract": "We have previously reported that heat stress induces expression of wild-type TP53 (formerly known as p53) activated factor 1 (CDKN1A, formerly known as WAF1) only when TP53 protein is wild-type using cells of a human glioblastoma cell line (A-172) and cells of its transformant (A-172/mp53/ 143) with a mutant TP53 (point mutation at codon 143 from Val to Ala) vector. Transfection of A-172 cells with the mutant TP53 vector abolished the heat-induced expression of CDKN1A, demonstrating the dominant negative nature of this TP53 mutant over the endogenous wild-type TP53. This kind of dominant negative TP53 mutant occurs frequently in various types of cancer. Overcoming this dominance or restoring the normal functions to these TP53 mutants is a new strategy for TP53-targeted cancer therapies. We examined whether glycerol can act as a chemical chaperone to correct the mutant TP53 conformation. No CDKN1A expression was induced after heating or treatment with glycerol at concentrations of 0.6 and 1.2 M in these transformants. In contrast, A-172/mp53/ 143 cells showed CDKN1A expression when they were heated in the presence of glycerol at 0.6 or 1.2 M, which was similar to the response of the parental and neo vector-transfected control cells. To test the generality of the effects of glycerol on mutant TP53, we used human osteosarcoma Saos-2 cells (lacking TP53) transfected with mutant TP53 and cells of two other human glioblastoma cell lines carrying mutant TP53. These cells showed similar CDKN1A expression when heated in the presence of glycerol at 0.6 or 1.2 M. These results suggest that glycerol is effective in restoring several TP53 mutants to normal TP53 function, leading to normal CDKN1A expression after heat stress. This observation provides a novel tool for correction of mutant TP53 conformation and may be applicable for TP53-targeted cancer therapy.",
  "pmid": "1.0190503E7",
  "nlm_unique_id": "0401245",
  "issn_linking": "0033-7587",
  "filename": "pubmed24n0338.extract.xlsx",
  "vernacular_title": " ",
  "authors": "T Ohnishi; K Ohnishi; X Wang; A Takahashi; K Okaichi",
  "doi": " "
}
{
  "country": "United States",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Translational Oncogenomics Unit, Regina Elena Cancer Institute, Rome, Italy.",
  "medline_ta": "OMICS",
  "title": "Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.",
  "delete": " ",
  "content": "期刊:15(6)\n页数:375_81\n摘要:TP53 is the most widely mutated gene across all cancer types. In head and neck cancer, approximately half of the tumors are found to contain TP53 mutations, which are correlated to an increased risk for locoregional recurrence and poor outcomes. In this study a mutational profiling of TP53 exons 5-8 was performed on tumor, peritumor and normal tissues from 57 HNSCC patients by direct sequencing of genomic DNA and cDNA. Cloning/sequencing in tumors carrying multiple TP53 mutations and semiquantitative SNaPShot mutation assay was performed in order to assess eventual allelic expression imbalances (AEI). We identified 24 out of 57 HNSCC patients (42%) carrying TP53 mutations and 5 patients carrying the R213R polymorphism. Cloning of the genomic DNA encompassing TP53 exons 5-8 from tumors with multiple TP53 mutations revealed that alleles carrying different types of TP53 mutations are present in these tumors. TP53 missense and nonsense mutations exhibit higher and lower TP53 transcript abundance compared to wild-type TP53 allele, respectively. Interestingly, three out of four patients with the R213R polymorphism analyzed were found positive for TP53 loss of heterozygosity (LOH) and also presented higher transcript abundance than the wild-type counterpart, specifically, in the tumor tissue and not in peritumor or normal tissues. HNSCC tumors present heterogenic cell populations carrying different TP53 mutations. All HNSCC samples analyzed show an alteration in the expression of mutated TP53 mRNA compared to the wild-type allele, most likely independently from the TP53 hemizygous status. The higher expression of R213R TP53 polymorphic allele in cancer tissue compared to normal tissue demonstrates a noninherited variation in allelic expression, independently from its mutation status for exons 5-8, suggesting a potential contribution to TP53 expression in HNSCC disease.\n期刊:Omics : a journal of integrative biology\n作者:Federica Ganci; Salvatore Conti; Giulia Fontemaggi; Valentina Manciocco; Sara Donzelli; Renato Covello; Paola Muti; Sabrina Strano; Giovanni Blandino; Giuseppe Spriano\n出版日期:2011.0\npmid:2.1348641E7\nmesh_terms:D018389:Codon, Nonsense; D004252:DNA Mutational Analysis; D005091:Exons; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D020125:Mutation, Missense; D011110:Polymorphism, Genetic; D017384:Sequence Deletion; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article\n化学列表:D018389:Codon, Nonsense; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\ndoi:10.1089/omi.2010.0142\n语言:eng\n附属机构:Translational Oncogenomics Unit, Regina Elena Cancer Institute, Rome, Italy.\nmedline_ta:OMICS\nnlm_unique_id:101131135\nissn:1536-2310\n国家:United States\ngrant_ids:[]",
  "pages": "375_81",
  "journal": "Omics : a journal of integrative biology",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D018389:Codon, Nonsense; D004252:DNA Mutational Analysis; D005091:Exons; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D020125:Mutation, Missense; D011110:Polymorphism, Genetic; D017384:Sequence Deletion; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D018389:Codon, Nonsense; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2011.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "15(6)",
  "languages": "eng",
  "abstract": "TP53 is the most widely mutated gene across all cancer types. In head and neck cancer, approximately half of the tumors are found to contain TP53 mutations, which are correlated to an increased risk for locoregional recurrence and poor outcomes. In this study a mutational profiling of TP53 exons 5-8 was performed on tumor, peritumor and normal tissues from 57 HNSCC patients by direct sequencing of genomic DNA and cDNA. Cloning/sequencing in tumors carrying multiple TP53 mutations and semiquantitative SNaPShot mutation assay was performed in order to assess eventual allelic expression imbalances (AEI). We identified 24 out of 57 HNSCC patients (42%) carrying TP53 mutations and 5 patients carrying the R213R polymorphism. Cloning of the genomic DNA encompassing TP53 exons 5-8 from tumors with multiple TP53 mutations revealed that alleles carrying different types of TP53 mutations are present in these tumors. TP53 missense and nonsense mutations exhibit higher and lower TP53 transcript abundance compared to wild-type TP53 allele, respectively. Interestingly, three out of four patients with the R213R polymorphism analyzed were found positive for TP53 loss of heterozygosity (LOH) and also presented higher transcript abundance than the wild-type counterpart, specifically, in the tumor tissue and not in peritumor or normal tissues. HNSCC tumors present heterogenic cell populations carrying different TP53 mutations. All HNSCC samples analyzed show an alteration in the expression of mutated TP53 mRNA compared to the wild-type allele, most likely independently from the TP53 hemizygous status. The higher expression of R213R TP53 polymorphic allele in cancer tissue compared to normal tissue demonstrates a noninherited variation in allelic expression, independently from its mutation status for exons 5-8, suggesting a potential contribution to TP53 expression in HNSCC disease.",
  "pmid": "2.1348641E7",
  "nlm_unique_id": "101131135",
  "issn_linking": "1536-2310",
  "filename": "pubmed24n0687.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Federica Ganci; Salvatore Conti; Giulia Fontemaggi; Valentina Manciocco; Sara Donzelli; Renato Covello; Paola Muti; Sabrina Strano; Giovanni Blandino; Giuseppe Spriano",
  "doi": "10.1089/omi.2010.0142"
}
{
  "country": "England",
  "keywords": "TP53; TP53 inhibitor PFTα; arsenic trioxide",
  "references": "33357454;25043190;19131956;18356920;12239215;18431400;18299451;21422471;20378816;20966922;20624968;26004085;10481009;19074867;23440206;18583568;19965631;28469388;30862715;16170029;20609355;15843497;19229248;12531793;12124315;25901683;27328919;20471733;26921335;19033363;12789273;23291299;12209159;18408733;16286925;20471942;24113773;29625050;19776742;22422168;21183792;16818652",
  "pmc": " ",
  "affiliations": "Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.",
  "medline_ta": "FEBS Open Bio",
  "title": "TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.",
  "delete": " ",
  "content": "期刊:12(3)\n页数:616_626\n摘要:Arsenic trioxide (ATO) has been shown to be effective in treating acute promyelocytic leukemia. TP53 mutated/null tumor cells are more sensitive to ATO treatment compared to tumor cells carrying wildtype TP53 gene copies. However, it is unclear whether TP53 inhibitors can increase the sensitivity of TP53 wildtype tumor cells to ATO. Here we show that breast, colon, and lung cancer cell lines with mutated/null TP53 are more sensitive to ATO-induced cell growth inhibition than cells with wildtype TP53. Moreover, inhibition of TP53 by a TP53 inhibitor, PFTα, increased the ATO sensitivity of TP53 wildtype tumor cells, coincident with ATO-induced cell growth arrest and cell apoptosis. Furthermore, combined treatment with ATO and PFTα synergistically inhibited tumor growth in mouse xenografts in vivo. Through microarray transcriptional analysis, we found that ATO-regulated genes were associated with TP53 and cell cycle signaling pathways. Cotreatment with PFTα enhanced ATO-induced dynamic transcriptional changes. Overall, our results provide evidence for using TP53 chemical inhibitors to enhance the ATO-mediated therapeutic response against TP53 wildtype tumor cells.\n期刊:FEBS open bio\n作者:Haiwei Wang; Xinrui Wang; Liangpu Xu; Ji Zhang\n出版日期:2022.0\npmid:3.5030298E7\nmesh_terms:D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D051379:Mice; D010087:Oxides; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D001152:Arsenicals; D010087:Oxides; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000077237:Arsenic Trioxide\n关键词:TP53; TP53 inhibitor PFTα; arsenic trioxide\ndoi:10.1002/2211-5463.13366\n参考文献:33357454;25043190;19131956;18356920;12239215;18431400;18299451;21422471;20378816;20966922;20624968;26004085;10481009;19074867;23440206;18583568;19965631;28469388;30862715;16170029;20609355;15843497;19229248;12531793;12124315;25901683;27328919;20471733;26921335;19033363;12789273;23291299;12209159;18408733;16286925;20471942;24113773;29625050;19776742;22422168;21183792;16818652\n语言:eng\n附属机构:Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;Medical Research Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.;State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.\nmedline_ta:FEBS Open Bio\nnlm_unique_id:101580716\nissn:2211-5463\n国家:England\ngrant_ids:[]",
  "pages": "616_626",
  "journal": "FEBS open bio",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D051379:Mice; D010087:Oxides; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D001152:Arsenicals; D010087:Oxides; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000077237:Arsenic Trioxide",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "12(3)",
  "languages": "eng",
  "abstract": "Arsenic trioxide (ATO) has been shown to be effective in treating acute promyelocytic leukemia. TP53 mutated/null tumor cells are more sensitive to ATO treatment compared to tumor cells carrying wildtype TP53 gene copies. However, it is unclear whether TP53 inhibitors can increase the sensitivity of TP53 wildtype tumor cells to ATO. Here we show that breast, colon, and lung cancer cell lines with mutated/null TP53 are more sensitive to ATO-induced cell growth inhibition than cells with wildtype TP53. Moreover, inhibition of TP53 by a TP53 inhibitor, PFTα, increased the ATO sensitivity of TP53 wildtype tumor cells, coincident with ATO-induced cell growth arrest and cell apoptosis. Furthermore, combined treatment with ATO and PFTα synergistically inhibited tumor growth in mouse xenografts in vivo. Through microarray transcriptional analysis, we found that ATO-regulated genes were associated with TP53 and cell cycle signaling pathways. Cotreatment with PFTα enhanced ATO-induced dynamic transcriptional changes. Overall, our results provide evidence for using TP53 chemical inhibitors to enhance the ATO-mediated therapeutic response against TP53 wildtype tumor cells.",
  "pmid": "3.5030298E7",
  "nlm_unique_id": "101580716",
  "issn_linking": "2211-5463",
  "filename": "pubmed24n1118.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Haiwei Wang; Xinrui Wang; Liangpu Xu; Ji Zhang",
  "doi": "10.1002/2211-5463.13366"
}
{
  "country": "England",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.",
  "medline_ta": "J Pathol",
  "title": "TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.",
  "delete": " ",
  "content": "期刊:207(1)\n页数:14_9\n摘要:TP53 mutations play an important role in the development of several cancers and are present in 20-40% of all breast carcinomas, contributing to increased genomic instability. In order to address the relationship of mutated TP53 to genomic complexity, the present study analysed 61 breast carcinomas for TP53 mutations and compared mutation status with the pattern of genomic imbalances as assessed by comparative genomic hybridization (CGH). Twenty per cent of the present series of breast carcinomas harboured TP53 mutations. An increasing number of abnormalities, as identified by CGH (higher genomic complexity), correlated significantly with mutant TP53. Among the chromosome arms most commonly altered (in more than 20% of the tumours), loss of 8p and gain of 8q were associated with TP53 mutations, whereas loss of 16q was associated with wild-type TP53. By performing supervised hierarchical clustering analysis of the CGH data, a cluster of chromosome imbalances was observed that showed differences between wild-type and mutant TP53 cases. Among these, loss of chromosome arm 5q revealed the strongest correlation with altered TP53. To investigate further the most commonly deleted region of 5q, gene expression patterns from two publicly available microarray data sets of breast carcinomas were evaluated statistically. The expression data sets identified potential target genes, including genes involved in ubiquitination and the known TP53 target CSPG2. The genomic complexity of breast carcinomas as assessed by CGH is associated with TP53 mutation status; breast cancers with TP53 mutations display more complex genomes than do those with wild-type TP53. The pattern of genomic imbalances associated with mutant TP53 is non-random, with loss of chromosome arm 5q being particularly closely associated with TP53 mutations.\n期刊:The Journal of pathology\n作者:Kristine Kleivi; Chieu B Diep; Nikos Pandis; Sverre Heim; Manuel R Teixeira; Ragnhild A Lothe\n出版日期:2005.0\npmid:1.6007576E7\nmesh_terms:D001943:Breast Neoplasms; D018270:Carcinoma, Ductal, Breast; D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5; D016000:Cluster Analysis; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm; D015536:Down-Regulation; D005260:Female; D016158:Genes, p53; D006801:Humans; D009154:Mutation; D009693:Nucleic Acid Hybridization\n出版物类型:D016428:Journal Article\n化学列表:D004273:DNA, Neoplasm\ndoi:10.1002/path.1812\n语言:eng\n附属机构:Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.\nmedline_ta:J Pathol\nnlm_unique_id:0204634\nissn:0022-3417\n国家:England\ngrant_ids:[]",
  "pages": "14_9",
  "journal": "The Journal of pathology",
  "_inference.semantic_vector": "AGArvwAgRb4AoMu9AKDCvgAgUj4AQIA+AICCvgBANL4AANU+AIDrvACg8z0AIKM8AEBIvQCgLj4A4Ii+AICGPwBge74AIK69AKBGvwBg174AQFU/ACBUvgAgRj4AgJo9AEDsvgCgE74AgC4/AKBqPgDgA74AYCQ/AACgvgBgpz4AgPM+AMDuPQDghb4AoJA+AEBbvgBghD4AIPw+AEAXPwAA3T4A4Iu+AMCKvwCA2L0A4Mm+AMCGvwAgfcAAwAQ/AEDUvgDAGb8AIIi+AAA3PgDAsD4AYOo+AOCRPgBgWz8AYK+7AGAuvwBAdT4AQJW/AEBePgDgxz4AAMk+AICEvgAgrD4AgLI+AECcPgAg7r4AwKe+ACBEvwCgsT4AAF0+AMBKPQBA1z4AQES+AOBEPwAgg74AYKw9ACCCPwAArD4A4Oe8AGAhvgCg6r0AoK0+AECpvQDgF78AQM8+AKAZPgBg7j4AQAo9AIDsPgBghr4A4J0+AIBZPgAAf70AAKQ+AOCLPwDAyr4AwGM+AACDvgBAbb8AwFc+AGCEvgAAZ7sAACa/AIAKPgAAkb4AIIU+AABavwBACj8AwDi/AMA8vgCAiL4AYNC+AMDMPAAAcz4AACC+ACBjvwDABz0AAMA+AGA9vwCAMD8AIHu+AEBKvgCAiz0AgB6+AOD+PgDAEr0AYA6/AOCOvgBANr4AYEc9AICjPgAgWr8AoDw+AOCsPgBgdz4AYKI+AAC9PgCgyT0AIJ89ACC+vgCgmT4AQAG/AOBFvABAhb8A4Ay/AICvvgDAGj8AQJA/AABvvgDg67wAgMM9AEDrvgDAF74AABE/AGCCvQCgLT4AYFg+AEAmvwAgQD4AYCG+AIAOvwBgm74AgIq7AOBuPgCAoj4AAII+AMA6vAAgRb8A4OM8AOCUvgAgEz4AoM2+AEAZvwBAqz4AYFi+AMBHPgCASL8AQH8+AKAZvwAguz4AoIW+AMCZOwAgk74AQP09AIAIPwCgjz0AALM+AMBUPwCAJb8AoBe/AIAtPQDAML8AQGc/ACDqPQDgBD8AAB4/AACOPgBAIT4AIN2+AABUvQCgsD8AAI++AAC3vgDAIL8A4K09AGCUvgBAlb4AgDS/AACtvQDgRz8A4IC9AKBhPwCgHT8A4NS9AGBWPwCge70A4D0/AGCKvgBAujwA4JQ9AECNugDABT8A4KI+AKA8PgDgpT4AgNS+AABgPwCAcD4A4O6+AEAMvwDgKD8AQMW+AGCdPACAhL0AACi+AECmPQAAF70AQIK+ACAZvgBAFz8AAMS+AEBgvACgdb4AIBa+AIBJvgCgib4A4AE+AGCqvgBgHb8AwAu/AOC4PQBARz4AQP4+AAC9PQBgRz4A4Ai+AIDovgCgNL4AYDc+AEBavgBgB78AQII8AMBDPgAg/70AINI9AGCwvQAgHj8AAK0+AOCtPgCgNr0AAIy/AAC6PgBgob4AIBa/AOCSvQAgOT4AoBM/AADZPADAA78AgNa+AIBMPgBA278AoIw+AEARPwBgGD8AYPc8AADCvgBAUDwAQJc6ACBfvwCAzb4AIMW9ACAtPgBAArwAgO++AAAFPQAAQj8AoDM+AGAnvgAAyT4AIJ89AKAGPwDg3T0AwNq9AKC8vACA6D4AYITAAOBdPgDgUz4A4EO+AKD+PgAADT8AIJY+AKAHPwDgCLwAYIw+AAD/PgDgmLwAoMG8AGCQPgBAqz0AQH2+AMAdvwDAGr0AAP09AED8OwCAET8AYB6/AGCcvgBg5L0AwBG/AKACvgCAEb8AgGA+AGD5vgBADb8AAGi+AABtvgAg3z4AANI9AOBvPgDgeT0AoEC/AOCgvgBgE70A4AS/AECaPgAAzr0AwOc+AOCavwAgRD4AAI+/AAC6vgAgIz0AIGM8AEADPgCgGj4AwIk+AMBsPwDgSD4A4LQ9ACAmPQDAqz4AoJq+AKA5vADAPj4AYKm+AGCavgCgsLwAII6/AGCNvgBAEL8AAJQ+AICtvgAg2D4AgFE+ACDZvgAglb4AoIw8AMAePQBAcL4AQG49ACBavQDgbD4AgMi9AIAkPgBAij0AQHu+AKCzPgDAsT0AgIW+AODcvgAAeb8AIFm+AACfvQDgiT8AgGM/AODKPQDgx74AwAM+AGBqPwBAub0AYC++AGAxPwDAJT8AIJu6AIBgPwBAxb4AQDm+ACCoPgCAjzwAYMW+ACDEvgBA4T4AYEA+AOAuPgBA674AwFK+AGDDvgDARr8AoIQ+AKCkvQDg0z4AYNK+AOAHPwCgJ74A4FS/AICIPgDgTr8AIBk+AGABvwDghb4AYHM6AICQvQBA/z0AoCq/AKCoPADAIb4AQKC8AMAPvwCg+zwAIIA/AKAMvwAg0D0AwGC+AOCOvgDg+z4AQEc9AECQvQCgfD0AQIu+ACCxvgBgpj0AAJi+ACCRPgAgWL0A4B69AAAtvwBA6T4AIEM+AAAEPADAPz0A4L2+AMD7OwCAqb4AQGC/AIANPgBAxz4AgJS+AMC7vgBAh70AwLQ9AKBZvQAAHr4AAFU7AMC3vgCgJ74AAM+9AICEPgDgfb4A4FC9AKBUvgAAwz4AIEG/AGCTPgDAYj8AgPe+ACCHPQDgpL0AwFI+AKD/PgBggT8AoM6+AICuPQBg7b4AYAa+AEBnvwCgbT4AQJG+AACDPgDAdr4AoAC/AGC/PgAAOz8AgDK+AIDxvQBgoz4AYGW9ACAhPwBgeL4AoA8/AEAevABAiz4AgJA+ACAbvwBAbL0AwEc+AOAEvwBgRbwA4Ja+AKC0PQDAUb8AgKo+AIAqvgDgzr4AAIk/AMDrPgCg8z4AAA8/AABUPQAgW78AgEe+AIDiPgCASj4AgHk/AAB5vADAkT4AIDy+AECEPQDANz0AgG6+AMBRvwAgDz8AAHw9AGAKvwAgWb4AQCc/AOCwvACgEj8AYAm+ACDJvgBA9j0AYEW+ACAqvgAg8r0A4Bg+AMCwPgAA6L0AYH6+AICyvADgwj0AAF0/AODdvgBgAr8AQBG/AOBMvwCAOT8AgKE+ACBWvgAAsj0AAEa9AAD4PQBgR74AwDW/AOBvPgAAVj4AAN4+AKBfvwAg2b4AoNE+AGDrPABgST4AoIa9AMA2PQCAyz4AICu/AED6vADgT74AwMo+AMDQOwBAmb8AQEc+AADDvgBgYL8AYJo8AGAFvADgVT4AIJ+9AEDkPgDgST8AwLY+AGAVPgAgIbwAgOk+AMAVPwAAA70AwJO/AMABPwCAtb0AIBq/AMBDPgDgpT0A4Jk+AODJvgBAfb4AwNw9AACZPgDgnz4AABs/AGAyPgAgqr4A4AY/AOC4vgCAzL4AIJs+AIB5PQAgEj8AAGA+AACkPgCgDz4A4Pg+AKD3PgDgxT4AwOQ8AIDxvADAXD8AYB2+AGCCvgCAGz4A4KQ+AIBSvwBAprwA4Kq8AOCPPgCgVj8AQKO/AGASPwBgPz8AQPS+AKD1vgBAgj0AoIE+AABjPgCARr4AIOo+AMB+PwCAvz0AQIS+AODQvgBAmT0AoP29AKANPwBgQj0AAIS+AKDDvQBgRr0AwPy+AOCWPgCAGz8A4HA+AGBavgBgpr4AAKU+AKCzvAAgbD8AgD2+AIB8vgBAHL8AIMS+AGAZvgDA2j4AwEe+AEDcPgCAGL4AQCi+AOAZPwCAEr8AAHq+AMB3PgBgRL8A4My+AOA+PgBAHz4AACG+AKCBvgBg374AAPM+AOCtvwAA+D4AYA0/AEAUPgBAw7sA4Ls9AODfvgBgvT0AQMs+AIABPwCA77wAADW8AKBVPwAghr4AQEi+AOARvgDApD4AIBm/AOAavwAAhz4AIO+8AACTvgBAeT4A4Dg+AIChvgDAn70AwPo9ACAMvwBAnD4AIJ4+AGBQvgCguj8AgLo+AKBlvwBAHT4A4HY/AOCvvgAgJD8AQPY+AGCZvgAACz8AwNe+AAD4PQAgJr8AgEO/ACAEvgBgPz8AoDW9ACC1PQCgY70AwNC9AADYvQBgH74A4Hs+AKCtvgBAbz4AQPO+AMCBvgCAHD4AwIC9AAA8PACA6D0AwES+AAANPgAgHb8AoIA+AKAvvgCgO74A4HO9",
  "mesh_terms": "D001943:Breast Neoplasms; D018270:Carcinoma, Ductal, Breast; D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5; D016000:Cluster Analysis; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm; D015536:Down-Regulation; D005260:Female; D016158:Genes, p53; D006801:Humans; D009154:Mutation; D009693:Nucleic Acid Hybridization",
  "chemical_list": "D004273:DNA, Neoplasm",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2005.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "207(1)",
  "languages": "eng",
  "abstract": "TP53 mutations play an important role in the development of several cancers and are present in 20-40% of all breast carcinomas, contributing to increased genomic instability. In order to address the relationship of mutated TP53 to genomic complexity, the present study analysed 61 breast carcinomas for TP53 mutations and compared mutation status with the pattern of genomic imbalances as assessed by comparative genomic hybridization (CGH). Twenty per cent of the present series of breast carcinomas harboured TP53 mutations. An increasing number of abnormalities, as identified by CGH (higher genomic complexity), correlated significantly with mutant TP53. Among the chromosome arms most commonly altered (in more than 20% of the tumours), loss of 8p and gain of 8q were associated with TP53 mutations, whereas loss of 16q was associated with wild-type TP53. By performing supervised hierarchical clustering analysis of the CGH data, a cluster of chromosome imbalances was observed that showed differences between wild-type and mutant TP53 cases. Among these, loss of chromosome arm 5q revealed the strongest correlation with altered TP53. To investigate further the most commonly deleted region of 5q, gene expression patterns from two publicly available microarray data sets of breast carcinomas were evaluated statistically. The expression data sets identified potential target genes, including genes involved in ubiquitination and the known TP53 target CSPG2. The genomic complexity of breast carcinomas as assessed by CGH is associated with TP53 mutation status; breast cancers with TP53 mutations display more complex genomes than do those with wild-type TP53. The pattern of genomic imbalances associated with mutant TP53 is non-random, with loss of chromosome arm 5q being particularly closely associated with TP53 mutations.",
  "pmid": "1.6007576E7",
  "nlm_unique_id": "0204634",
  "issn_linking": "0022-3417",
  "filename": "pubmed24n0522.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Kristine Kleivi; Chieu B Diep; Nikos Pandis; Sverre Heim; Manuel R Teixeira; Ragnhild A Lothe",
  "doi": "10.1002/path.1812"
}
{
  "country": "Greece",
  "keywords": "TP53; gene expression; maxillary cancer; microarray; mutation",
  "references": "26179207;21667036;17625587;12090464;18689542;22315133;19047086;12726864;26331536;17985332;20811663;10767298;18223210;25736868;25241968;21760703;11716177;22459764;17692090;20461718;21798897;12101396;25039283;15867223;10524633;24124604;21123374;18271932;15865943;21798893",
  "pmc": " ",
  "affiliations": "Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Otorhinolaryngology-Head and Neck Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Otorhinolaryngology-Head and Neck Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.",
  "medline_ta": "Oncol Lett",
  "title": "Particular gene upregulation and p53 heterogeneous expression in TP53-mutated maxillary carcinoma.",
  "delete": " ",
  "content": "期刊:14(4)\n页数:4633_4640\n摘要:It has been demonstrated that tumor protein p53 (TP53) mutation in maxillary squamous cell carcinoma, is more treatment-resistant compared with the carcinoma without TP53 mutation. However, the association between TP53 mutation and treatment resistance remains unclear. As a first step in understanding the biological differences between tumors with and without TP53 mutation, a comprehensive gene expression analysis of maxillary squamous cell carcinoma with or without TP53 mutation was performed. A total of 42 genes were identified to be differentially expressed by >4-fold. Quantification of their mRNA using quantitative polymerase chain reaction indicated 18 genes with high expression and three genes with low expression in TP53 mutated tumors vs. TP53 wild-type tumors. The 18 genes included eight cell adhesion (DSC3, GRHL1, EPPK1, PROM2, ANXA8, DSP, JUP, and KRT6B) and four cell growth inhibition (SFN, CLCA2, SAMD9 and TP63) genes. Among these genes, DSC3, SFN, and CSTA, whose expression was markedly increased, also demonstrated high protein expression in immunohistochemical staining of TP53 mutated tumors. The TP53 mutated tumors demonstrated high nuclear staining of the TP53 protein only in tumor cells at the tumor margins adjacent to the stroma, whereas the tumor interior was negative for TP53. However, all tumor cells of TP53 wild-type tumors exhibited positive nuclear staining for the TP53 protein. The combined findings suggest that TP53 mutated tumors possess a phenotype opposite to that associated with cancer progression and malignant transformation, and exhibit tumor cell heterogeneity between the tumor interior and margins.\n期刊:Oncology letters\n作者:Itsuhiro Kudo; Mariko Esumi; Yoshiaki Kusumi; Tohru Furusaka; Takeshi Oshima\n出版日期:2017.0\npmid:2.9085461E7\n出版物类型:D016428:Journal Article\n关键词:TP53; gene expression; maxillary cancer; microarray; mutation\ndoi:10.3892/ol.2017.6751\n参考文献:26179207;21667036;17625587;12090464;18689542;22315133;19047086;12726864;26331536;17985332;20811663;10767298;18223210;25736868;25241968;21760703;11716177;22459764;17692090;20461718;21798897;12101396;25039283;15867223;10524633;24124604;21123374;18271932;15865943;21798893\n语言:eng\n附属机构:Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Pathology, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Otorhinolaryngology-Head and Neck Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.;Department of Otorhinolaryngology-Head and Neck Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.\nmedline_ta:Oncol Lett\nnlm_unique_id:101531236\nissn:1792-1074\n国家:Greece\ngrant_ids:[]",
  "pages": "4633_4640",
  "journal": "Oncology letters",
  "_inference.semantic_vector": "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",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2017.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "14(4)",
  "languages": "eng",
  "abstract": "It has been demonstrated that tumor protein p53 (TP53) mutation in maxillary squamous cell carcinoma, is more treatment-resistant compared with the carcinoma without TP53 mutation. However, the association between TP53 mutation and treatment resistance remains unclear. As a first step in understanding the biological differences between tumors with and without TP53 mutation, a comprehensive gene expression analysis of maxillary squamous cell carcinoma with or without TP53 mutation was performed. A total of 42 genes were identified to be differentially expressed by >4-fold. Quantification of their mRNA using quantitative polymerase chain reaction indicated 18 genes with high expression and three genes with low expression in TP53 mutated tumors vs. TP53 wild-type tumors. The 18 genes included eight cell adhesion (DSC3, GRHL1, EPPK1, PROM2, ANXA8, DSP, JUP, and KRT6B) and four cell growth inhibition (SFN, CLCA2, SAMD9 and TP63) genes. Among these genes, DSC3, SFN, and CSTA, whose expression was markedly increased, also demonstrated high protein expression in immunohistochemical staining of TP53 mutated tumors. The TP53 mutated tumors demonstrated high nuclear staining of the TP53 protein only in tumor cells at the tumor margins adjacent to the stroma, whereas the tumor interior was negative for TP53. However, all tumor cells of TP53 wild-type tumors exhibited positive nuclear staining for the TP53 protein. The combined findings suggest that TP53 mutated tumors possess a phenotype opposite to that associated with cancer progression and malignant transformation, and exhibit tumor cell heterogeneity between the tumor interior and margins.",
  "pmid": "2.9085461E7",
  "nlm_unique_id": "101531236",
  "issn_linking": "1792-1074",
  "filename": "pubmed24n0925.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Itsuhiro Kudo; Mariko Esumi; Yoshiaki Kusumi; Tohru Furusaka; Takeshi Oshima",
  "doi": "10.3892/ol.2017.6751"
}
{
  "country": "Japan",
  "keywords": "Breast cancer; Diagnostic system; Prognostic factor; TP53 signature",
  "references": "16720680;16489069;25886164;19204204;12490681;20005174;23973262;29581837;11289122;16141321;18271932;21514041;25051299;12243922;27557300;22098854;26412349;8402644;12619115;24347518;11902578",
  "pmc": " ",
  "affiliations": "Department of Medical Oncology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, 4-1 Seiryo-machi, Aobaku, Sendai, 980-8575, Japan.;Biomedical Business Division, FALCO Biosystems Ltd., 346, Shimizu-cho Nijoagaru Kawaramachi-dori, Nakagyo-ku, Kyoto, Japan.;Department of Surgery, Hoshi General Hospital, 159-1, Mukaigawaramachi, Koriyama, Fukushima, Japan.;Department of Breast Oncology, Miyagi Cancer Center Hospital, 47-1, Nodayama, Shiote, Medeshima, Natori, Japan.;Department of Pathology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Medical Oncology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, 4-1 Seiryo-machi, Aobaku, Sendai, 980-8575, Japan. chikashi@tohoku.ac.jp.",
  "medline_ta": "Breast Cancer",
  "title": "TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.",
  "delete": " ",
  "content": "期刊:28(6)\n页数:1225_1234\n摘要:BACKGROUND\nTP53 status based on TP53 signature, a gene expression profile to determine the presence or absence of TP53 mutation, is an independent prognostic factor of breast cancer. The purpose of this study was to develop a simple diagnostic system for TP53 signature status.\n\n\nMETHODS\nWe developed a multiplex reverse transcription-polymerase chain reaction system to determine TP53 status. Based on this system, prospectively collected 189 patients with stage I and II breast cancer were determined to have TP53 mutant signature or TP53 wild-type signature. The prognostic significance of the TP53 signature by the diagnostic system was analyzed.\n\n\nRESULTS\nThe diagnostic accuracy of TP53 status and reproducibility of this diagnosis system was confirmed. Using the diagnostic system, 89 patients were classified as TP53 mutant signature and the remaining 100 cases were classified as TP53 wild-type signature. Recurrence-free survival (RFS) among patients with TP53 mutant signature was significantly shorter than that among those with TP53 wild-type signature. On univariate and multivariate analyses, the TP53 signature status was an independent predictor of RFS. RFS among patients with TP53 mutant signature was significantly shorter than that among those with TP53 wild-type signature in a cohort of estrogen receptor-positive breast cancer. Although a difference was not significant, no recurrent cases was observed in TP53 wild-type signature group in triple negative breast cancer.\n\n\nCONCLUSION\nThis simple and precise diagnostic system to determine TP53 signature status may help in prognostic assessment, therapeutic decision-making, and treatment optimization in patients with breast cancer.\n期刊:Breast cancer (Tokyo, Japan)\n作者:Shin Takahashi; Takafumi Fukui; Tadashi Nomizu; Yoichiro Kakugawa; Fumisyoshi Fujishima; Takanori Ishida; Noriaki Ohuchi; Chikashi Ishioka\n出版日期:2021.0\npmid:3.4302605E7\nmesh_terms:D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D009154:Mutation; D011446:Prospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D059467:Transcriptome; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D023361:Validation Study\n化学列表:D014408:Biomarkers, Tumor; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\n关键词:Breast cancer; Diagnostic system; Prognostic factor; TP53 signature\ndoi:10.1007/s12282-021-01250-z\n参考文献:16720680;16489069;25886164;19204204;12490681;20005174;23973262;29581837;11289122;16141321;18271932;21514041;25051299;12243922;27557300;22098854;26412349;8402644;12619115;24347518;11902578\n语言:eng\n附属机构:Department of Medical Oncology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, 4-1 Seiryo-machi, Aobaku, Sendai, 980-8575, Japan.;Biomedical Business Division, FALCO Biosystems Ltd., 346, Shimizu-cho Nijoagaru Kawaramachi-dori, Nakagyo-ku, Kyoto, Japan.;Department of Surgery, Hoshi General Hospital, 159-1, Mukaigawaramachi, Koriyama, Fukushima, Japan.;Department of Breast Oncology, Miyagi Cancer Center Hospital, 47-1, Nodayama, Shiote, Medeshima, Natori, Japan.;Department of Pathology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Japan.;Department of Medical Oncology, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, 4-1 Seiryo-machi, Aobaku, Sendai, 980-8575, Japan. chikashi@tohoku.ac.jp.\nmedline_ta:Breast Cancer\nnlm_unique_id:100888201\nissn:1340-6868\n国家:Japan\ngrant_ids:[{'grant_id': '24701000', 'grant_acronym': '', 'country': None, 'agency': 'Japan Society for the Promotion of Science'}, {'grant_id': 'no grant number', 'grant_acronym': '', 'country': None, 'agency': 'Miyagi Health Care Association'}]",
  "pages": "1225_1234",
  "journal": "Breast cancer (Tokyo, Japan)",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D009154:Mutation; D011446:Prospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D059467:Transcriptome; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D014408:Biomarkers, Tumor; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[{'grant_id': '24701000', 'grant_acronym': '', 'country': None, 'agency': 'Japan Society for the Promotion of Science'}, {'grant_id': 'no grant number', 'grant_acronym': '', 'country': None, 'agency': 'Miyagi Health Care Association'}]",
  "other_id": " ",
  "pubdate": "2021.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D023361:Validation Study",
  "issue": "28(6)",
  "languages": "eng",
  "abstract": "BACKGROUND\nTP53 status based on TP53 signature, a gene expression profile to determine the presence or absence of TP53 mutation, is an independent prognostic factor of breast cancer. The purpose of this study was to develop a simple diagnostic system for TP53 signature status.\n\n\nMETHODS\nWe developed a multiplex reverse transcription-polymerase chain reaction system to determine TP53 status. Based on this system, prospectively collected 189 patients with stage I and II breast cancer were determined to have TP53 mutant signature or TP53 wild-type signature. The prognostic significance of the TP53 signature by the diagnostic system was analyzed.\n\n\nRESULTS\nThe diagnostic accuracy of TP53 status and reproducibility of this diagnosis system was confirmed. Using the diagnostic system, 89 patients were classified as TP53 mutant signature and the remaining 100 cases were classified as TP53 wild-type signature. Recurrence-free survival (RFS) among patients with TP53 mutant signature was significantly shorter than that among those with TP53 wild-type signature. On univariate and multivariate analyses, the TP53 signature status was an independent predictor of RFS. RFS among patients with TP53 mutant signature was significantly shorter than that among those with TP53 wild-type signature in a cohort of estrogen receptor-positive breast cancer. Although a difference was not significant, no recurrent cases was observed in TP53 wild-type signature group in triple negative breast cancer.\n\n\nCONCLUSION\nThis simple and precise diagnostic system to determine TP53 signature status may help in prognostic assessment, therapeutic decision-making, and treatment optimization in patients with breast cancer.",
  "pmid": "3.4302605E7",
  "nlm_unique_id": "100888201",
  "issn_linking": "1340-6868",
  "filename": "pubmed24n1094.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Shin Takahashi; Takafumi Fukui; Tadashi Nomizu; Yoichiro Kakugawa; Fumisyoshi Fujishima; Takanori Ishida; Noriaki Ohuchi; Chikashi Ishioka",
  "doi": "10.1007/s12282-021-01250-z"
}
{
  "country": "United States",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Institute of Pathology, Department of Gynaecology, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg, Germany. mchoschz@uke.uni-hamburg.de",
  "medline_ta": "Int J Gynecol Pathol",
  "title": "Role of TP53 mutations in vulvar carcinomas.",
  "delete": " ",
  "content": "期刊:30(5)\n页数:497_504\n摘要:Human papillomavirus (HPV)-independent development of vulvar carcinomas is common and the disruption of the TP53 pathway seems to play a key role in these tumors. Overexpression of TP53 in precursor lesions (differentiated VIN) and associated invasive carcinomas is regarded as an important diagnostic feature of this subtype of vulvar cancer. To determine the relationship of TP53 mutation status with clinicopathologic parameters, HPV status, and patient outcome, 18 squamous cell carcinomas of the vulva with TP53 overexpression along with 21 immunohistochemically TP53-negative tumors were analyzed. TP53 mutations were found in 17 (43.6%) of vulvar cancers, 18 (46.2%) tumors were HPV associated, and 8 (20.5%) carcinomas showed no relation to HPV infection or TP53 mutations. The presence of TP53 mutations was significantly linked to TP53 overexpression (P=0.002) and negative HPV status (P=0.012). The specificity of TP53 protein overexpression for the occurrence of TP53 mutations was 68.2%, with a positive predictive value of 66.7%. The most frequent mutation types were C:G →T:A transitions (57.9%). This mutation pattern strongly indicates the important role of oxidative stress in vulvar carcinogenesis. There were no relationships between TP53 mutation status and tumor stage, grading, nodal status, depth of invasion, or patient prognosis. In summary, TP53 mutations play a crucial role in a substantial proportion of vulvar carcinomas and are probably associated to cellular oxidative stress in chronically degenerative diseases of the vulva, such as lichen sclerosus. These data support the potential utility of restoring TP53 function as a therapeutic alternative in vulvar cancer. Further studies are necessary to clarify the prognostic implications of TP53 mutations in vulvar carcinomas.\n期刊:International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists\n作者:Matthias Choschzick; Widianto Hantaredja; Pierre Tennstedt; Frederike Gieseking; Linn Wölber; Ronald Simon\n出版日期:2011.0\npmid:2.1804386E7\nmesh_terms:D002294:Carcinoma, Squamous Cell; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D009154:Mutation; D030361:Papillomavirus Infections; D011237:Predictive Value of Tests; D046888:Tissue Array Analysis; D016159:Tumor Suppressor Protein p53; D014846:Vulvar Neoplasms\n出版物类型:D016428:Journal Article\n化学列表:C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\ndoi:10.1097/PGP.0b013e3182184c7a\n语言:eng\n附属机构:Institute of Pathology, Department of Gynaecology, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg, Germany. mchoschz@uke.uni-hamburg.de\nmedline_ta:Int J Gynecol Pathol\nnlm_unique_id:8214845\nissn:0277-1691\n国家:United States\ngrant_ids:[]",
  "pages": "497_504",
  "journal": "International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D002294:Carcinoma, Squamous Cell; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D009154:Mutation; D030361:Papillomavirus Infections; D011237:Predictive Value of Tests; D046888:Tissue Array Analysis; D016159:Tumor Suppressor Protein p53; D014846:Vulvar Neoplasms",
  "chemical_list": "C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2011.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "30(5)",
  "languages": "eng",
  "abstract": "Human papillomavirus (HPV)-independent development of vulvar carcinomas is common and the disruption of the TP53 pathway seems to play a key role in these tumors. Overexpression of TP53 in precursor lesions (differentiated VIN) and associated invasive carcinomas is regarded as an important diagnostic feature of this subtype of vulvar cancer. To determine the relationship of TP53 mutation status with clinicopathologic parameters, HPV status, and patient outcome, 18 squamous cell carcinomas of the vulva with TP53 overexpression along with 21 immunohistochemically TP53-negative tumors were analyzed. TP53 mutations were found in 17 (43.6%) of vulvar cancers, 18 (46.2%) tumors were HPV associated, and 8 (20.5%) carcinomas showed no relation to HPV infection or TP53 mutations. The presence of TP53 mutations was significantly linked to TP53 overexpression (P=0.002) and negative HPV status (P=0.012). The specificity of TP53 protein overexpression for the occurrence of TP53 mutations was 68.2%, with a positive predictive value of 66.7%. The most frequent mutation types were C:G →T:A transitions (57.9%). This mutation pattern strongly indicates the important role of oxidative stress in vulvar carcinogenesis. There were no relationships between TP53 mutation status and tumor stage, grading, nodal status, depth of invasion, or patient prognosis. In summary, TP53 mutations play a crucial role in a substantial proportion of vulvar carcinomas and are probably associated to cellular oxidative stress in chronically degenerative diseases of the vulva, such as lichen sclerosus. These data support the potential utility of restoring TP53 function as a therapeutic alternative in vulvar cancer. Further studies are necessary to clarify the prognostic implications of TP53 mutations in vulvar carcinomas.",
  "pmid": "2.1804386E7",
  "nlm_unique_id": "8214845",
  "issn_linking": "0277-1691",
  "filename": "pubmed24n0701.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Matthias Choschzick; Widianto Hantaredja; Pierre Tennstedt; Frederike Gieseking; Linn Wölber; Ronald Simon",
  "doi": "10.1097/PGP.0b013e3182184c7a"
}
{
  "country": "England",
  "keywords": " ",
  "references": "28886379;17380161;19410540;32404993;31291648;29149101;26009011;16170357;17344317;9153395;26572807;18431400;8242751;7664346;9659898;10097101;24355989;10807576;11463392;11463391;14500851;14585359;12952892;19148184;16118324;7700629;9892649;15781865;29892060;19759539;23236145;1552940;7922305;9242615;11507077;18259198;19491259;23665218;30366906;22713868;30775651;21779515;17251932;17251933;14743206;15060172;1589764;8344492;15607980;18477611;17182091;2663235;27869164;24157709;22847613;20332115;24343302;22265415;26067754;25201187;10802655;19664188;19345189;17363555;19783986;29099488;33644030;26578795;22682249;9632751;7624121;15607981;24651012;23238012;23538418;28429788;26874923;29211704;21637290;20404560;11929951;23151579;23524243;29238070;27143546;11960327;17158228;27775703;20298590;18852133;21268072;28578487;31138775;19773755;20857345;11875500;24030633;29168598;18442053;26452133;26463477;27533450;23545415;27258787;31307507;21241062;15558054;20436301;23864164;10617466;12174820;12612087;26250460;25663456;29029480;23630318;33357454",
  "pmc": " ",
  "affiliations": "The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.;The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. strasser@wehi.edu.au.;The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. gkelly@wehi.edu.au.",
  "medline_ta": "Cell Death Differ",
  "title": "Should mutant TP53 be targeted for cancer therapy?",
  "delete": " ",
  "content": "期刊:29(5)\n页数:911_920\n摘要:Mutations in the TP53 tumour suppressor gene are found in ~50% of human cancers [1-6]. TP53 functions as a transcription factor that directly regulates the expression of ~500 genes, some of them involved in cell cycle arrest/cell senescence, apoptotic cell death or DNA damage repair, i.e. the cellular responses that together prevent tumorigenesis [1-6]. Defects in TP53 function not only cause tumour development but also impair the response of malignant cells to anti-cancer drugs, particularly those that induce DNA damage [1-6]. Most mutations in TP53 in human cancers cause a single amino acid substitution, usually within the DNA binding domain of the TP53 protein. These mutant TP53 proteins are often expressed at high levels in the malignant cells. Three cancer causing attributes have been postulated for mutant TP53 proteins: the inability to activate target genes controlled by wt TP53 (loss-of-function, LOF) that are critical for tumour suppression, dominant negative effects (DNE), i.e. blocking the function of wt TP53 in cells during early stages of transformation when mutant and wt TP53 proteins are co-expressed, and gain-of-function (GOF) effects whereby mutant TP53 impacts diverse cellular pathways by interacting with proteins that are not normally engaged by wt TP53 [1-6]. The GOF effects of mutant TP53 were reported to be essential for the sustained proliferation and survival of malignant cells and it was therefore proposed that agents that can remove mutant TP53 protein would have substantial therapeutic impact [7-9]. In this review article we discuss evidence for and against the value of targeting mutant TP53 protein for cancer therapy.\n期刊:Cell death and differentiation\n作者:Zilu Wang; Andreas Strasser; Gemma L Kelly\n出版日期:2022.0\npmid:3.5332311E7\nmesh_terms:D000970:Antineoplastic Agents; D002471:Cell Transformation, Neoplastic; D006801:Humans; D050505:Mutant Proteins; D009154:Mutation; D009369:Neoplasms; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D016454:Review; D013485:Research Support, Non-U.S. Gov't\n化学列表:D000970:Antineoplastic Agents; D050505:Mutant Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\ndoi:10.1038/s41418-022-00962-9\n参考文献:28886379;17380161;19410540;32404993;31291648;29149101;26009011;16170357;17344317;9153395;26572807;18431400;8242751;7664346;9659898;10097101;24355989;10807576;11463392;11463391;14500851;14585359;12952892;19148184;16118324;7700629;9892649;15781865;29892060;19759539;23236145;1552940;7922305;9242615;11507077;18259198;19491259;23665218;30366906;22713868;30775651;21779515;17251932;17251933;14743206;15060172;1589764;8344492;15607980;18477611;17182091;2663235;27869164;24157709;22847613;20332115;24343302;22265415;26067754;25201187;10802655;19664188;19345189;17363555;19783986;29099488;33644030;26578795;22682249;9632751;7624121;15607981;24651012;23238012;23538418;28429788;26874923;29211704;21637290;20404560;11929951;23151579;23524243;29238070;27143546;11960327;17158228;27775703;20298590;18852133;21268072;28578487;31138775;19773755;20857345;11875500;24030633;29168598;18442053;26452133;26463477;27533450;23545415;27258787;31307507;21241062;15558054;20436301;23864164;10617466;12174820;12612087;26250460;25663456;29029480;23630318;33357454\n语言:eng\n附属机构:The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.;The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. strasser@wehi.edu.au.;The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. gkelly@wehi.edu.au.\nmedline_ta:Cell Death Differ\nnlm_unique_id:9437445\nissn:1350-9047\n国家:England\ngrant_ids:[]",
  "pages": "911_920",
  "journal": "Cell death and differentiation",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000970:Antineoplastic Agents; D002471:Cell Transformation, Neoplastic; D006801:Humans; D050505:Mutant Proteins; D009154:Mutation; D009369:Neoplasms; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D000970:Antineoplastic Agents; D050505:Mutant Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D016454:Review; D013485:Research Support, Non-U.S. Gov't",
  "issue": "29(5)",
  "languages": "eng",
  "abstract": "Mutations in the TP53 tumour suppressor gene are found in ~50% of human cancers [1-6]. TP53 functions as a transcription factor that directly regulates the expression of ~500 genes, some of them involved in cell cycle arrest/cell senescence, apoptotic cell death or DNA damage repair, i.e. the cellular responses that together prevent tumorigenesis [1-6]. Defects in TP53 function not only cause tumour development but also impair the response of malignant cells to anti-cancer drugs, particularly those that induce DNA damage [1-6]. Most mutations in TP53 in human cancers cause a single amino acid substitution, usually within the DNA binding domain of the TP53 protein. These mutant TP53 proteins are often expressed at high levels in the malignant cells. Three cancer causing attributes have been postulated for mutant TP53 proteins: the inability to activate target genes controlled by wt TP53 (loss-of-function, LOF) that are critical for tumour suppression, dominant negative effects (DNE), i.e. blocking the function of wt TP53 in cells during early stages of transformation when mutant and wt TP53 proteins are co-expressed, and gain-of-function (GOF) effects whereby mutant TP53 impacts diverse cellular pathways by interacting with proteins that are not normally engaged by wt TP53 [1-6]. The GOF effects of mutant TP53 were reported to be essential for the sustained proliferation and survival of malignant cells and it was therefore proposed that agents that can remove mutant TP53 protein would have substantial therapeutic impact [7-9]. In this review article we discuss evidence for and against the value of targeting mutant TP53 protein for cancer therapy.",
  "pmid": "3.5332311E7",
  "nlm_unique_id": "9437445",
  "issn_linking": "1350-9047",
  "filename": "pubmed24n1128.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Zilu Wang; Andreas Strasser; Gemma L Kelly",
  "doi": "10.1038/s41418-022-00962-9"
}
{
  "country": "United States",
  "keywords": " ",
  "references": "12626903;22584434;22102901;15766527;16618717;9822382;22700443;22022355;22016468;20970032;10334521;8419262;21779514;16989803;11319280;19501586;16172461;21865946;22993345;17875987;17914404;16651716;17699775;17540598;21239505;17656095;2841597;18197166;12196370;20033209;12093899;10430607;17998284;23010994",
  "pmc": " ",
  "affiliations": "Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California, USA.",
  "medline_ta": "PLoS One",
  "title": "TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.",
  "delete": " ",
  "content": "期刊:8(8)\n页数:e70604\n摘要:Recent reports have indicated that KRAS and TP53 mutations predict response to therapy in colorectal cancer. However, little is known about the relationship between these two common genetic alterations. Micro-RNAs (miRNAs), a class of noncoding RNA implicated in cellular processes, have been increasingly linked to KRAS and TP53. We hypothesized that lethal-7a (let-7a) miRNA regulates KRAS through TP53. To investigate the relationship between KRAS, TP53, and let-7a, we used HCT116 KRAS(mut) human colorectal cancer cells with four different genotypic modifications in TP53 (TP53(-/-), TP53(+/-), TP53(mut/+), and TP53(mut/-) ). Using these cells we observed that K-Ras activity was higher in cells with mutant or knocked out TP53 alleles, suggesting that wild-type TP53 may suppress K-Ras activity. Let-7a was present in HCT116 KRAS(mut) cells, though there was no correlation between let-7a level and TP53 genotype status. To explore how let-7a may regulate K-Ras in the different TP53 genotype cells we used let-7a inhibitor and demonstrated increased K-Ras activity across all TP53, thus corroborating prior reports that let-7a regulates K-Ras. To assess potential clinical implications of this regulatory network, we examined the influence of TP53 genotype and let-7a inhibition on colon cancer cell survival following chemoradiation therapy (CRT). We observed that cells with complete loss of wild-type TP53 alleles ((-/-) or (-/mut)) were resistant to CRT following treatment with 5-fluorouracil and radiation. Further increase in K-Ras activity with let-7a inhibition did not impact survival in these cells. In contrast, cells with single or double wild-type TP53 alleles were moderately responsive to CRT and exhibited resistance when let-7a was inhibited. In summary, our results show a complex regulatory system involving TP53, KRAS, and let-7a. Our results may provide clues to understand and target these interactions in colorectal cancer.\n期刊:PloS one\n作者:Carrie Luu; Eileen L Heinrich; Marjun Duldulao; Amanda K Arrington; Marwan Fakih; Julio Garcia-Aguilar; Joseph Kim\n出版日期:2013.0\npmid:2.3936455E7\nmesh_terms:D000483:Alleles; D059248:Chemoradiotherapy; D015179:Colorectal Neoplasms; D015972:Gene Expression Regulation, Neoplastic; D045325:HCT116 Cells; D006801:Humans; D035683:MicroRNAs; D009154:Mutation; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D016159:Tumor Suppressor Protein p53; D018631:ras Proteins\n出版物类型:D016428:Journal Article\n化学列表:C117307:KRAS protein, human; D035683:MicroRNAs; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C487931:mirnlet7 microRNA, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins\ndoi:10.1371/journal.pone.0070604\n参考文献:12626903;22584434;22102901;15766527;16618717;9822382;22700443;22022355;22016468;20970032;10334521;8419262;21779514;16989803;11319280;19501586;16172461;21865946;22993345;17875987;17914404;16651716;17699775;17540598;21239505;17656095;2841597;18197166;12196370;20033209;12093899;10430607;17998284;23010994\n语言:eng\n附属机构:Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California, USA.\nmedline_ta:PLoS One\nnlm_unique_id:101285081\nissn:1932-6203\n国家:United States\ngrant_ids:[]",
  "pages": "e70604",
  "journal": "PloS one",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000483:Alleles; D059248:Chemoradiotherapy; D015179:Colorectal Neoplasms; D015972:Gene Expression Regulation, Neoplastic; D045325:HCT116 Cells; D006801:Humans; D035683:MicroRNAs; D009154:Mutation; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D016159:Tumor Suppressor Protein p53; D018631:ras Proteins",
  "chemical_list": "C117307:KRAS protein, human; D035683:MicroRNAs; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C487931:mirnlet7 microRNA, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2013.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "8(8)",
  "languages": "eng",
  "abstract": "Recent reports have indicated that KRAS and TP53 mutations predict response to therapy in colorectal cancer. However, little is known about the relationship between these two common genetic alterations. Micro-RNAs (miRNAs), a class of noncoding RNA implicated in cellular processes, have been increasingly linked to KRAS and TP53. We hypothesized that lethal-7a (let-7a) miRNA regulates KRAS through TP53. To investigate the relationship between KRAS, TP53, and let-7a, we used HCT116 KRAS(mut) human colorectal cancer cells with four different genotypic modifications in TP53 (TP53(-/-), TP53(+/-), TP53(mut/+), and TP53(mut/-) ). Using these cells we observed that K-Ras activity was higher in cells with mutant or knocked out TP53 alleles, suggesting that wild-type TP53 may suppress K-Ras activity. Let-7a was present in HCT116 KRAS(mut) cells, though there was no correlation between let-7a level and TP53 genotype status. To explore how let-7a may regulate K-Ras in the different TP53 genotype cells we used let-7a inhibitor and demonstrated increased K-Ras activity across all TP53, thus corroborating prior reports that let-7a regulates K-Ras. To assess potential clinical implications of this regulatory network, we examined the influence of TP53 genotype and let-7a inhibition on colon cancer cell survival following chemoradiation therapy (CRT). We observed that cells with complete loss of wild-type TP53 alleles ((-/-) or (-/mut)) were resistant to CRT following treatment with 5-fluorouracil and radiation. Further increase in K-Ras activity with let-7a inhibition did not impact survival in these cells. In contrast, cells with single or double wild-type TP53 alleles were moderately responsive to CRT and exhibited resistance when let-7a was inhibited. In summary, our results show a complex regulatory system involving TP53, KRAS, and let-7a. Our results may provide clues to understand and target these interactions in colorectal cancer.",
  "pmid": "2.3936455E7",
  "nlm_unique_id": "101285081",
  "issn_linking": "1932-6203",
  "filename": "pubmed24n0766.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Carrie Luu; Eileen L Heinrich; Marjun Duldulao; Amanda K Arrington; Marwan Fakih; Julio Garcia-Aguilar; Joseph Kim",
  "doi": "10.1371/journal.pone.0070604"
}
{
  "country": "New Zealand",
  "keywords": "DNA-binding domain; NGS; TP53 mutation; adjuvant endocrine therapy; advanced breast cancer",
  "references": "22722201;17180510;27806348;30577793;19806023;27503997;32847835;25964252;19927155;24803582;20696891;22722193;27018799;19097774;31045815;28980058;16820204;23396013;32873579;30691046;30035249;29616097;16489069;24099077;23077249;32695676;18544968;16869955;32416097;29125602;27956838;27626385;28886379;21570352;30623031;31395785;29180605;31452792;32061310;25643697;17401424;30224644;22698404;30285883;31168460;20404251;22551440;17388661;27611952",
  "pmc": " ",
  "affiliations": "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Huidu Shanghai Medical Sciences, Shanghai, 201499, People's Republic of China.;Huidu Shanghai Medical Sciences, Shanghai, 201499, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.",
  "medline_ta": "Cancer Manag Res",
  "title": "Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing.",
  "delete": " ",
  "content": "期刊:13()\n页数:3303_3316\n摘要:PURPOSE\nThe status of TP53 mutations was measured in cell-free DNA from patients with metastatic breast cancer (MBC) to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.\n\n\nPATIENTS AND METHODS\nBlood samples were taken from a total of 187 patients diagnosed with MBC who were treated at the Department of Breast Oncology, Peking University Cancer Hospital between January 2013 and March 2020. Next-generation sequencing was used to investigate the TP53 mutation spectra of circulating free DNA in these blood samples.\n\n\nRESULTS\nAmong the 187 MBC patients, TP53-mutated patients had a significantly shorter median disease-free survival (DFS) and overall survival (OS) compared with TP53 wild-type patients (P=0.001 and P=0.006, respectively). Additionally, in hormone receptor positive/HER2 negative (HR+/HER2-) and triple negative (TNBC) cohorts, TP53-mutated patients had a significantly shorter median DFS than TP53 wild-type patients (P=0.038 and P=0.023, respectively). The 79 patients with TP53 mutations carried 87 somatic TP53 mutations, of which most (77.0%) mapped to the DNA-binding domain (DBD) of the protein encoded by TP53 exons 5-8. In patients with TP53 mutations, those occurring in the non-DBD had a significantly shorter median DFS and OS than TP53 wild type (P<0.001 and P=0.001, respectively). Additionally, patients with non-missense mutations in the DBD had a significantly shorter median DFS and OS than TP53 wild-type patients (P=0.001 and P<0.001, respectively). TP53-mutated patients had a significantly shorter DFS than TP53 wild-type patients in the adjuvant endocrine therapy sensitive group (P=0.008), but differences in the endocrine therapy resistant group were not significant.\n\n\nCONCLUSION\nTP53-mutated MBC patients had a significantly worse outcome than TP53 wild-type patients especially those in HR+/HER2- and TNBC cohorts. Of TP53-mutated patients, those with non-missense mutations in the DBD had worse breast cancer-related survival. TP53 mutations were also associated with endocrine resistance.\n期刊:Cancer management and research\n作者:Han Bai; Jianjun Yu; Shidong Jia; Xiaoran Liu; Xu Liang; Huiping Li\n出版日期:2021.0\npmid:3.3889023E7\n出版物类型:D016428:Journal Article\n关键词:DNA-binding domain; NGS; TP53 mutation; adjuvant endocrine therapy; advanced breast cancer\ndoi:10.2147/CMAR.S298729\n参考文献:22722201;17180510;27806348;30577793;19806023;27503997;32847835;25964252;19927155;24803582;20696891;22722193;27018799;19097774;31045815;28980058;16820204;23396013;32873579;30691046;30035249;29616097;16489069;24099077;23077249;32695676;18544968;16869955;32416097;29125602;27956838;27626385;28886379;21570352;30623031;31395785;29180605;31452792;32061310;25643697;17401424;30224644;22698404;30285883;31168460;20404251;22551440;17388661;27611952\n语言:eng\n附属机构:Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Huidu Shanghai Medical Sciences, Shanghai, 201499, People's Republic of China.;Huidu Shanghai Medical Sciences, Shanghai, 201499, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China.\nmedline_ta:Cancer Manag Res\nnlm_unique_id:101512700\nissn:1179-1322\n国家:New Zealand\ngrant_ids:[]",
  "pages": "3303_3316",
  "journal": "Cancer management and research",
  "_inference.semantic_vector": "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",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2021.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "13()",
  "languages": "eng",
  "abstract": "PURPOSE\nThe status of TP53 mutations was measured in cell-free DNA from patients with metastatic breast cancer (MBC) to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.\n\n\nPATIENTS AND METHODS\nBlood samples were taken from a total of 187 patients diagnosed with MBC who were treated at the Department of Breast Oncology, Peking University Cancer Hospital between January 2013 and March 2020. Next-generation sequencing was used to investigate the TP53 mutation spectra of circulating free DNA in these blood samples.\n\n\nRESULTS\nAmong the 187 MBC patients, TP53-mutated patients had a significantly shorter median disease-free survival (DFS) and overall survival (OS) compared with TP53 wild-type patients (P=0.001 and P=0.006, respectively). Additionally, in hormone receptor positive/HER2 negative (HR+/HER2-) and triple negative (TNBC) cohorts, TP53-mutated patients had a significantly shorter median DFS than TP53 wild-type patients (P=0.038 and P=0.023, respectively). The 79 patients with TP53 mutations carried 87 somatic TP53 mutations, of which most (77.0%) mapped to the DNA-binding domain (DBD) of the protein encoded by TP53 exons 5-8. In patients with TP53 mutations, those occurring in the non-DBD had a significantly shorter median DFS and OS than TP53 wild type (P<0.001 and P=0.001, respectively). Additionally, patients with non-missense mutations in the DBD had a significantly shorter median DFS and OS than TP53 wild-type patients (P=0.001 and P<0.001, respectively). TP53-mutated patients had a significantly shorter DFS than TP53 wild-type patients in the adjuvant endocrine therapy sensitive group (P=0.008), but differences in the endocrine therapy resistant group were not significant.\n\n\nCONCLUSION\nTP53-mutated MBC patients had a significantly worse outcome than TP53 wild-type patients especially those in HR+/HER2- and TNBC cohorts. Of TP53-mutated patients, those with non-missense mutations in the DBD had worse breast cancer-related survival. TP53 mutations were also associated with endocrine resistance.",
  "pmid": "3.3889023E7",
  "nlm_unique_id": "101512700",
  "issn_linking": "1179-1322",
  "filename": "pubmed24n1081.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Han Bai; Jianjun Yu; Shidong Jia; Xiaoran Liu; Xu Liang; Huiping Li",
  "doi": "10.2147/CMAR.S298729"
}
{
  "country": "England",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.",
  "medline_ta": "Carcinogenesis",
  "title": "High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.",
  "delete": " ",
  "content": "期刊:23(6)\n页数:949_57\n摘要:Human Tp53 is normally a short-lived protein. Tp53 protein is stabilized and levels are increased in response to a variety of cellular stresses, including those induced by genotoxic anticancer drugs and environmental exposures. To engineer an efficient assay based on this property, we constructed and integrated a Tp53-specific reporter system into human cancer cells, termed p53R cells. We tested a range of conventional chemotherapeutic agents as well as over 16 000 diverse small compounds. Ionizing radiation and two-thirds of conventional chemotherapeutic agents, but only 0.2% of diverse compounds activated Tp53 activity by two-fold or greater, consistent with the presumptive genotoxic activation of Tp53 function. Cytotoxicity was independent of TP53 genetic status when paired, syngeneic wild-type TP53 and TP53-null cells in culture were treated with compounds that activated Tp53. From the unbiased survey of random compounds, Tp53 activation was strongly induced by an analog of AMSA, an investigational anti-cancer agent. Tp53 was also strongly induced by an N-oxide of quinoline and by dabequine, an experimental antimalarial evaluated in humans; dabequine was reported to be negative in other screens of mutagenicity and clastogenicity but carcinogenic in animal studies. Further exploration of antimalarial compounds identified the common medicinals chloroquine, quinacrine, and amodiaquine as Tp53-inducers. Flavonoids are known to have DNA topoisomerase activity, a Tp53-inducing activity that is confirmed in the assay. A reported clinical association of Tp53 immunopositive colorectal cancers with use of the antihypertensive agents was extended by the demonstration of hydralazine and nifedipine as Tp53-inducers. p53R cells represent an efficient Tp53 functional assay to identify chemicals and other agents with interesting biologic properties, including genotoxicity. This assay may have utility in the identification of novel chemotherapeutic agents, as an adjunct in the pharmaceutical optimization of lead compounds, in the exploration of environmental exposures, and in chemical probing of the Tp53 pathway.\n期刊:Carcinogenesis\n作者:Taylor A Sohn; Ravi Bansal; Gloria H Su; Kathleen M Murphy; Scott E Kern\n出版日期:2002.0\npmid:1.2082016E7\nmesh_terms:D000677:Amsacrine; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D002470:Cell Survival; D003110:Colonic Neoplasms; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D016158:Genes, p53; D006801:Humans; D008156:Luciferases; D010190:Pancreatic Neoplasms; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D013487:Research Support, U.S. Gov't, P.H.S.\n化学列表:D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D000677:Amsacrine; D008156:Luciferases\ndoi:10.1093/carcin/23.6.949\n语言:eng\n附属机构:Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.\nmedline_ta:Carcinogenesis\nnlm_unique_id:8008055\nissn:0143-3334\n国家:England\ngrant_ids:[{'grant_id': 'CA 62924', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'CA68228', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}]",
  "pages": "949_57",
  "journal": "Carcinogenesis",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000677:Amsacrine; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D002470:Cell Survival; D003110:Colonic Neoplasms; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D016158:Genes, p53; D006801:Humans; D008156:Luciferases; D010190:Pancreatic Neoplasms; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D000677:Amsacrine; D008156:Luciferases",
  "grant_ids": "[{'grant_id': 'CA 62924', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'CA68228', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}]",
  "other_id": " ",
  "pubdate": "2002.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D013487:Research Support, U.S. Gov't, P.H.S.",
  "issue": "23(6)",
  "languages": "eng",
  "abstract": "Human Tp53 is normally a short-lived protein. Tp53 protein is stabilized and levels are increased in response to a variety of cellular stresses, including those induced by genotoxic anticancer drugs and environmental exposures. To engineer an efficient assay based on this property, we constructed and integrated a Tp53-specific reporter system into human cancer cells, termed p53R cells. We tested a range of conventional chemotherapeutic agents as well as over 16 000 diverse small compounds. Ionizing radiation and two-thirds of conventional chemotherapeutic agents, but only 0.2% of diverse compounds activated Tp53 activity by two-fold or greater, consistent with the presumptive genotoxic activation of Tp53 function. Cytotoxicity was independent of TP53 genetic status when paired, syngeneic wild-type TP53 and TP53-null cells in culture were treated with compounds that activated Tp53. From the unbiased survey of random compounds, Tp53 activation was strongly induced by an analog of AMSA, an investigational anti-cancer agent. Tp53 was also strongly induced by an N-oxide of quinoline and by dabequine, an experimental antimalarial evaluated in humans; dabequine was reported to be negative in other screens of mutagenicity and clastogenicity but carcinogenic in animal studies. Further exploration of antimalarial compounds identified the common medicinals chloroquine, quinacrine, and amodiaquine as Tp53-inducers. Flavonoids are known to have DNA topoisomerase activity, a Tp53-inducing activity that is confirmed in the assay. A reported clinical association of Tp53 immunopositive colorectal cancers with use of the antihypertensive agents was extended by the demonstration of hydralazine and nifedipine as Tp53-inducers. p53R cells represent an efficient Tp53 functional assay to identify chemicals and other agents with interesting biologic properties, including genotoxicity. This assay may have utility in the identification of novel chemotherapeutic agents, as an adjunct in the pharmaceutical optimization of lead compounds, in the exploration of environmental exposures, and in chemical probing of the Tp53 pathway.",
  "pmid": "1.2082016E7",
  "nlm_unique_id": "8008055",
  "issn_linking": "0143-3334",
  "filename": "pubmed24n0399.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Taylor A Sohn; Ravi Bansal; Gloria H Su; Kathleen M Murphy; Scott E Kern",
  "doi": "10.1093/carcin/23.6.949"
}
{
  "country": "England",
  "keywords": " ",
  "references": " ",
  "pmc": " ",
  "affiliations": "Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84112-0565, USA.",
  "medline_ta": "Br J Haematol",
  "title": "TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.",
  "delete": " ",
  "content": "期刊:158(6)\n页数:763_71\n摘要:The TP53 (p53) pathway can be inhibited by TP53 mutation or deletion or by MDM2 overexpression. Both occur in Burkitt lymphoma (BL), but many cases lack either abnormality. Expression patterns of the TP53 inhibitor MDM4 have not been reported in BL, and increased MDM4 could deregulate the TP53 pathway in cases without TP53 or MDM2 abnormalities. We investigated TP53 pathway disruption in paediatric BL patient samples (n = 30) by studying MDM4, MDM2, and CDKN1A (p21) protein and mRNA expression; TP53 mutations; TP53 protein expression; and gene copy number abnormalities. MDM4 protein was expressed in 30/30 tumours, and MDM2 protein was weakly expressed in 7/30 (23%). All cases were negative for CDKN1A protein, and CDKN1A mRNA levels were decreased. TP53 mutations were detected in 5/28 (18%) cases and confirmed by sequencing. TP53 protein was expressed in 15/30 (50%) cases, including 7/8 with TP53 genetic alterations. MDM2 protein and mRNA expression levels did not correlate with lack of TP53 genetic changes or TP53 protein expression; however, there was an inverse relationship between detectable TP53 protein expression and MDM4 copy number gains and mRNA expression. The TP53 pathway is deregulated in paediatric BL cases, and increased MDM4 expression may be the primary mechanism in some cases.\n期刊:British journal of haematology\n作者:Vasiliki Leventaki; Vladimir Rodic; Sheryl R Tripp; Michael G Bayerl; Sherrie L Perkins; Phillip Barnette; Joshua D Schiffman; Rodney R Miles\n出版日期:2012.0\npmid:2.2845047E7\nmesh_terms:D002051:Burkitt Lymphoma; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004273:DNA, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006801:Humans; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D051736:Proto-Oncogene Proteins c-mdm2; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:C493956:CDKN1A protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004273:DNA, Neoplasm; C482775:MDM4 protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2\ndoi:10.1111/j.1365-2141.2012.09243.x\n语言:eng\n附属机构:Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84112-0565, USA.\nmedline_ta:Br J Haematol\nnlm_unique_id:0372544\nissn:0007-1048\n国家:England\ngrant_ids:[]",
  "pages": "763_71",
  "journal": "British journal of haematology",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D002051:Burkitt Lymphoma; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004273:DNA, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006801:Humans; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D051736:Proto-Oncogene Proteins c-mdm2; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "C493956:CDKN1A protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004273:DNA, Neoplasm; C482775:MDM4 protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2012.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "158(6)",
  "languages": "eng",
  "abstract": "The TP53 (p53) pathway can be inhibited by TP53 mutation or deletion or by MDM2 overexpression. Both occur in Burkitt lymphoma (BL), but many cases lack either abnormality. Expression patterns of the TP53 inhibitor MDM4 have not been reported in BL, and increased MDM4 could deregulate the TP53 pathway in cases without TP53 or MDM2 abnormalities. We investigated TP53 pathway disruption in paediatric BL patient samples (n = 30) by studying MDM4, MDM2, and CDKN1A (p21) protein and mRNA expression; TP53 mutations; TP53 protein expression; and gene copy number abnormalities. MDM4 protein was expressed in 30/30 tumours, and MDM2 protein was weakly expressed in 7/30 (23%). All cases were negative for CDKN1A protein, and CDKN1A mRNA levels were decreased. TP53 mutations were detected in 5/28 (18%) cases and confirmed by sequencing. TP53 protein was expressed in 15/30 (50%) cases, including 7/8 with TP53 genetic alterations. MDM2 protein and mRNA expression levels did not correlate with lack of TP53 genetic changes or TP53 protein expression; however, there was an inverse relationship between detectable TP53 protein expression and MDM4 copy number gains and mRNA expression. The TP53 pathway is deregulated in paediatric BL cases, and increased MDM4 expression may be the primary mechanism in some cases.",
  "pmid": "2.2845047E7",
  "nlm_unique_id": "0372544",
  "issn_linking": "0007-1048",
  "filename": "pubmed24n0732.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Vasiliki Leventaki; Vladimir Rodic; Sheryl R Tripp; Michael G Bayerl; Sherrie L Perkins; Phillip Barnette; Joshua D Schiffman; Rodney R Miles",
  "doi": "10.1111/j.1365-2141.2012.09243.x"
}
{
  "country": "Switzerland",
  "keywords": "TP53 mutation; chronic lymphocytic leukemia; genetic analysis model; mutation database; variant classification guidelines",
  "references": "31365877;26639348;27503198;21930502;27680515;20975744;26024390;30371878;28297623;27600092;30530801;15580553;21152010;26919551;11136261;2052620;29625049;25287991;22297721;30602617;27178240;24665023;23782158;21457909;33230179;7888675;29715056;34285062;31166681;15108276;7795639;20676075;28254861;32726532;29696732;25741868;31974198;26206375;30514802;7949187;8241511;28592889;33257846;27993330;27328919;28566340;29979965;13369537;27666373;11337480;21727090;24487276;24501221;22025002;20354512;26837699;24071849;31023700;26911189;34174984;32015491;1588788;25583119;24478183;32209572;29467486;30224644;29226803;30262567;26675346;15851479;16397025;19561590;12826609",
  "pmc": " ",
  "affiliations": "Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.",
  "medline_ta": "Front Oncol",
  "title": "Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases.",
  "delete": " ",
  "content": "期刊:12()\n页数:808886\n摘要:Locus-specific databases are invaluable tools for both basic and clinical research. The extensive information they contain is gathered from the literature and manually curated by experts. Cancer genome sequencing projects generate an immense amount of data, which are stored directly in large repositories (cancer genome databases). The presence of a TP53 defect (17p deletion and/or TP53 mutations) is an independent prognostic factor in chronic lymphocytic leukemia (CLL) and TP53 status analysis has been adopted in routine clinical practice. For that reason, TP53 mutation databases have become essential for the validation of the plethora of TP53 variants detected in tumor samples. TP53 profiles in CLL are characterized by a great number of subclonal TP53 mutations with low variant allelic frequencies and the presence of multiple minor subclones harboring different TP53 mutations. In this review, we describe the various characteristics of the multiple levels of heterogeneity of TP53 variants in CLL through the analysis of TP53 mutation databases and the utility of their diagnosis in the clinic.\n期刊:Frontiers in oncology\n作者:Thierry Soussi; Panagiotis Baliakas\n出版日期:2022.0\npmid:3.5251978E7\n出版物类型:D016428:Journal Article; D016454:Review\n关键词:TP53 mutation; chronic lymphocytic leukemia; genetic analysis model; mutation database; variant classification guidelines\ndoi:10.3389/fonc.2022.808886\n参考文献:31365877;26639348;27503198;21930502;27680515;20975744;26024390;30371878;28297623;27600092;30530801;15580553;21152010;26919551;11136261;2052620;29625049;25287991;22297721;30602617;27178240;24665023;23782158;21457909;33230179;7888675;29715056;34285062;31166681;15108276;7795639;20676075;28254861;32726532;29696732;25741868;31974198;26206375;30514802;7949187;8241511;28592889;33257846;27993330;27328919;28566340;29979965;13369537;27666373;11337480;21727090;24487276;24501221;22025002;20354512;26837699;24071849;31023700;26911189;34174984;32015491;1588788;25583119;24478183;32209572;29467486;30224644;29226803;30262567;26675346;15851479;16397025;19561590;12826609\n语言:eng\n附属机构:Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.\nmedline_ta:Front Oncol\nnlm_unique_id:101568867\nissn:2234-943X\n国家:Switzerland\ngrant_ids:[]",
  "pages": "808886",
  "journal": "Frontiers in oncology",
  "_inference.semantic_vector": "2zbvvCVper63bds8krRMvkka6T6SrI0+bmkGvtvOZT0lsQ8+JYn8vRcVzb0lCTS8kjRnvSWJ5T6SJEq920aKPtvuFD63Tbo823aJvTc1kz23RRQ+bs+Fvm4bBz6S5AE9Sbbzvbettz0luY8+t10hvklixr1JXpg+ty1nPCX5kD0AsFE+JbmXvdu6V74AzC0+t6mwvUnS7j7bhnY+STLcPduWfT63lSi+twXjvrcdvD3blg2/SXXgvkkSVsAlcUU+SYLgvUkU4LzJI0W+JSmZPdu20joliZM+t8kSPm4TnD6SBJc9bnuhvgDoR75JEgK/SdL9PZJknLxue0c+SRafPgDIPD5Jctk+ALoZviXtkL1umxa/khQCvyXFwT23TVM+JRm5vm6rAT7bVk88bms7PNu6wr4AwEw+koTaPiXp2T6SnBy+ksRRPAAo9b0lb/c9krSRvNvOrb63jco+AJIKvZJQnT2fHtK+250bPiVlEr6S3Kc+kiR6O25Pkr2S5Lg9kkRiP0liuL0AOBc+20YLviVp2L5Jijs+SaqrvgBSCz4lKQS/iecHPm57kr7bdp49khSSvrd5or1Joq2+bhsiPZKE674AaHS+t23bN25buj4lmw8+kmTDvkk2Mz637SE+AJaTvrft2D5Jkn48kl7CvZJU2j2SnHq+bmc1vm77C72SjA2+SUqLvUnCQD6SRIu92ybNPm77Wr7b7l89breHvtsmkb4lVf09t003Pkn++D3btm08SYJqviUp3j3b1qa+JT4lPrctP7+SfDK+SVyDvgC8m7233XU+2977vQBAjj1uYxE+23AFvm7jlb6SJOc+bjs1vW47Nz63rRu+Jenyvm676z3bRpK9kgRkvm7rp75JMkk+23aTvQDYQD7bpv09t1UgvUmSPb9Jcja8SfL4vreN3z1uRyK+kmRmPG4TAT9JH4E+ty11PSXJ8jzb7l2+bvufvgAA0T5umZ6+bithvkmSpLhJoiA+bnt8PpKkkz6SRJw8JdkGPwAqHr+37ea+JZnUvdsGRb5JUjo/u0sOvkmSPT3bfAE/koRgPSVRhz3bTim+JUmwO9t2jz8AwPA822imvklSVr4lqWm+tzVHvpI8YT7bdn++t81IPZKEYT1JEuG9Sf4DPwC8fL3bVni92yYMP1u2H77bJhY/biuIvklS1T6SRHe+JUn0PADQUj0lwQe+t+ldPpJYIj4lSca8AGDqPrctTT6S8DY+AKC2vQCQnj4AABC7gOcJPumGI71u+8S+kqT+vUmSIjsAsCK+Jfk+Pm6qsj63PbW+t608vtu2+b1u65i9Se4CPttmH70lidy9JTGMvbdta7tJ0kc+SUL/vSXpNr7bdjk9t9WnPdv2L71JYk++JamMPW57Gz3b9sW8klSevtscyj3bxiq+AEhFPm6LN77bNjU9kuQBviV58T6S5Bc9SRLTPW5bXLwluSa/bttBPpK0Ur6SpO29dw8qPkkaHT637es8t+0ePtsK1L63PbS+txltPLddiL+3BaK+AJSQPklyOT1J+oK+tz1WPJKwoD3blii+24bPvkmC8r1J1gA+JQlSPbceCz4A8DK+bputvEkiyj4AKMM9AHAovyXnMz5JIgy+2wIkPm5TFD5urwk+t/F9vklyJT1ue6zA2+YXP7c12r3bAgm+25iiPm5tDz4AhKU+t42TPklmBT6SJAW729ZyvSXpdj1u22K7t62FvCXzTL4lq4O+AHyAviXJPD4lqaI9t+2BvUlCZL5uW8K+AOiRvZI0RD7uWji+JQlLPkniIL8ASJc8247dvm5RDr9JshY+JamMvtuGJT1us6i+JZUHPgBk2b23JY++ALDWvQA4CL6SFM6+tx0iPwAQO75JQsu9SdLwvgBAk7xuizq/bn+wvretej5uWz6+krwKvSXZN763rRg+W1+kPrel0D1uRWW+JTFEvttWDT8A9EG+STJfvSW5HL0AMME+ty3bvSVtnb5uoxm+btmsvhvkDD5uGwu+khy4vm6rgT6Ss1Y+kvTTvm7LRj4A0ES+JQJvPW5Fkj23Tba+26wAvEmS1LtL45y+JW0/PgDASz4AQPI8kkTePtujBz4l6aS9SSazvgDQpb7bds++tw0fvbctd71us8A+ScJNviWbUr7rtsQ9t83fPrd9Ej5Jkk29t43LPkmKWj4AqAm8JSlkP7dtdL4AAGa9SSKpvm6LKr6SlE6+JZkdv0kOcT5u6689bhrFviVJ6bxJMqO9kqQRvm4bGb9JsuY9brswPSVhnj7b9iO9JWk/vW57Ib63jTW/t0l9Pm5LFb9JChO9ktTyvUmy4bzbWgE+bpMoPttGub1uywO/khw5vrc9Jj6SHLM9gCRlvpLEUz6SVJ4+CYCWviWJLj5J0pW9AJBBPgBomj1uy189kqwQvSVlFD63te49t20OvtuW9z7bNmm8JVk9vds+Ij0lyTq9btsYPJLkAz0AEHA+AJiNvgAAXjy3rYQ9bvMpPgBwwrwA0IK+bvtQvgCgB74AQHa+koSLvgAQ/r0AQNC922q8PrddaT2SJGa+AADMvbftuLslKWA8AJQcPgAQAL0AQJm9SZJkPm7DfjwlWQm9bjtZPds2MT9uv7m+btuovZIkPDxJ8jE+27YVPyUpxj4lyfG+27Y2vLdVqb63+ZS+bostvgBgOz2SxGM927YAvSXRbr4AYKm+brtGvklUAT8lSR89SRI5vdv2Ab4AkBE/SZJfPdu2p71u34E+twW7vUn6GL1luaK+t7W7viXpBjxuE849SRKjvdvWDz0AAKS8biMTPpLcor5JIg29kuRGvdsOqb4lyQw/bvtePm6jDT9uMKA+AHBgvpL8hr4AtEE+JbckPtsmwb5uGx4/brMbPklKgD4A0Iy+SSIZPred0T7bpuK+ABC8vpKEkj2S8JE+paWkPds2rL2SJCK8AFrjvQDSj74StRS+Jc+1vZIEsr5u24U+JZkOPbdlKz6S9GU+t2RXvknyt7y37fc8AAByPLdJ2T6SFOo+bvsLvpLqBL/bFme+Sfo+viX5kjzb5lg+bhuTvdvEPj3b1qs+JQP+PNswCL5uO+i+bgu4PgCwjD5uYSc9brvTvbdtEzxuGxk/tz2KvQAALrzbNtc9khRrPpKziz5u29W+kiR5PQDA9D1uqbk9SbLrPUliR76SJFS7ADDWPZJUv70lyUK82/acvZJUiT0lybI+kogIPiUpaL1J6Ds+ADAkvrftMLxuG+8+JaHQPm5bxDzbdry+koQAP7fN6T0l8Xq+JVCFPpIuaL1Jkta8ksRFviVpzL5JovM+Wx8NPyWJ7T0l+Rs+SZIWO5JcDL+3jWA9ktgJv5LtM77uf10+SRLPveugwT5uQc8+ALidPkkiC7ySfJo+t70SP5LECz63bXY+215oPiUBOD5JkgQ9ACDdvpIUdz6SUDw+2wbEvgAQrT2SxLs9JQmOOpK0TD7bqmm+AKAiPkk6Nz/b3m6+klapPdvqhz0AANg9SWL2vUne5j23ze0+gMD0PkmSVDxJula+d/OWvdtWkj23aaA92xYuvrf1Eb6S1IK+254Dvm4DjL6SNH2+SfLEPpKE6T63PZc+khR8vtuWMb2SSAQ/SZL8vSWZKj8lTzA+l6mSvduKlb6SpMS+AIDmPEkidD4lyS2+AOAKPiXXgb5JUs++2zZoPm4rWr4lfR2+tz33PQBgkL0lkcw927a4vCXj5j23Kwg+2wTrPQAAsb5uIcQ+bmsiv5IUIT/bMkM+27bnuwAApTySiJo+t81fPknyHD4A2qM7206RPgDgO77bMga+blvLPrc9Xr6SRD48t3M0vSWdgz7bbpq+225/viXpaT0lkE0+SUwUvttqhz5uQzI+2+Z3vrct8r0AwPM+2x6HvgBgz71uL1o+buuNvrf9BT8AELA+t2H7vpJVgD0uSHw+JZlAvknAbT6S7cc9JdmzvQDoZz2SHIK+t43CvADGsb63rWu+kmS+viUB8z4A4HW+21I8vpIEXb6SsBU+t/EjvgCghL23bf+7W7xqvG7blTtur+69bqOCvkmEjD4Aqjc9AIDQPdvm+r23GYi+klIfPm5Lxr5uq7i9t60CPiVJmrq3Xak9",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D016454:Review",
  "issue": "12()",
  "languages": "eng",
  "abstract": "Locus-specific databases are invaluable tools for both basic and clinical research. The extensive information they contain is gathered from the literature and manually curated by experts. Cancer genome sequencing projects generate an immense amount of data, which are stored directly in large repositories (cancer genome databases). The presence of a TP53 defect (17p deletion and/or TP53 mutations) is an independent prognostic factor in chronic lymphocytic leukemia (CLL) and TP53 status analysis has been adopted in routine clinical practice. For that reason, TP53 mutation databases have become essential for the validation of the plethora of TP53 variants detected in tumor samples. TP53 profiles in CLL are characterized by a great number of subclonal TP53 mutations with low variant allelic frequencies and the presence of multiple minor subclones harboring different TP53 mutations. In this review, we describe the various characteristics of the multiple levels of heterogeneity of TP53 variants in CLL through the analysis of TP53 mutation databases and the utility of their diagnosis in the clinic.",
  "pmid": "3.5251978E7",
  "nlm_unique_id": "101568867",
  "issn_linking": "2234-943X",
  "filename": "pubmed24n1126.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Thierry Soussi; Panagiotis Baliakas",
  "doi": "10.3389/fonc.2022.808886"
}
{
  "country": "United States",
  "keywords": "TP53; chronic lymphocytic leukemia; clonal evolution; next generation sequencing; p53",
  "references": " ",
  "pmc": " ",
  "affiliations": "Central European Institute of Technology, Center of Molecular Medicine, and Faculty of Medicine, Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic.",
  "medline_ta": "Hum Mutat",
  "title": "TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.",
  "delete": " ",
  "content": "期刊:35(6)\n页数:663_71\n摘要:In leukemia, TP53 mutations are not frequent but clearly associate with impaired survival and therapy response. Here, we describe the biological and clinical consequences of TP53 dysfunction as well as the methodical aspects of TP53 analysis in chronic lymphocytic leukemia (CLL). In CLL, TP53 defects are routinely analyzed as part of disease prognostication. Deletions of TP53 locus (17p) have been uniformly detected using I-FISH for several years. Since monoallelic mutations have also been shown to have negative prognostic impact, it is recommended to examine both TP53 mutations and deletions. Several methods are used to detect TP53 mutations, and next-generation sequencing (NGS) is becoming a convenient option for routine analysis. Besides this, ultradeep NGS permits the detection of minor clones carrying TP53 mutations, even below 1%. The prognostic impact of minor TP53-defective subclones is currently unknown, nevertheless they unequivocally bear the risk of being selected by therapy. Prospective studies assessing the consequences of carrying such clones are in progress.\n期刊:Human mutation\n作者:Jitka Malcikova; Sarka Pavlova; Katerina Stano Kozubik; Sarka Pospisilova\n出版日期:2014.0\npmid:2.4415659E7\nmesh_terms:D004252:DNA Mutational Analysis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D011379:Prognosis; D017384:Sequence Deletion; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D016454:Review\n化学列表:C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53\n关键词:TP53; chronic lymphocytic leukemia; clonal evolution; next generation sequencing; p53\ndoi:10.1002/humu.22508\n语言:eng\n附属机构:Central European Institute of Technology, Center of Molecular Medicine, and Faculty of Medicine, Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic.\nmedline_ta:Hum Mutat\nnlm_unique_id:9215429\nissn:1059-7794\n国家:United States\ngrant_ids:[]",
  "pages": "663_71",
  "journal": "Human mutation",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D004252:DNA Mutational Analysis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D011379:Prognosis; D017384:Sequence Deletion; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2014.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D016454:Review",
  "issue": "35(6)",
  "languages": "eng",
  "abstract": "In leukemia, TP53 mutations are not frequent but clearly associate with impaired survival and therapy response. Here, we describe the biological and clinical consequences of TP53 dysfunction as well as the methodical aspects of TP53 analysis in chronic lymphocytic leukemia (CLL). In CLL, TP53 defects are routinely analyzed as part of disease prognostication. Deletions of TP53 locus (17p) have been uniformly detected using I-FISH for several years. Since monoallelic mutations have also been shown to have negative prognostic impact, it is recommended to examine both TP53 mutations and deletions. Several methods are used to detect TP53 mutations, and next-generation sequencing (NGS) is becoming a convenient option for routine analysis. Besides this, ultradeep NGS permits the detection of minor clones carrying TP53 mutations, even below 1%. The prognostic impact of minor TP53-defective subclones is currently unknown, nevertheless they unequivocally bear the risk of being selected by therapy. Prospective studies assessing the consequences of carrying such clones are in progress.",
  "pmid": "2.4415659E7",
  "nlm_unique_id": "9215429",
  "issn_linking": "1059-7794",
  "filename": "pubmed24n0781.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Jitka Malcikova; Sarka Pavlova; Katerina Stano Kozubik; Sarka Pospisilova",
  "doi": "10.1002/humu.22508"
}
{
  "country": "United States",
  "keywords": "P53; TP53; acute myeloid leukemia; leukemia; therapy",
  "references": " ",
  "pmc": " ",
  "affiliations": "Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.",
  "medline_ta": "Genes Chromosomes Cancer",
  "title": "The role of TP53 in acute myeloid leukemia: Challenges and opportunities.",
  "delete": " ",
  "content": "期刊:58(12)\n页数:875_888\n摘要:The tumor suppressor gene TP53 is one of the most frequently mutated genes in human cancer. The central role of the TP53 protein in several fundamental processes such as cancer, aging, senescence, and DNA repair has ensured enormous attention. However, the role of TP53 in acute myeloid leukemia (AML) is enigmatic. Unlike many other human cancers, a vast majority of AMLs display no genomic TP53 alterations. There is now growing appreciation of the fact that the unaltered TP53 status of tumor cells can be exploited therapeutically. As most AMLs have an intact TP53 gene, its physiological tumor-suppressive roles could be harnessed. Therefore, the use of pharmacological activators of the TP53 pathway may provide clinical benefit in AML. Conversely, even though the frequency of TP53 mutations in AML is substantially lower than in other human cancers, TP53 mutations are associated with chemoresistance and high risk of relapse. In patients with TP53 mutations, these alterations may lead to novel, selective vulnerabilities, creating opportunities for therapeutic targeting of TP53 mutant AML. The mutational status of TP53 therefore poses challenges and opportunities in terms of advancing effective treatment strategies in AML. An increasing armamentarium of small-molecule activators of the TP53 pathway, and a growing understanding of molecular pathways triggered by mutant TP53 have accelerated efforts aimed at targeting TP53 function in AML. In combination with standard AML chemotherapy or emerging targeted therapies, pharmacological targeting of the TP53 pathway may provide therapeutic benefit in AML.\n期刊:Genes, chromosomes & cancer\n作者:Karina Barbosa; Sha Li; Peter D Adams; Aniruddha J Deshpande\n出版日期:2019.0\npmid:3.1393631E7\nmesh_terms:D016158:Genes, p53; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D009154:Mutation; D016159:Tumor Suppressor Protein p53\n出版物类型:D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't; D016454:Review\n化学列表:D016159:Tumor Suppressor Protein p53\n关键词:P53; TP53; acute myeloid leukemia; leukemia; therapy\ndoi:10.1002/gcc.22796\n语言:eng\n附属机构:Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.;Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.\nmedline_ta:Genes Chromosomes Cancer\nnlm_unique_id:9007329\nissn:1045-2257\n国家:United States\ngrant_ids:[{'grant_id': 'P01 AG031862', 'grant_acronym': 'AG', 'country': 'United States', 'agency': 'NIA NIH HHS'}, {'grant_id': 'NIH/NCI P30 CA030199', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'P01 AG031862-11', 'grant_acronym': 'AG', 'country': 'United States', 'agency': 'NIA NIH HHS'}]",
  "pages": "875_888",
  "journal": "Genes, chromosomes & cancer",
  "_inference.semantic_vector": "cjnnveSoWr4A3P69cnx8vo7jrj6OS0U+AABzu6v+wj1VpXo+pGqLvjmOKT2rgqE9q9psPeSY7j5VxY6+gC7fPse5aT4clzw+q+CbveQ4Tb3HwUQ+Of4zvo7sAT6rDGk+AKDiPfkIP77k2IA+cviivuSg970cp7w+APhHvswTrT2Oo8s+x3HHPDk9mr5VJb0+cqz8vQDQvz7k9Ac+HMczu+SomLzOTpa+coAXv8fxdT0cF5S+xxEFv+T4X8DHcQg+jlPuPQBylr4ABN+9jmMVvI7RPT0A4IQ+xzGcPsc5vD5yjBU+5ABrvqu6cr45fjS/cpINPschdr4cB0i8ckxaPRz7pT3HUVE+AJikPeSclL4AiB+/x3n1vhwF7r2rQCk9x1KRvsc7BT6rqtU8HKegvY5rkL6Oo9w9VWWqPqsqID8cVzm9juPFPY6Nlj3HweQ+cpxlOzle777HeVo+XCEAvquS6D5VYaS+Of67Pcd5fr5ybFw+VeUcPY6bTD7V1YM+q0pWP47aQb4c5zM9x3HDvHIs2b45diO9q60rvjmujb0AcCC/jnsePlUJWL4cxSI9cjzfvlUNBz4AxD++jkWePVWts75Vvbu+5OxzPcct0T6Oo8q9Oe4WvKtqCz3HcUK9ckgCvhwXDD85Gim+qxoEPdzyrz0A6JC+gqsgPjm+H75yZJq+qyJSPgJkFL4cb068OQ7lPlUxIr4AFAo+AACuuxxHtj1V1Yo8VegoPnLuiT6rypy95LiWvlW1RT4AFLq9jqsxPo7zS79ylF6+clw+vRyfW745fto9ALyQveTo7r3k6N09Of4Avse5lL7HRdM+VX0ivgBcgD6OQ9S9jqPSvhygiD7kuHY9jtzCvHIEar45ntI+cizZPqsqvDzk+FI8VceSvVV1Nb85fmS9jlNpvjkOW72rmlO+Oe4oPcc8wD7kOKo+HKsHPsfRab451jS+OY6AvmRvGT5VM4q+ACiavlX1UD45TsA8AMBZPo7nQj7kfJ0+csy/PuRQIL8c9/S+jgN0PsflnL7kaEY/jgwOvuSYxryO1Rc/AIAgPjl2lT4AYD++jhd/vI4zgD8cV689cvTkvnK82r5VBQC+OWZlvgBgQz7H7ba+wPEKPgBEDj45xhq+x2HUPgDAazwAKEC+HHcNPzly0D1VzQI/5JZTvsfxPz1VZd++5Oh1vqu8rz6rGjU+ACxwPjl+MD4AcI6+jgPmPuSTtj6rUmA9Vd0kvo5TBD/HsS+9OZpHPqtOlb3kWJK+x9HmvRy3Ez4AqEW+ADx5vMfRvz4AnAe/q6qivccRKb4cD0u+OU76PQB1Kr0cX7g9AAC0POuKyb7OS0i+HPf/PFUtoTwADHU+ACD2PHIc5r1VPbw9AMBOPavqs705nmi9q96SPQBEPL0cR/68shRePuTo/b7kXGs9ctGrPVXpnj5VVdi8q3KJPsfxrrxyLDW/juE4vRzA7r4ck6+9Ob4IPnIcxz7HbZQ9x6GJvOScFL7HgdS9x7HQPMfRqb8ce2u+Ob7WPqtMAr5yPFq+ckMCPuRUGz4AcKG+AGDSvuSu2r1V7WM+q+rJvMeRljxyZDi9AJhdPlU9jD5VLUa9cixmv47jE76Ow32+ckyUPnIc6z2OMzC9xxClvXIc8Twcx6fAAPCpPjkiiL6rKk+9q7K1PnKgpj7k2PQ9cqyqPgDGjT7kCNE9q6qVvcd5aj05jpi8OW4zPcfxX76rOta+OaaGvjkOyLwAgFw9VRVPveTOUz6OO4C+AGA1vBy/BD5yrIG95DiCPuTF6b4AIG89OT5fvlUVDL+Oc9w9joXAvccFkD1yiFC+VY1PvXJMtz2VOgm+cjSPvauKebwcp8m+HBUMPznez76rqhy8clQEv+TzFb7H8UG/jmPYvjmeFj7eOIM9VfXzvce5qb0ct8M+jkPTPsfxXT5VIam9x9wSvRz2VT7kuMu+HEfPvcd6jD5V/WA+DkUcPqvqCb6r+ji/crSEvuRojrxybMI9cvTXvo7v0D6COS8+jsuzvscxLLwct3G+HMfRugBkF72rVtS+AGB/PTmWir4AfIa+5EihPseBbL05srW9jvfmPlXVy7sAQJy9ckTIvjlkAb+OM26+q8rWPY4ftz45xuU+OeZHvlXlEz5Vgw0+AFDvPjm+aL3kCIW+ORHKPsdVyj6OM409q0pOP3IpW77HsV09x3H/vgAmwb5VtZW+x3kAv6t6XT7kOFc+HIdQvlUtA76Ogw885Oj+PXI8Jb+rKrO9jmO6PBwPFz6OcwO+ANAcPY4jSr4AwCu/AIaHPsdx/r7H0QI85JhGvo4LjT7kwH0+cnwKPo7j073Hod6+cpwAPEvZmj7kuIQ8qwhIPhyvkT3kaJ4+cuQ0vhwPyT45Nte9cnx5PuQOC74c11k95OhYvRz7hrwAUOQ9HH+5vo4bzD5yzFe+5IjavBwakT05TtK8jrE4PgBwkD1VBUw+qx62vQDw/b2rqmG8x+kevRxt1b1y1HS+HEdjPMdxBr0AYKm+VYVLvlXtMz1VDTW9cgqDPjme0b3kQE2+VXVBvVU9Wb6rzku+jlsovhwPMz2rcl69OY6mvQDQ6z2O95S+ck9svqvO/j7yiZS+qwq4vDkOFL1V24o+VbXJPuRocj0cF3a+HKeCvlWV176rSsq+OZbSvo5j4z0AYOg85OQSvlVVub2Oi6C+HIniveSItz45xtM9OY62PHIkar3kELE+x3FbvBw3yb3kbBw+csw9vnJcVr2Ob4s+8s6cvlVBwTxysCk+ckyyvavK+z4cr4W8q5ahPXJMK76ritS95CAcPRyf2b05HvI+juq9Pjlurz7HAcM+HOuEvuQg2b4c3dq9OQ5au8cpv77HcTg/VaWhvse5yT5yxKq+jvufPquavD6rnja+OZaevjmOOT3kENE8HGgovqs+F75VxdU9OQ7PvByXGL6+udy9x2klvnIcyL0AwDc+x/F4Phznnj0AKJE+jqNhPjkZQz2rCwg95LO9vVVNBj+rjrY+HKt/vgDQ4L459o2+x1GPvuSoSD1yHMA+5AiNvgDACT6Oo64+OeAbvuQASb6O4Qm/x6GpPqvCeD5V/zi+jhOdvY6nnL5y7BY/HF8kvnLEVLzHXRw+Oe7JPjluFD1y6Ay/qwIXPcdJFD5ylEo+x3Ehu1UVJT4AxDm+HEPzPXIcxjyrlMO9HH+SPVU1VL7k0I4+qzqpPsfxqzoAMke+VWUivhxbMD45nm4+VZnePuS4Jz6revC+AHisPqtmCj6Ou1e+jmO/vsdx2bwcx8C9HN+Rvo7fhr4cs9A+jiOyPqsKPz0AwMU+AHByPscJIb8cJ0M9cpRyvjnOkr0AAII6Vfm4vTnO8T7H8U0+Vb04PceXJD0AyLc+Oc76PlX1cb2Oi/w9AEx5PlWVxT5y+Kw9q5aCvuRiCD5V5ag+OYYkvhx/vT2r+uE9OQ4cvMdRpz2OCxe+x1GyPRzHND/HAU6+jlPDvo4D0D6Oq24+OX7dvcfBnD7HtNA+cmjXPjkOBj2rSpI8xxGFvjmOorscw1c+cmgMvgAQWL050oi+cvQJvgAoWb7kgJS+jtNAPTkOKD9VhSw/HEdBvo7vEr7kOMk+HAflvQA4Pz8cB8u8jkNbPav6vL0AoFC+OY6Yu4ComT6rrsy9x+GgPQBs6L6ruGG95KhgPlVFh7xVwRS+5IgePsfRGL8APJm9HJdovgDKUj5VVVO7AEc/vuRQmr5yiLU+HCcqvxy7Bj/k2DM+x13uPRwnRj6O58Q+jnmZveTAXT4cd6o+y5GNPgAwAT5VhRw+5GiRPjluer6rko6+x7EGveR4JL3kmFO+HBfRvqsCxT3k+MA+jvcLvnIc9zrk+6E95GQsvgAA6DlVlbg+ANgQvhy3xL4AkHo+qypuvscNBj/Hgco+AFj/vuS47ztVVbA+chwGvatOtD6O7yw9cn4LPsdhtb3kMMq+HEfsvDnOyb6r+i6+q6qNvuQoFD9yHL+8cqzWvsdxwr1VFcs9jrstvI7j87wcT68+B0r6vccxDb2r6sa+VVVuvqvypD05DjU+OZbLPByHIrurcuW95HhqPlW1p77kuNG7AIgLPgBxHL6r5qm9",
  "mesh_terms": "D016158:Genes, p53; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D009154:Mutation; D016159:Tumor Suppressor Protein p53",
  "chemical_list": "D016159:Tumor Suppressor Protein p53",
  "grant_ids": "[{'grant_id': 'P01 AG031862', 'grant_acronym': 'AG', 'country': 'United States', 'agency': 'NIA NIH HHS'}, {'grant_id': 'NIH/NCI P30 CA030199', 'grant_acronym': 'CA', 'country': 'United States', 'agency': 'NCI NIH HHS'}, {'grant_id': 'P01 AG031862-11', 'grant_acronym': 'AG', 'country': 'United States', 'agency': 'NIA NIH HHS'}]",
  "other_id": " ",
  "pubdate": "2019.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013485:Research Support, Non-U.S. Gov't; D016454:Review",
  "issue": "58(12)",
  "languages": "eng",
  "abstract": "The tumor suppressor gene TP53 is one of the most frequently mutated genes in human cancer. The central role of the TP53 protein in several fundamental processes such as cancer, aging, senescence, and DNA repair has ensured enormous attention. However, the role of TP53 in acute myeloid leukemia (AML) is enigmatic. Unlike many other human cancers, a vast majority of AMLs display no genomic TP53 alterations. There is now growing appreciation of the fact that the unaltered TP53 status of tumor cells can be exploited therapeutically. As most AMLs have an intact TP53 gene, its physiological tumor-suppressive roles could be harnessed. Therefore, the use of pharmacological activators of the TP53 pathway may provide clinical benefit in AML. Conversely, even though the frequency of TP53 mutations in AML is substantially lower than in other human cancers, TP53 mutations are associated with chemoresistance and high risk of relapse. In patients with TP53 mutations, these alterations may lead to novel, selective vulnerabilities, creating opportunities for therapeutic targeting of TP53 mutant AML. The mutational status of TP53 therefore poses challenges and opportunities in terms of advancing effective treatment strategies in AML. An increasing armamentarium of small-molecule activators of the TP53 pathway, and a growing understanding of molecular pathways triggered by mutant TP53 have accelerated efforts aimed at targeting TP53 function in AML. In combination with standard AML chemotherapy or emerging targeted therapies, pharmacological targeting of the TP53 pathway may provide therapeutic benefit in AML.",
  "pmid": "3.1393631E7",
  "nlm_unique_id": "9007329",
  "issn_linking": "1045-2257",
  "filename": "pubmed24n1000.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Karina Barbosa; Sha Li; Peter D Adams; Aniruddha J Deshpande",
  "doi": "10.1002/gcc.22796"
}
{
  "country": "Switzerland",
  "keywords": "TP53; bladder cancer; immunosuppression; multi-omics studies; tumor microenvironment",
  "references": "34249445;29907586;30885723;25605792;30500901;30089241;25690850;28886379;17496320;29588320;20182602;31334127;23564178;28783155;32784716;33033240;27560171;31350295;31257581;33813769;19597352;28178185;16007211;33958107;30988029;31892734;34599020;34253573;31604537;27153492;28382138;33538338;33033253;28622513;34733856;19014601;21810677;17108103;25480168;28160444;31316092;25287865;25645694;16129368;18524989;32144194;28281901;34952583;29573965;31686860;22186996;33391264;32938908;33244139;10738214",
  "pmc": " ",
  "affiliations": "Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.",
  "medline_ta": "Front Genet",
  "title": "TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study.",
  "delete": " ",
  "content": "期刊:13()\n页数:1057302\n摘要:Background: The tumor suppressor gene TP53 is frequently mutated or inactivated in bladder cancer (BLCA), which is implicated in the pathogenesis of tumor. However, the cellular mechanisms of TP53 mutations are complicated, yet well-defined, but their clinical prognostic value in the management of BLCA remains controversial. This study aimed to explore the role of TP53 mutation in regulating the tumor microenvironment (TME), elucidate the effects of TP53 activity on BLCA prognosis and immunotherapy response. Methods: A TP53-related signature based on TP53-induced and TP53-repressed genes was used to construct a TP53 activity-related score and classifier. The abundance of different immune cell types was determined using CIBERSORT to estimate immune cell infiltration. Moreover, the heterogeneity of the tumor immune microenvironment between the high and low TP53 score groups was further evaluated using single-cell mass cytometry (CyTOF) and imaging mass cytometry (IMC). Moreover, pathway enrichment analysis was performed to explore the differential biological functions between tumor epithelial cells with high and low TP53 activity scores. Finally, the receptor-ligand interactions between immune cells and tumor epithelial cells harboring distinct TP53 activity were analyzed by single-cell RNA-sequencing. Results: The TP53 activity-related gene signature differentiated well between TP53 functional retention and inactivation in BLCA. BLCA patients with low TP53 scores had worse survival prognosis, more TP53 mutations, higher grade, and stronger lymph node metastasis than those with high TP53 scores. Additionally, CyTOF and IMC analyses revealed that BLCA patients with low TP53 scores exhibited a potent immunosuppressive TME. Consistently, single-cell sequencing results showed that tumor epithelial cells with low TP53 scores were significantly associated with high cell proliferation and stemness abilities and strongly interacted with immunosuppressive receptor-ligand pairs. Conclusion: BLCA patients with low TP53 scores have a worse prognosis and a more immunosuppressive TME. This TP53 activity-related signature can serve as a potential prognostic signature for predicting the immune response, which may facilitate the development of new strategies for immunotherapy in BLCA.\n期刊:Frontiers in genetics\n作者:Yuting Tao; Xia Li; Yushan Zhang; Liangyu He; Qinchen Lu; Yaobang Wang; Lixin Pan; Zhenxing Wang; Chao Feng; Yuanliang Xie; Zhiyong Lai; Tianyu Li; Zhong Tang; Qiuyan Wang; Xi Wang\n出版日期:2022.0\npmid:3.6568387E7\n出版物类型:D016428:Journal Article\n关键词:TP53; bladder cancer; immunosuppression; multi-omics studies; tumor microenvironment\ndoi:10.3389/fgene.2022.1057302\n参考文献:34249445;29907586;30885723;25605792;30500901;30089241;25690850;28886379;17496320;29588320;20182602;31334127;23564178;28783155;32784716;33033240;27560171;31350295;31257581;33813769;19597352;28178185;16007211;33958107;30988029;31892734;34599020;34253573;31604537;27153492;28382138;33538338;33033253;28622513;34733856;19014601;21810677;17108103;25480168;28160444;31316092;25287865;25645694;16129368;18524989;32144194;28281901;34952583;29573965;31686860;22186996;33391264;32938908;33244139;10738214\n语言:eng\n附属机构:Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, China.;Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.;Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.\nmedline_ta:Front Genet\nnlm_unique_id:101560621\nissn:1664-8021\n国家:Switzerland\ngrant_ids:[]",
  "pages": "1057302",
  "journal": "Frontiers in genetics",
  "_inference.semantic_vector": "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",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "13()",
  "languages": "eng",
  "abstract": "Background: The tumor suppressor gene TP53 is frequently mutated or inactivated in bladder cancer (BLCA), which is implicated in the pathogenesis of tumor. However, the cellular mechanisms of TP53 mutations are complicated, yet well-defined, but their clinical prognostic value in the management of BLCA remains controversial. This study aimed to explore the role of TP53 mutation in regulating the tumor microenvironment (TME), elucidate the effects of TP53 activity on BLCA prognosis and immunotherapy response. Methods: A TP53-related signature based on TP53-induced and TP53-repressed genes was used to construct a TP53 activity-related score and classifier. The abundance of different immune cell types was determined using CIBERSORT to estimate immune cell infiltration. Moreover, the heterogeneity of the tumor immune microenvironment between the high and low TP53 score groups was further evaluated using single-cell mass cytometry (CyTOF) and imaging mass cytometry (IMC). Moreover, pathway enrichment analysis was performed to explore the differential biological functions between tumor epithelial cells with high and low TP53 activity scores. Finally, the receptor-ligand interactions between immune cells and tumor epithelial cells harboring distinct TP53 activity were analyzed by single-cell RNA-sequencing. Results: The TP53 activity-related gene signature differentiated well between TP53 functional retention and inactivation in BLCA. BLCA patients with low TP53 scores had worse survival prognosis, more TP53 mutations, higher grade, and stronger lymph node metastasis than those with high TP53 scores. Additionally, CyTOF and IMC analyses revealed that BLCA patients with low TP53 scores exhibited a potent immunosuppressive TME. Consistently, single-cell sequencing results showed that tumor epithelial cells with low TP53 scores were significantly associated with high cell proliferation and stemness abilities and strongly interacted with immunosuppressive receptor-ligand pairs. Conclusion: BLCA patients with low TP53 scores have a worse prognosis and a more immunosuppressive TME. This TP53 activity-related signature can serve as a potential prognostic signature for predicting the immune response, which may facilitate the development of new strategies for immunotherapy in BLCA.",
  "pmid": "3.6568387E7",
  "nlm_unique_id": "101560621",
  "issn_linking": "1664-8021",
  "filename": "pubmed24n1169.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Yuting Tao; Xia Li; Yushan Zhang; Liangyu He; Qinchen Lu; Yaobang Wang; Lixin Pan; Zhenxing Wang; Chao Feng; Yuanliang Xie; Zhiyong Lai; Tianyu Li; Zhong Tang; Qiuyan Wang; Xi Wang",
  "doi": "10.3389/fgene.2022.1057302"
}
{
  "country": "United States",
  "keywords": "Myelodysplastic syndromes; TP53 mutations; del(5q); immunohistochemistry; next generation sequencing",
  "references": "24972774;24656536;27133825;21519010;23175121;32812335;32414002;26416416;27967292;24682512;7718890;30858953;27081179;30635634;22331955;24220272;1607637;32747829;30927980;1969059;23297687",
  "pmc": " ",
  "affiliations": "U.O. Ematologia-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.C. Ematologia, Ospedale Belcolle Viterbo, Italy.;U.O. di Emolinfopatologia-Policlinico S. Orsola Malpighi Bologna Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.C. di Microbiologia e Virologia-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;SC di Ematologia-Azienda USL di Reggio Emilia-IRCCS Italy.;U.O. Ematologia con TMO-A.O.U. Policlinico Vittorio Emanuele di Catania Italy.;U.O. Ematologia Oncologica-A.O.U. Federico II di Napoli Italy.;U.O. Ematologia-Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Italy.;U.O.C. Ematologia-Policlinico Universitario Agostino Gemelli di Roma Italy.;U.O. Ematologia-ASST Grande Ospedale Metropolitano Niguarda Milano Italy.;Clinica di Ematologia-Università Politecnica delle Marche e A.O.U. Ospedali Riuniti di Ancona Italy.",
  "medline_ta": "Am J Blood Res",
  "title": "Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.",
  "delete": " ",
  "content": "期刊:11(4)\n页数:417_426\n摘要:TP53 gene mutations are common in Myelodysplastic Syndromes (MDS) with del5q and have a clinical and prognostic significance. Next Generation Sequencing (NGS) is an accurate, but expensive, technique, and not commonly available. Immunohistochemistry (IHC) for TP53 expression has been recently used as a surrogate to assess TP53 mutations. To compare the concordance between TP53 expression in IHC and TP53 mutations by NGS, 30 cases with MDS harbouring a del5q abnormality were evaluated. Overall, 10/30 patients (33.3%) had TP53 mutations by NGS, while 16/29 (55.1%) had TP53 overexpression in IHC. TP53 expression by IHC had a 70% sensitivity to identify patients with TP53 mutation by NGS, but its specificity was low (52.6%, kappa = 0.198; P = 0.24). In addition, ROC curve analyses showed that the overall diagnostic value (accuracy) of TP53 expression in IHC to identify patients with TP53 mutation by NGS was 68% in the whole study sample and 67% in patients with isolated del5q-. In both cases, the areas under the curves did not attain the statistical significance (P = 0.11 and P = 0.29, respectively). Based on the ROC curve, the cut-off of 2.3% TP53 expression in IHC was shown to be the best cut-off to identify TP53 mutations: using this cut-off, the agreement between TP53 expression and TP53 mutation by NGS reached statistical significance (kappa = 0.42; P = 0.023). In conclusion, the agreement between TP53 expression in IHC and TP53 mutation analysis by NGS is rather unsatisfactory in MDS patients with del5q at the standard cut-off. Thus, the IHC technique cannot be considered a valid alternative to NGS evaluation of TP53 mutational status in these patients.\n期刊:American journal of blood research\n作者:Esther N Oliva; Roberto Latagliata; Elena Sabattini; Corrado Mammì; Maria Cuzzola; Maria Grazia D'Errigo; Maria Concetta Cannatà; Irene Bova; Isabella Capodanno; Giuseppe Alberto Palumbo; Fabrizio Pane; Gianluigi Reda; Luana Fianchi; Marta Riva; Antonella Poloni\n出版日期:2021.0\npmid:3.4540351E7\n出版物类型:D016428:Journal Article\n关键词:Myelodysplastic syndromes; TP53 mutations; del(5q); immunohistochemistry; next generation sequencing\n参考文献:24972774;24656536;27133825;21519010;23175121;32812335;32414002;26416416;27967292;24682512;7718890;30858953;27081179;30635634;22331955;24220272;1607637;32747829;30927980;1969059;23297687\n语言:eng\n附属机构:U.O. Ematologia-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.C. Ematologia, Ospedale Belcolle Viterbo, Italy.;U.O. di Emolinfopatologia-Policlinico S. Orsola Malpighi Bologna Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.C. di Microbiologia e Virologia-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;U.O.S.D. Genetica Medica-Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy.;SC di Ematologia-Azienda USL di Reggio Emilia-IRCCS Italy.;U.O. Ematologia con TMO-A.O.U. Policlinico Vittorio Emanuele di Catania Italy.;U.O. Ematologia Oncologica-A.O.U. Federico II di Napoli Italy.;U.O. Ematologia-Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Italy.;U.O.C. Ematologia-Policlinico Universitario Agostino Gemelli di Roma Italy.;U.O. Ematologia-ASST Grande Ospedale Metropolitano Niguarda Milano Italy.;Clinica di Ematologia-Università Politecnica delle Marche e A.O.U. Ospedali Riuniti di Ancona Italy.\nmedline_ta:Am J Blood Res\nnlm_unique_id:101569577\nissn:2160-1992\n国家:United States\ngrant_ids:[]",
  "pages": "417_426",
  "journal": "American journal of blood research",
  "_inference.semantic_vector": "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",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2021.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "11(4)",
  "languages": "eng",
  "abstract": "TP53 gene mutations are common in Myelodysplastic Syndromes (MDS) with del5q and have a clinical and prognostic significance. Next Generation Sequencing (NGS) is an accurate, but expensive, technique, and not commonly available. Immunohistochemistry (IHC) for TP53 expression has been recently used as a surrogate to assess TP53 mutations. To compare the concordance between TP53 expression in IHC and TP53 mutations by NGS, 30 cases with MDS harbouring a del5q abnormality were evaluated. Overall, 10/30 patients (33.3%) had TP53 mutations by NGS, while 16/29 (55.1%) had TP53 overexpression in IHC. TP53 expression by IHC had a 70% sensitivity to identify patients with TP53 mutation by NGS, but its specificity was low (52.6%, kappa = 0.198; P = 0.24). In addition, ROC curve analyses showed that the overall diagnostic value (accuracy) of TP53 expression in IHC to identify patients with TP53 mutation by NGS was 68% in the whole study sample and 67% in patients with isolated del5q-. In both cases, the areas under the curves did not attain the statistical significance (P = 0.11 and P = 0.29, respectively). Based on the ROC curve, the cut-off of 2.3% TP53 expression in IHC was shown to be the best cut-off to identify TP53 mutations: using this cut-off, the agreement between TP53 expression and TP53 mutation by NGS reached statistical significance (kappa = 0.42; P = 0.023). In conclusion, the agreement between TP53 expression in IHC and TP53 mutation analysis by NGS is rather unsatisfactory in MDS patients with del5q at the standard cut-off. Thus, the IHC technique cannot be considered a valid alternative to NGS evaluation of TP53 mutational status in these patients.",
  "pmid": "3.4540351E7",
  "nlm_unique_id": "101569577",
  "issn_linking": "2160-1992",
  "filename": "pubmed24n1102.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Esther N Oliva; Roberto Latagliata; Elena Sabattini; Corrado Mammì; Maria Cuzzola; Maria Grazia D'Errigo; Maria Concetta Cannatà; Irene Bova; Isabella Capodanno; Giuseppe Alberto Palumbo; Fabrizio Pane; Gianluigi Reda; Luana Fianchi; Marta Riva; Antonella Poloni",
  "doi": " "
}
{
  "country": "Switzerland",
  "keywords": "PDAC; TP53; mutant TP53 reactivators; nutlin-3a; targeted therapy",
  "references": "29416738;28280038;29980405;20418756;30196236;31488557;15860351;27179933;18791272;31399545;19416474;26790143;34315763;34178628;29361690;24183261;26086967;33430525;11571724;34088837;12552960;10761703;20818419;33449813;33451973;25499621;21415220;27908881;32492656;21869603;31420046;33600210;29258181;31930046;22308459;24725405;27865459;2631796;7774811;24768524;31986125;29670092;24407515;2530586;29229669;29320420;18685611;17351335;26870698;33008426;27189670;33139625;32966993;32559497;24209622;30140002;12507923;23335087;25715028;26187504;8656025;27421096;33917370",
  "pmc": " ",
  "affiliations": "Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Department of Health Promotion, Maternal and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.;Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.;Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.",
  "medline_ta": "Cells",
  "title": "Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.",
  "delete": " ",
  "content": "期刊:11(5)\n摘要:The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of the properties of wild-type (WT) TP53. APR-246 is one such molecule, and it is referred to as a mutant TP53 reactivator. To understand the potential of APR-246 to sensitize PDAC cells to chemotherapy, we introduced a vector encoding WT-TP53 into two PDAC cell lines, one lacking the expression of TP53 (PANC-28) and one with a gain-of-function (GOF) mutant TP53 (MIA-PaCa-2). APR-246 increased drug sensitivity in the cells containing either a WT or mutant TP53 protein with GOF activity, but not in cells that lacked TP53. The introduction of WT-T53 into PANC-28 cells increased their sensitivity to the TP53 reactivator, chemotherapeutic drugs, and signal transduction inhibitors. The addition of WT-TP53 to PDAC cells with GOF TP53 also increased their sensitivity to the drugs and therapeutics, indicating that APR-246 could function in cells with WT-TP53 and GOF TP53. These results highlight the importance of knowledge of the type of TP53 mutation that is present in cancer patients before the administration of drugs which function through the reactivation of TP53.\n期刊:Cells\n作者:Stephen L Abrams; Przemysław Duda; Shaw M Akula; Linda S Steelman; Matilde L Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppe Montalto; Maria Rita Emma; Melchiorre Cervello; Dariusz Rakus; Agnieszka Gizak; James A McCubrey\n出版日期:2022.0\npmid:3.5269416E7\nmesh_terms:D000230:Adenocarcinoma; D021441:Carcinoma, Pancreatic Ductal; D045744:Cell Line, Tumor; D006801:Humans; D010190:Pancreatic Neoplasms; D011812:Quinuclidines; D016159:Tumor Suppressor Protein p53; D010190:Pancreatic Neoplasms\n出版物类型:D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\n化学列表:D011812:Quinuclidines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C533410:eprenetapopt\n关键词:PDAC; TP53; mutant TP53 reactivators; nutlin-3a; targeted therapy\ndoi:10.3390/cells11050794\n参考文献:29416738;28280038;29980405;20418756;30196236;31488557;15860351;27179933;18791272;31399545;19416474;26790143;34315763;34178628;29361690;24183261;26086967;33430525;11571724;34088837;12552960;10761703;20818419;33449813;33451973;25499621;21415220;27908881;32492656;21869603;31420046;33600210;29258181;31930046;22308459;24725405;27865459;2631796;7774811;24768524;31986125;29670092;24407515;2530586;29229669;29320420;18685611;17351335;26870698;33008426;27189670;33139625;32966993;32559497;24209622;30140002;12507923;23335087;25715028;26187504;8656025;27421096;33917370\n语言:eng\n附属机构:Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40139 Bologna, Italy.;Department of Health Promotion, Maternal and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.;Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.;Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Molecular Physiology and Neurobiology, University of Wrocław, 50-335 Wrocław, Poland.;Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.\nmedline_ta:Cells\nnlm_unique_id:101600052\nissn:2073-4409\n国家:Switzerland\ngrant_ids:[]",
  "pages": " ",
  "journal": "Cells",
  "_inference.semantic_vector": "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",
  "mesh_terms": "D000230:Adenocarcinoma; D021441:Carcinoma, Pancreatic Ductal; D045744:Cell Line, Tumor; D006801:Humans; D010190:Pancreatic Neoplasms; D011812:Quinuclidines; D016159:Tumor Suppressor Protein p53; D010190:Pancreatic Neoplasms",
  "chemical_list": "D011812:Quinuclidines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C533410:eprenetapopt",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't",
  "issue": "11(5)",
  "languages": "eng",
  "abstract": "The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of the properties of wild-type (WT) TP53. APR-246 is one such molecule, and it is referred to as a mutant TP53 reactivator. To understand the potential of APR-246 to sensitize PDAC cells to chemotherapy, we introduced a vector encoding WT-TP53 into two PDAC cell lines, one lacking the expression of TP53 (PANC-28) and one with a gain-of-function (GOF) mutant TP53 (MIA-PaCa-2). APR-246 increased drug sensitivity in the cells containing either a WT or mutant TP53 protein with GOF activity, but not in cells that lacked TP53. The introduction of WT-T53 into PANC-28 cells increased their sensitivity to the TP53 reactivator, chemotherapeutic drugs, and signal transduction inhibitors. The addition of WT-TP53 to PDAC cells with GOF TP53 also increased their sensitivity to the drugs and therapeutics, indicating that APR-246 could function in cells with WT-TP53 and GOF TP53. These results highlight the importance of knowledge of the type of TP53 mutation that is present in cancer patients before the administration of drugs which function through the reactivation of TP53.",
  "pmid": "3.5269416E7",
  "nlm_unique_id": "101600052",
  "issn_linking": "2073-4409",
  "filename": "pubmed24n1225.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Stephen L Abrams; Przemysław Duda; Shaw M Akula; Linda S Steelman; Matilde L Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppe Montalto; Maria Rita Emma; Melchiorre Cervello; Dariusz Rakus; Agnieszka Gizak; James A McCubrey",
  "doi": "10.3390/cells11050794"
}
{
  "country": "Switzerland",
  "keywords": "SPOP; TP53; biomarkers; metastatic prostate cancer; mutation; prognosis",
  "references": "34133717;30553611;34322378;35438056;30209161;32355326;18094376;32220891;30089598;23550210;31176623;34843402;34325986;32424106;26000489;34496240;33311589;34370973;34974131;29330202;32393735;31358900;34353330;33785256;32684626;33542230;34601169;32624276;29979965;35364375;35120664;34783071;31874108;30124983;33762355;34987184;35511402;32404993;33531470;35449224",
  "pmc": " ",
  "affiliations": "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.",
  "medline_ta": "Front Oncol",
  "title": "Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.",
  "delete": " ",
  "content": "期刊:12()\n页数:957404\n摘要:Background\nAlthough TP53 and SPOP are frequently mutated in metastatic prostate cancer (PCa), their prognostic value is ambiguous, and large sample studies are lacking, especially when they co-occur with other genetic alterations.\n\n\nMethods\nGenomic data and patients' clinical characteristics in PCa were downloaded from the cBioPortal database. We extensively analyzed other gene alterations in different mutation status of TP53 and SPOP. We further subdivided TP53 and SPOP mutation into subgroups based on different mutation status, and then evaluated the prognostic value. Two classification systems for TP53 survival analysis were used.\n\n\nResults\nA total of 2,172 patients with PCa were analyzed in our study, of which 1,799 were metastatic PCa patients. The mutual exclusivity analysis showed that TP53 and SPOP mutation has a strong mutual exclusion (p<0.001). In multivariable analysis, truncating TP53 mutations (HR=1.773, 95%CI:1.403-2.239, p<0.001) and other TP53 mutations(HR=1.555, 95%CI:1.267-1.908, p<0.001) were independent negative prognostic markers in metastatic PCa, whereas SPOP mutations(HR=0.592, 95%CI:0.427-0.819, p<0.001) were an independent prognostic factor for better prognosis. Mutations in TP53 were significantly associated with wild-type status for SPOP and CDK12, structural variants/fusions for TMPRSS2 and ERG, AR amplification and PTEN deletion (p<0.001). And truncating TP53 mutations have higher AR amplification rates than other TP53 mutations (p=0.022). Consistently, truncating TP53 mutations had a worse prognosis than other TP53 mutations (p<0.05). Then Kaplan-Meier survival curve showed that Co-occurring TP53 mutations in AR amplification or PTEN deletion tumors significantly reduced survival (p<0.05). Furthermore, those with SPOP-mutant tumors with co-occurring TP53 truncating mutations had shorter overall survival than those with SPOP-mutant tumors with wild-type or other TP53 mutations.\n\n\nConclusions\nThis study found that TP53 and SPOP mutations were mutually exclusive and both were independent prognostic markers for metastatic PCa. Genomic alteration and survival analysis revealed that TP53 and SPOP mutations represented distinct molecular subtypes. Our data suggest that molecular stratification on the basis of TP53 and SPOP mutation status should be implemented for metastatic PCa to optimize and modify clinical decision-making.\n期刊:Frontiers in oncology\n作者:Jie Zhou; Yiming Lai; Shengmeng Peng; Chen Tang; Yongming Chen; Lingfeng Li; Hai Huang; Zhenghui Guo\n出版日期:2022.0\npmid:3.6119488E7\n出版物类型:D016428:Journal Article\n关键词:SPOP; TP53; biomarkers; metastatic prostate cancer; mutation; prognosis\ndoi:10.3389/fonc.2022.957404\n参考文献:34133717;30553611;34322378;35438056;30209161;32355326;18094376;32220891;30089598;23550210;31176623;34843402;34325986;32424106;26000489;34496240;33311589;34370973;34974131;29330202;32393735;31358900;34353330;33785256;32684626;33542230;34601169;32624276;29979965;35364375;35120664;34783071;31874108;30124983;33762355;34987184;35511402;32404993;33531470;35449224\n语言:eng\n附属机构:Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.;Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.\nmedline_ta:Front Oncol\nnlm_unique_id:101568867\nissn:2234-943X\n国家:Switzerland\ngrant_ids:[]",
  "pages": "957404",
  "journal": "Frontiers in oncology",
  "_inference.semantic_vector": "XaTZvbqAtr266PK5dJETvnTBHT50kfU+upgivaP7B73RJVY9jKIavkbDG76Muvg9F120tkYXh7svKj896SrHPgBkLD50YcO8LyoOvRfdKL506YA+dFGGvjo2rT7pyrI9jM5XvtHtubwXndA96ab/vYz+HL5dlO4+6S5uPi/m9D1daXa+Rjd1vYwepL26eHk+FxE2vXSJRD4vkok+jNMoPumKFD5dpNG+o0u+vi+ycD50wXW+XZoGv3TxaMDposm86cppvgBgDT4AlKy9XZhgPnFPYD4vuqk+jNYjPtFF7T5GJyY+FywMvgBQob0XjQm/bHaTPeniIz0vkpM9L7rvPACQcb10oSc+0a45vtFdRb7RWD++o4spv13YcD4v+jQ8RmervtH7mL26qEK9RneYPOmiF7/RayA+uigOP9OKgT6Mhq69o4vLvqOLcT10zZs+dGG7vC9aAr9dwZ0+L4qcvaNLoD50/VS9o4sjPUaxn74vKog+XZwnPoxuR74AcH0+L1pYP11ExD0XXaY80R2KvSNe1L7RPYA+6fpRvqPjSb3pwK++6ToCPtHjnb4vTgi+XeDKvgDETL50yYC+Rl+LPnThcL6MLuU86YbuvS9mdD6ja9i8L3K3vgC4zT4XfYI9oysYPtGl9z6MNge+LxoQvnQPFD4AwL++XSwEPrrIP74AGLW+F0kAvi9itD0vCta9jO74Pl0ksb7RpZM+ANYAvkZ3tL7porE8ukC2PQDcNj66KA29F639vbooVD3RnQK+FyAIPkZXTb90wZG9XQoIvkbno750oZc7uqUXvulyI71d1B49FyXXvS9ajb4XndQ+uhCKPaPjKj66JFm+o+vYvgAALD0vytS96URRvtFleL26LLk+o0uSPbpFfj7RdTI+jAqJvUaHOb/RhRI8jJbUvnRxersXnau+ukguvUZ+iT6jC0k+L3qrvXTlqb5drIu9Fw2QvtFVCT8AgKa+o2sUPukGkT6jy7o7RqeBPgC4qD7pcnQ+Rnf8PnRhCL+6VBy/o9e2vRddcTzp4kw/xgulPbroPTxdtKU+KYeYPhfdvruj0bK+Rtpjvozujz90+RG9ugjmvi9qOL4XDZK+AJSEvrpQAj66aF++o8XiPd3WILwXzV++LxraPqMnlL5G7xK+RucbP0bugr66uAY/RkXivi9ekT6jy46+unh5PqMjkj7REYc+dBHZPtEJtD5dmpG+gLbEPi9ifD4vYkY+6SKnvIx2Cj9dqEm+AFCmPen8lj4AcAC/6TaTvgzvwD4AIDC+uuwVPaNnBz7pugC+0Z94vgBcKb0X7T6+L2FqvtHl7bwXPUa9uqh2O7oAyb2jewI+RvfaPYyCGr6j3qE+6d7JPdHrpL4v9uq9XUAfPtENmL7R5Ss90QVMvqNToz7pIn6+dAEAvdF1q75GF5e86UZOvnRBzT7pMva9FwWqPqOLX73pQlW/ukhAvQDI/77RAXG+XTR5PnR5Ij5Grzg8XXQbuwBgmL3pip+9tEo7vozusL/p0ju+uojuPqOr4z1G18S9XXQSO9Ghr7668Jy+0QMPvy/Kdr7p7dG9RldCvLqIQT5dNBm+dJ8tPoxmDj8veqM8L2K9vgCQtz2Mbhm8T8WdPbNAlT4vdlM+XcS2vumSRr0XPabAo5cTP0bXmr7GBYC+upCLPqNL7j5dJLs+DzVBPQCADr4XBeI88yICPhd5rT3UwgA+6faIPnTxV73RwUC+uqCAvqMrR71dZK8+RgPdPRddY7yM3i6/0VW1vV3UqD1dVE49dEkhPi+a4r5GT5c+6eLsvXSi3L6Mdi4+jC4KPNGT1jxd9LG9ujnXPRdZ9z0MxJq+L7ovvrp4DD26+Mi+o9tLPqPLcL5d0Oe9o7sZv6MbB74AUDu/F73ivUa3Gz8AkA6+jLIPPoxOYT50Y5S9ukjuPowixD4AcNk9F+1aPXTBnT7p4u+86SJMPUYvqb3Rpdo9L+Itvoxo2L6Mtgi/RuOYvdFdaz500S+8Rqpjvl0kRD50Edc9Rr+qvrogDD5dgNm90R2OPdE5Q750WVe+0eWLPaMzqT0AkHi+dLHiPelmDr0AjO+9dAGuPl1TmT46wXs+L5o/vl2U1r50cfi9Rtfzvbpctz0vKvw+RjdpvozGSb4XfVE9Rje1Pkbzij5d7pi9XTTkPtH1tj5GT/m86bLCPgB8Cb5GV/w86ao5vkZcw75dlHS96WrvvhfzFD7Rz8c90a2zvRc9nL6Mtks9jL69PIwa976Mwrk+umgBPF1+mz4X7U2+RolWvbrABb6Mhpm+uhjiPi+aNr+jdS69o7s+vkZq2T3pqjA+dIGEPkY3er6Mvqa+L0x0PS8Ygb6jS168dPF8PYyGED6je6k+6UaMvvkqFT6Mjs89ozwSPtGdIL66sF8+XVTkPKMr0D1Gl347o3tfvrrI/T6MTjQ9o/WnPunynT0A9GC+XUR4vqOrGL109Rk+0dEavrpEmT6jy8686eKMPV3cFj4vKsK9XQABvtFxS766oIe+F4WKvi+SQ75ddN67F7W1PnRxGr4ANgG/ujhsvrokAT4Xqeg9jHI8PhddLb1dJJ080R8RPtFlpD1drA2+AGB5PUa3yz6jewW/0XULPaMnib6MFhK9L1KxPqPTFD4v2vu+Rk+RvkaHwL4XdXO9F7SsvtE1Qb1G95S9gPCavrpYFb5pq76+jC6Wuroo7j6j8wA8XZTCPaN6a75dBH8+ukJEPkafkb7popc+uqhLvUZ/jj5Gv5a9o2tYvrqoab0A0E4+dDFbvV0MDjyMbhO8F7cUPhfxCD1Gf70+ushfvl10vL4vjgI/0R2BPnTh9D5GN/k+dAHCvhflbL6M3ja9Fy05vl23Mb4XcRM/6eqQPbrocj6jq7G9RoUWPkYHyT7RldG9AJCOvowu/DvRGYE+o7ORvmnZeL7pepM+XeTrPS8a+L1Gfwq+0b2dvhd9pb0vuuA+umURPkYXyT2j2wU+RsHqvRfdy7yMcJi+F9mavulOUD6MvkY9utj2vkbvwb5GCSi+XZODvqPjKz4v+h8+XYw2vYzOGL4XhUg+L6rVPUZ3YD0vutq+jNxAPgAApT4AoLo9AAA9PC/5DL7pMhk/o5ENvgCA/j3RGdY86fqiPrqEbz2MDhG/F7W3Pbp4lb0Xx6+9AIBpPNH7CL666HE7F5W8PbqoBL4vtB+9F/DcPV3Etj0A+CK9HWAJvrpgNj7RdV8+dFGAO3RFiz4XXSk/AFB5PRdd6ToAAMO+XXwMP3QnmT68Lz++RkEcvheNvL3pwPO9L86Gvozzrr0XDR4/dOF7PqObwj0vwqI+dKZvPYyG0r6MLlo9jI6HvgBw5j1dGrI+L9rLPRfVhj4XvbY9AEDuPgAgE71Gt7Y+dHEYPoweXr7pdo09Rh8PPV1cQz4XLS4+XTjevS/GPT5dFH8+0bE4vqMzyj2jn4Q+F72YvnQByz4AyEC+uqRUPl0U6j4XjSG96Z/bvTTdRD4X7xg+uuRivgCanj1Gn9k+RvsFP5nYAj6MRtm9AHjIvhddNr508S29dCUJvkaOTb4AfKG+jE4gvnRxcb4v2oO+L9rtPqM7AD+MglU+Rpf9vdFxPb4GsYM+o5djvUYHIj+MrhC+dKGRPQAYlD26sIy+0RVlPi9qjz50acS+jP67Pl3kub5dmHa+6fLoPi86hL501b296UKSPUavx76j22m+jB4Jvo+enD7pHuM9urCEPV0cSb6Mhrg+Rrctv7rQeD7pDIo913kMPoC5Qz6Mbqo+XaTTPaM9TD7R1zY+XQSVPl0wsr1G95c9XSESPwAdsb5daE6+utAIvozOVL2jC+G+dKSevtGL/L26MBs+o+tjvqNvNT5dhK8+o+uYvtHlEz26mD4+ADRUvkYMVr6MbvA6XeQCv9HNJT+MLgQ/F3W/vgCAEj0XVI8+jK7mvSNx5D1dhKY9L7oHvunCoz2MNJW+F+UAvroogr2j8d2+jIqTvi9iDD/pjCC+ANgbvoxaAb9ArbW90U8yPkYnrD0AfYU+Ri+FvrpY9D3pot+9XbTVvl1UKj1GR7s9L8rxvS/iXj3R5fC9uggJPgA8FL8vxsK9F80wPuniWDxdWDU+",
  "mesh_terms": " ",
  "chemical_list": " ",
  "grant_ids": "[]",
  "other_id": " ",
  "pubdate": "2022.0",
  "source_from": "pubmed",
  "publication_types": "D016428:Journal Article",
  "issue": "12()",
  "languages": "eng",
  "abstract": "Background\nAlthough TP53 and SPOP are frequently mutated in metastatic prostate cancer (PCa), their prognostic value is ambiguous, and large sample studies are lacking, especially when they co-occur with other genetic alterations.\n\n\nMethods\nGenomic data and patients' clinical characteristics in PCa were downloaded from the cBioPortal database. We extensively analyzed other gene alterations in different mutation status of TP53 and SPOP. We further subdivided TP53 and SPOP mutation into subgroups based on different mutation status, and then evaluated the prognostic value. Two classification systems for TP53 survival analysis were used.\n\n\nResults\nA total of 2,172 patients with PCa were analyzed in our study, of which 1,799 were metastatic PCa patients. The mutual exclusivity analysis showed that TP53 and SPOP mutation has a strong mutual exclusion (p<0.001). In multivariable analysis, truncating TP53 mutations (HR=1.773, 95%CI:1.403-2.239, p<0.001) and other TP53 mutations(HR=1.555, 95%CI:1.267-1.908, p<0.001) were independent negative prognostic markers in metastatic PCa, whereas SPOP mutations(HR=0.592, 95%CI:0.427-0.819, p<0.001) were an independent prognostic factor for better prognosis. Mutations in TP53 were significantly associated with wild-type status for SPOP and CDK12, structural variants/fusions for TMPRSS2 and ERG, AR amplification and PTEN deletion (p<0.001). And truncating TP53 mutations have higher AR amplification rates than other TP53 mutations (p=0.022). Consistently, truncating TP53 mutations had a worse prognosis than other TP53 mutations (p<0.05). Then Kaplan-Meier survival curve showed that Co-occurring TP53 mutations in AR amplification or PTEN deletion tumors significantly reduced survival (p<0.05). Furthermore, those with SPOP-mutant tumors with co-occurring TP53 truncating mutations had shorter overall survival than those with SPOP-mutant tumors with wild-type or other TP53 mutations.\n\n\nConclusions\nThis study found that TP53 and SPOP mutations were mutually exclusive and both were independent prognostic markers for metastatic PCa. Genomic alteration and survival analysis revealed that TP53 and SPOP mutations represented distinct molecular subtypes. Our data suggest that molecular stratification on the basis of TP53 and SPOP mutation status should be implemented for metastatic PCa to optimize and modify clinical decision-making.",
  "pmid": "3.6119488E7",
  "nlm_unique_id": "101568867",
  "issn_linking": "2234-943X",
  "filename": "pubmed24n1154.extract.xlsx",
  "vernacular_title": " ",
  "authors": "Jie Zhou; Yiming Lai; Shengmeng Peng; Chen Tang; Yongming Chen; Lingfeng Li; Hai Huang; Zhenghui Guo",
  "doi": "10.3389/fonc.2022.957404"
}